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F\BSI RA( 'I 
Ihc dc\astating crrcct the IllV pandemic has had on thc human population in the last 
t\\cnt) fi\c years has highlighted the great need to dcvelop a prophylactic HIY vaccine. 
Ihc manufacture or a \'accine has proven difficult though. with a number or successrul 
dcsigns in animal models having little success in humans. In \'ie\\ or this. there has been 
a nCL'd ror nmel \ accine approaches that are able to elicit clTecti\e cellular and hUll10ral 
immune responses. both or which are believed to be important in thc cradication of the 
\ InIS. Onc such approach is the usc of HIV-I Gag VLPs as \accine candidates. In this 
study. thc production of t\\O chimaeric Gag YLP vaccine candidates (GagRT and 
(jagl:';) \\as optimized in insect cells. and their ability to enhance a mUrIne Immune 
response in a 1)1\'/\ prime-YLP boost vaccine strategy \\as e\aluated. 
lhe optimal conditions ror maximized chimaeric VI Y production \\ere determined by 
naluating the effects of four factors on the expression of the respective YLPs using 
factorial analysis or variance (ANOY A) and \vestern blots. The factors investigated were 
inscct cell line. cell density. multiplicity of infection (MOl) and infCction time. The cell 
line and ccll density used were the most important ractors affecting the expression orboth 
\ II> constructs. \\hile MOl had little to no effect. The optimal conditions for both 
candidates \\cre similar. both demonstrating high yields of intact YLPs \vhen produced in 
the Sj9 inscct cell line. at a cell density or 1 x 1 0(' cells l1111. MOl of 5 and an infection time 
or ()() hours post infection. 
OnL'e these conditions \\ere determined. large scale YLP production \\as imestigated. 
and VLPs \\ ere puritied using a micro-/ultrafiltration method. Ihis method proved to be 
bctter than sucrose gradient density ultracentrifugation and Optiprep I~ gradient density 
ultracentrifugation in terms of the quality and quantity ofYLPs that \vere purified. 
Ihc resulting VLPs were utilized in mouse immunogenicity experiments to evaluate the 
ability of the respecti\ e YLPs to enhance a cellular and humoral immune response alter 











I LIspot assays \vere used to detect and assess the specificity of the cellular immune 
response stimulated. and the new LA V Blot 1 western blot kit \\as used to measure the 
humoral immune response induced. 
80th sets of experiments demonstrated a dominant (Jag CD4+ I-cell response and a 
strong boost effect was observed for mice inoculated with a 100 ng boost of the 
respective ehimaeric VIPs. Although there was only a poor Gag CD~+ T-cell response to 
(iagRT \'LPs. (iagTN VIPs stimulated a strong Gag-specific CD8-t- T-cell response. In 
addition. there \vas a positive response to stimulation by a Tat ('04+ T-cell peptide in the 
(iag!'.! experiment. and a strong RT CD4+ T-cell and C[)8+ T-cell response for the 
(iagR! experiments. indicating a broad cellular immune response \\as induced by both 
\·LPs. '\io apparent Gag antibody immune response was elicited in either of the 
experiments. 
In conclusion. \\hile both chimaeric VLP constructs GagRT and GagTN demonstrated 
the ability to significantly enhance a cellular immune response which appeared to be 
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111111/1111 illlllll/l/Oi/cjieicllc\' l'lnts (I I IV) IS a LClltil'irus, from the subfamily 
()rtlwrclml'irill{/c. and family RctrO\'iridac (Flint et al.. 1999: MacGregor ct al.. 20(5). 
111\' in hU11lJns CJn be either of two species. IIIV-I or IIIV-2. based on the serological 
properties Jnd sequence analysis of the viral genome (Luci\\'. 1(96). Of the two species, 
111\' - 1 is the most prom i nentl y found and is divided genut ypieall y into three groups. 
nJmely the mJjor ( '\11). outl ier (0) and nOI1-M 110n-0 (N) groups. The M group is the most 
dominJnt in the human population, with as many as 10 sub-types and I J eircubting 
recomhinant forms (CRrs) identified to date (Young et al.. 2(06) . 
. \ HIV-I int'cction results in the destruction of host CD4+ T-Iymphocytes. an essential 
component of the immune system. Consequently. infected individuals Jre eventually 
diJgnoscd \\ith ,'\equired Immune Deficiency Syndrome (AIDS). a lethal syndrome that 
hJS led to O\er 29 million deaths \vorldwide the last 25 years (UNAIDS. 2007). Third-
\\mld regillns JppeJr to he the most affected hy IllY. In pJrticular. H IY -I subtype C is 
responsible for the majority of the infections throughout the \\orld. and is the most 
ellllllllon of the HIV subtypes in sub-Saharan Africa. the Indian continent and China, \vith 
Jppro\.imatcly ]t).5 million people infected in 2()06 (UNAIDS, 200()). Consequently, 
there is a desperate need for the development of a safe. effeeti\e and Jtlordable IllY 
\JCelne, 
1.7 HIV-J structure and genomic organization 
111\'-1 is J single stranded (ss) RNA virus with a genome SILe of 9.2 kb that is 
encapsulated in a cone-shaped nucleocapsid, within an enveloped. icosahedral protein 
shell (Fig. 1.1) (Flint et al.. 19(9). Infectious HIY virions contain two ickntieal copies of 
the genome that have positive polarity with respect to translation (Luci\\. 19(6). The 
\iral genome encodes for nine proteins which arc divided into four distinct groups (Fig. 










(al I h~ slructural l'rok Ln S, {Jag and ~n>, "hlch ar~ enl,.,ded I,)r by Ih<' f"f and en" 
g~n~s r~Sl'ectj\ ' ~ly. rhc gug g~ne ~lIcnJ~s I'r551"t, (h~ precursor of (he Vlf]Oll 
c~l";d prf1(e;ns (Deml d aL. 2005: FI;n1 e( al.. 19'99: Freed. 1998: Lnc;\\. 199(» 
ThcS<e I'r<>t eins lIlcllL{l~ [Joe 1'1 7 m~(rj~ pm1cin (\IA), Ih~ 1'24 capsid pro(~;n ((",A). 
th~ 1'7 nncl~ocap>l(1 p''l't e in (NC), t h~ pU Iln~~'f pmt~ill (U) and ,mali sracer 
P<'p(ides. 1'2 and 1'1 (SP 2 ~nd SI'I r~' pecti\'eI}) (Deml ~t.1.. 2005: Fr~~d, l~q::;: 
/l.lal'Gregor el aI., 20(5), 
~ .. """" 1~1 ~, 
"""",. ~.,=,"'.,. 
1OIl6I.,s1 AT, 
T I", 11 11'_1 
"""UTe \ mUll with the 
oppro'''na(~ I"'''''M' M 'he 
l, bc"lIeJ pmL,",", 1'-'-,,", 
(I rc"C"J. lW~II" 
transmembrane (rl>.1) l'n\'clf1pe giyc"prole ins (Env !!-p), gp l20 ",I(] b'P41 
respect;\'ely (I I!~h\, I '-J<J6: Wang, L,;, anu Li, 199R). 
(h) I 'h~ "n7yme l'mteins are en"xied by 11", pol g~nc, which when Iran ,ialeu, 
""presses (rn, precursor. I'rI60"·'voI , for the \'inml en7}llle~: ' nt egra»e (iN), 
prot~ase (PR), r~\ erse 1r~nscripta s~ (R TJ. and R.'Ja sc-ll, 
Icl The regulatory pmll'ins ar~ tJoe lr~nscriptimJa1 lransacti\atm (T~I) and , ' ir~ 1 
'" preS>lon r"gu (ator (R~,). both or" hlch are en«,.j~d by .,\'erbppmg ~"Ol1'. and 
are essentl J I f(}r \ ir~ I r~pl i C.lll,n 
(ul The linai grnllp are (rn, "cce"<1f) or all~iliar} prolelTl' IVpu. Vpr. vir _"I(] Nd), 










uniffi~ lIlt it~ in ~ombaling IIIV- I 
In \' i ~'" of th~ gn,,, 'ng nllmber o f III V -positive md,viduals. many appro"ch~s h", e heen 
tool~d at to ~rad i eat~ the ,irus, In the last Ie" }~" rs. hlgh ty m:liv~ anti- re\l'o , -i'llt th~'-apy 
{H.\,\RT ) ha, pn)\ed to be a slIc l'cssl'lI1 llletlwd to Cllntrol ItI\' infecti ons. ll1iti7ing 
protease inh l hllors and n ud"o, id" analog, , udl ~ s ~Li doti eox _, th ymitiinc (AZT) to Inhib it 
re'~l-se tmn,criptlOn oj' Ht\' (Flint ct al. . 1999: Yoshi~a"a d al .. 200 11. 1I0',"'er. 
IL\,\KT lS an ap~n,,,e ","thoti anti Ih ~ rd(H'~ (],tlic"lr 1(\ ane" for p~ti~nh in 
dc'~ l oping Cl'"ntr ie< (Chugh and Seth. 2004; Yosh i 7a,,~ e! al.. 2(~) 1 1_ l 'lll1 h ~rm" re. 
"hi le I IAAI{ I h~s h ~el1 ~ble to reduc ~ th e viral mCeetion in most indi,idllats. it does not 
dllnil1ate the ,i rllS (t .ll~i" _ 1 9,)!> J. t n fa ct. druij- resi,tam "if us has f"~entt y been ddected. 
makmg HAART a )'Of'f l "ng-t~llll treatmenl {,\beCiregur et ,,\.. 20()S; Yo,hua"a d aI., 
lOOt I. 
A HtV-l GENOME OflGANtZATtON 
yag 
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/ D- '''-----D 
0-- -~- 0 
I'i~" r< I.! - I he 111 \_1 
genom,: highli gh"ng 'he 
g">: 01"'" r,"d", ~ fm"'e 
IfcoHi (t-,~eJ. IW~!) , 
Ihus, th e de,etopm ~nt of ~ ,aecine '~~n" 10 he the hest o~ IL on 10 ~omln t an I IIV- I 
1l1fection. al1 d prevenl It> spread (Doan et at.. 2(05). A ,aceine tradi tiomt ly stimulales 
the hosl mtlLl'J I defense, ag" ,n ' l ii.lt'eign p"rti cte,. elicitin g; ~n imn1l1n~ fesponse and til", 
rro,,,ling protection_ Ilo"ewr. m th e ea,~ of Ht V. thi, i, compt icated by a n","b ~r of 
raLl ors. Fi ,-<tty. 1 tlV "ttac k< the i m mUll e system di reetl y. mf eLling T -I ympho(')1es "s \\ dt 
a, mOllOc)-1"> an J macmphages (LOCI"'. 1996; Kabel. 2002)_ It ,lo,-1y incap~cit~t~> th. 











integrates into the host genome. making it impossible to differentiate bet\\cen host and 
\ iral IX\.\ alter integration. and thus it is difficult to eliminate thc virus \\ithout harming 
thL' host cell as \\cll (Luciw. 199()). Lastly. HIV is able to escape detection from the 
Immune s\stem \\hen in its latent Corm because no \iral protcins arc displayed on thc 
infected cell's surface for immunc recognition purposes (Alcami et al.. 2(05). 
lurthermlll'e. the IIIV genome has a high mutation rate in certain regions. resulting in 
immune escape mutants: this makes it very difficult to design a broad spectrum IIIV 
\accine that prmides immunity against all variants in humans (Paliard et aL 20(0). 
Scientists have O\ercome some of these problems by looking at strategies that will 
enhance the host's initial ccllular and humoral immune responses to HIV (Yao ct al.. 
2()(),' l. 10 du this. the molecular and cellular basis for the host illlmune rcsponse. as wcll 
as \arious 111\' imlllunogens. has been studied in detail (NabeL 2002). 
1.4 Gene targets for an H IV -1 vaccme 
I raditional mcthods to develop a HIV-1 vaccll1e utilised li\e-attenuated vIruses or 
chemically inactivated \iruses as possible dclivery \ehicles (NabeL 2002: Noad and Roy. 
2()()J). [here \\as somc success in using whole killecillIV-I in micc. hO\vcver. thcre 
prmcd to be many safety concerns involvcd in using this method. bccausc of the 
likelihood of incomplete inactivation of chemically inactivated viruses. or revcrsion to 
\ irulcnce hy li\e-attenuated viruses (Noad and Roy. 20m). 
A sarer approach imolvcd the incorporation of HIV antigens into vaccines. in an attcmpt 
It) el icit broad. strong. adaptive immune responses against H IV -I. Some of the most 
comnlllnly used antigens were those encoded for by the em' gene (gp 120. gp 160 and gp 
.f 1 ). as these \\ere the only proteins that demonstrated induction of both a cell-mcdiated 
immune rcsponse and neutralising antibodies (Nabs) in rodcnt and non-human primatc 
trials (Dcml et aL 2005: (iardiner et al.. 2005: Lcung et al.. 20()4; Yao et al.. 20OJ; 
Young ct al.. 2006: Zanotto ct aI., 2(05). NAbs are particularly important because they 
arc belie\ed to prO\idc protectivc immunity against IIlV -I by cfTeeti\cly blocking its 











2()().j). II()\\ e\ er. due to the inabil ity of the host immune system to access neutralizing 
1'11\ epitopes* on primary IIIV-I isolates, and the high \ariability of the ell1' gene, Env 
\acL'ines had disappointing results in human clinical trials (Pontcsilli et aL 199~: 
Sandstrom and \Vahren, 1999). 
Fxpression products of the po! gene (Gag-Pol fusion protein. p 160. RI'. [N, PRJ were 
also e\.plored as potential vaccinc targets. specifically because the po! gene is a conserved 
regiol1 \\ithin the H[V genome and has been shmvn to elicit cross-clade cytotoxic T 
lympllllcytes ((,IL) responses in infected IIIV individuals (Betts et aL 1997). Zur 
\legede et al (Lur Megede et aL 20(3) demonstrated that a DNA \accine expressing a 
g{{g-po! fusion gene \\as able to induce strong Pol-specific T- and 8-cell responses. 
I hm ever. a concern when using po! expression products in vaccines is the potential 
deleterious en/ymatic activity of IN, RI'. and PR components. This has been avoided in 
recent studies by inactivating these proteins before they are used as vaccine components 
(Kong et al.. 2()()3). 
[n most cases. accessory and regulatory II [V protei ns \\ere incorporated into \anous 
\aecine designs as additional components to Gag. Em or Pol. as they \\ere able to 
enhance L'ell-mediated immune responses against IIIV due to the presence of several CTL 
epitopes in the functional regions of these proteins (Yu et aL 200S). These proteins are 
also inacti\ ated before use or shufned to prevent toxicity problems that may anse as a 
result of their expression. 
Of all the [11\'-1 proteins. most current strategies arc utilizing the (Jag-based antigens 
because they appear to be the best potential vaccine candidates for T-cell responses. The 
gag gene has been identitied as a highly conserved region in the genome. [n addition, the 
organi/ation of the (Jag proteins within PrSS,!CI); and within HIV virions is also highly 
consenni (Doan et a!.. 200S: Nabel, 2002). This suggests its use in a \accine could 
pnnide protection against many H[V variants. Furthermore. the full length (Jag 
polyprotein. PrSS);Ci);. is able to induce anti-I-I[V antibody production. along with long-
li\ed helper I cell (Til) and CTL responses (Doan et a!., 200S: Yoshizawa et al.. 20(1). 
* rC);'OIlS ot' all allt Igell that Illteract \\ ith the alltigell b illJ illg site of all ulluboJ\ or T-cell receptor 











1.5 H IV \accines llsing Gag-based antigens 
PrSS:':"': is integrally involved in immature virion particle assembly. the incorporation of 
\iral accessllry proteins into virions and membrane-targeting functions (Deml et a!.. 
2U()): !\abe!. 20(2). Studies have shown that PrSS""" (499 amino acids) alone. in its 
unprocessed form. is sufficient to produce and release non-infectious virus-like particles 
(\TPs) or HIV when expressed in yeast. insect and mammalian cells (Doan et al.. 200S: 
Yao et al.. 20(3). The resemblance of these VLPs to IIIV virions means that a similar 
Immune response. to that induced by infectious virions. could be induced by the VLPs 
([kml et a!.. 2()()): Noad and Roy. 200]). llence. Gag antigens arc of particular interest 
to \ accine researchers. and have been included in the design or a number of different IIIV 
\accine approaches. 
1.5.1 Gene-based HctOl'S to deliver Gag antigens 
(Jene-based \ectors. both viral and non-viraL have proven to be successful transport 
\ehicles ror potential vaccines containing the gag gene or Gag antigens (l\iabeL 20(2). 
/.5,1, J I'im! lH'{OI'S 
\'iral \ ectors such as poxvlruses [canarypox. fowlpox and modified VaCCll1la Ankara 
(\:1\':\)]. adenmirllses and adeno-associated viruses (AAV) ha\e been employed to 
deli\er (jag antigens to host cells for vaccine purposes (Nabel. 2002: Walther and Stein. 
2U(JO), These \ectors either have viral replication genes that are replication-incompetent 
in humans. or these genes are deleted and replaced with genes encoding IIIV protein/s 
('\Jabe!. 2()02).Ihl:y are generally able to produce large quantities of the protein of 
interest and to elicit strong host immune responses to the IIIV proteins that they carry. 
Se\eral studies have demonstrated success using viral vectors for vaccine purposes 
(iherardi et a!.. 2()04; NabeL 2002: Xin et a!.. 2007). however there are safety concerns 
\\hich remain an issue, In 2007. the Merck phase I human clinical trial vaccinating 
individuals \\ith a recomhinant. inactivated adcnmirlls-S \cctor \accinc containing thc 
<.c:,IC:, flO!. and IIC/ genes. railed to elicit protection against 111\' inkctiun, in addition to 










,lllllld tri~ll~ hci'mc am \~jccillc testing in hunLl1b. 
:\lln-\iral \ectors such as DNA plasmids and liposomes prO\ide another option for 
transportation of a vaccine to host cells (Oeml et aL 2(05). In particular, several ON A 
prlltotype \accines have been used to carry the HIV-I gag gene as \\ell as other illY-I 
gl.'nes intll host cells (including antigen presenting cells-APCs), where translation of the 
plJsmids produces the desired viral protein/so In this way. peptides of the recombinant 
protein expressed can be processed via both major histocompatibility complex (MHC) 
classcs I and II, inducing humoral and cellular immune responses. These vaccines have 
demllnstrated a safe, eost-ctTcctive and stable naturc, in addition to being able to elicit 
bUlh arms or the adaptive immune response in mice (Chugh and Seth, 2()()4: Yoshizawa 
et al.. 20() I). Ilmve\er, the immune responses elicited are not as strong as those induced 
by \iral \ectors in larger animals (Deml et aI., 2005; Ramakrishna et aL 20(4). Also, 
there are some possible dangers to using DNA vaccines in humans such as autoimmune 
responses due to anti-DNA antibody acculllulation, and potential tumour formation due to 
chromosomal integration. Further research is therefore necessary before \'iral and non-
\iral \ectnrs are used commercially. 
('ombinations llr \'iral and non-viral vcctor vaccines have recently emcrged as a method 
tll imprme the immune responses in animal models. In an interesting mix of viral 
\ector l)0;.\ \accine approaches, Zhang et 01. (Zhang et al., 20()4) illustrated the use of 
papilloJ11a\irus pseudO\iruses to express Gag in mice. and elicit effecti\c C rIo and anti-
I II\' antibody responses, as well as develop memory immunity against Gag. Such 
strategies haH? demonstrated success in other similar studies, and will be discussed 
further in sections to follow. 
1.5.2 Gag subunit yaccines 
Subunit \ aecines use recombinant proteins to present single \'iral antigens \vithin the 











immullc rcspollscs. as \\as demonstrated in a rccent study where a vaccine comprising of 
a IIIV-I (iag p24-lmmunoglobulin A (Ig A) fusion protein successfully induced T-cell 
and antibody rcsponses in miee (Obregon et a!.. 2()06). While using protein subunits is a 
sakr approach than live-attenuated vaccines and viral vectors. a major dra\\back of these 
\ accinl's is (he large quantities of the antigen required to elicit a responsc. In many cascs 
adiLl\ants must be uscd to enhance effects. making this a potentially expensivc alternativc 
(:\abcl. 20()2: Noad and Roy. 2003). However. new types of subunit vaccines using 
particulatc antigcns (such as immunostimulating complexes. \'irosomes and YLPs) have 
becn sh()\\n to elicit effcctive adaptive immune responses using smaller quantities of 
\accine (lkml et a!.. 200S: Doan et al.. 200S). 
1.5.3 Gag YLPs 
\'LPs are an attractive option for use as IIIY-I vaccines for several reasons. Firstly. they 
arc analogous in sizc and morphology to immature I-IIY-I \iral particles. but without the 
R:\/\ genome (Yao ct a!.. 20(3). This makes them non-infcctious and therefore sare to 
usc in repeated applications. Secondly. they arc readily taken up into APCs. hence are 
able to stimulate strong CTL and anti-IllY antibody responses (Nabcl. 2002; Noad and 
Roy. 2()():I). Thirdly. they arc stable. replication-deficient and can be produced in large 
quantities (Noad and Roy. 2003). 
Ihc gag gene product. PrSS gag• whcn expressed from an appropriate construct. IS 
translated \\ithin the cytoplasm of thc host cell and targetcd to the plasma membrane 
\\herc it accumulatcs (Flint et a!.. 1999; Yoshizawa et al.. 200}). It then buds out of the 
cell in (hc !'l)J"Jll ofVLPs (Fig. 1.3) (Deml et al.. 200S). Upon release hom the cell. VLPs 
arc cl1\elopcd in a lipid bilayer derived hom the host cell mcmbranc. A number of 
cukaryotic ccllular cxpression systems havc bcen utilizcd to express IIIV VLPs in this 
\\ay I'm \ accinc production purposes (Doan et a!.. 200S). 
!, 5, 3,1. Ga'?, I LP nprcssioll S1'stcms 
Onc of the most commonly used viral expressIon systems utilized for Gag VLP 











anJ Ro l _ 200~). It mak~< U'~ of flw b~culo\;rllsc·'. Alliogrophu ca/itor/lim nlLLiliple 
n"clear r"lyh~Jn"i, \lrus (Ad,II\PV) or n()mhn mOrl (silkworm) nuckar pollhc,jrosi, 
\lrll> IBml\I'V) (Ciioc(lllRI .. 2(~ll) . Ihe b,culmit'l" c,prcssion syskm ~lIo\\s for th" 
production of brg~ ammLllls of VI f's in hosi in"",! cel l •. I hc'c cd ls CJtl b<; cu l1urcd 
without mammaliall-d~riwd 'uppkmenl '. dccrea.ing the jXlssibility of opportlln;,tl c 
hlll1l~n pathogen cunlamina11011. IbclLlo\irnse< also ha\c a rcslnctcn h()sl range (tl<> 
h.1llnl"u! dt,:c[ on human<] hut are LlslLaily chemically illaclj\alcJ at'kr the V[.P 
pnxluc1irm proc~s> (''load ~nd Roy. 2(03). In,,,c'\ n-lI, ~rl' ~b() ~~'Y to hamlle arrl are 
inlCctc'<J at a high lll"lilplicity of l"kelion [~10I}. making II", exrr~ssi()n system very 
Ilsd'u I to gcneral~ h igil yidds or r~comhi n"nl prOl~ins. H 0\' ~v"r, one of lhe drawhac h of 
prOOucing rccolllio,nmlf prokins " , i"'1X1 c"lI, is lhal lh,,} havc d;ff~rt>I11 glyco,ylalio" 
p~lterns \0 Ifiose of 1\1~l\1l\1alian ccll" h is unck~r "hclhn 1llls is a probkm yd. ~, l h~ 
role of glycosylallol1 ,aries tor diffcrent proteins. and is t h~rd'orc' (kp"ndUH on lh~ 
nalure or prol~i"tha l is he'mg c·~pr~s,~J. 
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Vaccilli<l 'tfUS rccombinmltS hnvc als(\ been used 1(\ proJuceG~g VLPs in Ilep2 ''';.] TK. 
14~1l cd l ~ (llumJn Il -ce ll 'j (Doan d aL 2005: YOlLng el aL. 2(~)(J). Ih i, expr""ion 
'y'l~m Us", "ild typc' ,ac'nnla "rus (VV) to ,nfect cdls. "hich arc lh,'n Iran<feckd w;lh 
a plasmid e'prc"il1g the protein of ;111er~'L I h~ gene or ;nlcr~'l is illcorpomlcd HHO th~ 
,iral g~l1()lll~, and \'1.1 " ~re cons"'lu~nll Y 'lTr"tcd into th" ,upernntant (\1' cui lured cells 
(Young el al.. 2(06). Tlw \'V nl'rc:;"on sy,lem i, not ~s com mOil a< Ih~ haculo\'irlLs 
,)sl~m. kcausc il produce, lower (jag vr P yic'ld, and host cells ar~ mol'C Jiftlcult 10 











'\on-\iral \ ~ctors such as DNA plasmids have also b~en uscd to transfer the gag g~ne 
into host cclls ill \'il'O, as mcntioned previously, Furthermore. DNA \ectors have been 
uscd to npress (jag in yeast cells as well, These VLPs are surrounded by a yeast 
membrane. and bud from yeast spheroplasts (yeast cells lacking cell \\alls) (Doan et al.. 
2()():,: Sakuragi ct al.. 2(02), 
/.5,3, ') /)Cl'imliolls oLGa?, VLPs 
In addition to full length Pr55~a~ self assembling into VLPs. specific truncated forms of 
pr:':,""~ are also able to form VLPs which arc slightly smaller in size compared to the 
infectious \ irions. but have similar ultrastructure and biophysical properties (Deml et al.. 
2()():,: Doan ct al.. 2005: Luo et a\., 1992: Royer et al.. 1991: Wang. Lai. and Li, 1(98), 
[)eletions in the ('-terminal protease-encoding region including certain parts of CA 
(amino acids 2 I 1-241) and L1 (amino acids 436-471 ). can occur with I ittle effect on VLP 
i'ormation (\\ang. Lai. and Li. 1(98), In light of this. investigations ha\c been made 
nploring thc incorporation off(Jreign peptides into Gag VLPs, 
(here are t\\O types of chimaeric VLPs that have been created in recent years, Type I 
VIPs include those \vhich have foreign peptides integrated into or fused with the Gag 
polypmtein (either the truncated or full form of Pr55"a,,). \\hile type II VLPs include 
thosc which ha\c foreign peptides associating with the outer surface of the VLP (Deml et 
al.. 2()():,), 
I ype I VLPs can be subdivided into two groups, namely Type I fl'ameshitt VLPs and 
Iype I in-frame VLPs, Type I fl'ameshift: VLPs occur as a result of inserting a gene of 
interest du\\nstream of gag so that it is in the sallle frame as po!. I ranslation of the 
recombinant protein occurs through a (-I) ribosomal ti'ameshitt at the gag-pol fi'ameshift 
signal. at a frequency of about 5 (%. as would usually happen if Gag-Pol (p 1(0) was being 
translated (Deml et a\., 2005: .lacks et a\., 1(88), Therefore. the VLPs produced will carry 
the foreign protein on 5 (~) of the incorporated Gag molecules, It is beliewd that due to 
the \tm ratio of chimaerie VLPs to Gag VLPs, Type I t\'ameshift VLPs are able to 











Ihe second group o( type L Type I in-frame VLPs. ill\olve inserting a gene of interest in 
place o( non-essential components of Pr55t:ag or an in-frame fusion of the gene of interest 
to thc (,-terlllinus of a truncated form of (Jag (Deml et al.. 2005: Luo et al.. 1(92), 
Research has shO\\11 the inclusion of short polypeptides such as the gpl20 V3 loop (Luo 
ct al.. 19 l)2) into these VLPs (Wagner et al.. 1994a: Wagner et al.. 1(96). but nothing 
larger than 2()0 amino acids (Deml et al.. 20(5), 
Ihe polypeptides chosen for Type I and" VLPs are commonly derived 11'om other IIIV 
antigens. such as [11\ (highly immunogenic). Nef (early phase protein) and Pol proteins. 
so as to elicit an enhanced immune response, Both VLP types are able to stil1lulatelh and 
( 'II. responses, 
Simian immunodeficiency V1rus (SIV) Gag polyprotein precursor. Pr57t:a". also forms 
VLPs and has been studied in some detail due to the similarities between SIV and HIV- L 
the resemblance ofSIV infections in rhesus macaques to the HIV-1 infections in humans. 
and the accessibility of the macaque model to study immune responses to (Jag-based 
antigens (])oan et al.. 20(5), Furthermore. chimaeric SIV and HIV-I VLPs (known as 
SI 11\' VLPs) have been investigated to augment the immune responses elicited in non-
human primates (Notka et al.. 1(99), These VLPs contain an SIV backbone but have their 
Clll', iii! and reI' genes replaced by the respective HIV-I genes (Dale et al.. 2002: Doan et 
al.. 2(05). 
1,6 1111111unogenicity of Gag VLPs 
The rate at \\hich AIDS progresses in an individual is primarily dependent on the host 
immune response (Doan et al.. 2(05), Ideally. a IIIV vaccine should induce an immune 
response \\hich is able to protect against infection or lower the \iral load and stop the 
progression of \iral infection (Flint et al.. 19(9), Recent studies have shown that "elite 
controllers" (HIV-infected individuals who naturally control viral loads) generally 
display a more pronounced Gag-specific CD8+ I-cell response. \\hereas anti En\,-










hlrthermore. (rag VLPs appear to signitieantly stimulate cellular and humoral immune 
responses in non-human primate clinical trials. Nevertheless. there arc still se\eral areas 
oj" 111\'-1 imlllunology that are not well understood and require further clarification. 
Ihus. to de\ clop an elTeetive vaccine it is necessary to look at the Illolecular basis behind 
the immune responses in more detail. 
1.6.1 Elicited immune response 
An immune response to a viral agent IS divided into two branches. the innate (non-
spee i tic) and adapti \t.: (specific) responses (Fl int ct a!.. 1999). The innate response 
components function to immediately begin combating the infection. \\hilc also acting to 
stimulate the adapti\c immune response. Gag VLPs are able to activate the innate 
immune response by acting as danger signals and eliciting cytokine and interferon 
productIOn by dendritic cells (DCs) (Deml ct al.. 20(5). Innate immune response 
acti\ation also occurs in the presence of pathogen-associated molecular patterns 
(P.\\1/>S) such as lipopolysaccharides and nucleic acids. It is thought that the response 
elicited b~ (iag VLPs is partly due to contaminating components hom VLP preparations. 
as the most prominent VLP immune responses are those induced by yeast- and 
hacllIO\irlls-derived VLP preparations. 
While the innate immune response is an important initial defense. the adaptive response 
is necessary for \iral inl'ection eradication and long-term protection (rIint et al.. 1999). It 
is made up of t\\ 0 parts. namely the cellular and humoral responses. The induction of an 
adaptive immune response requires the presentation of antigens in MHC class I and 11-
peptide complexes (Deml et al.. 2005: Flint et al.. 1999). The interaction of a I'll-cell 
receptor \\ith the MHC class II-peptide complex. in addition to the binding of co-
receptors. acti\ateslll cells. so initiating the release of cytokines and Til-cell proliferation 
and differentiation. The cytokines that are secreted establish \\hich of the t\\O responses 
occurs. as the eytokines are responsible for CTL and 8-cell activation (Fig, 1.4) (Flint et 
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The cdl-mediated of cellular r.:spon,c primarily involves Ihe actiOTls 01" Th l cells and 
kilkr T-edls (CTLs or C08+ -I cdls). Thl cell stimulation result s in the rcica'c (lfth~ 
cyl()kifh:~ IL-2. IL-12 and IFI\--r by Thl cells, to activate CI Ls (l lim ct a1.. [<.lIN). CI I.s 
then inlcr.ld wiih the MHC class I-v iml pcpli"" c"ompb.cs on inlected ho SI cells. 
injc(.1ill g CIl7ymcs into the infected "cillo induce apuplosis. Th~ CTL response is mainl, 
responsibic for cOlltrolling the viral illfection and sllppressi ng: viraemia in 11IV-infcd~<J 
in <Ji viduals (Paliard ct al.. 2(}()()j. An illcrease ill C I Ls aoo i"h cells show all apparent 
<J~crea,c in virus loat! ;n HIV+ paticnts, c·oniirmin8 thcsc cdls· im·ol,·cmcnt in ami-HIY 
ac!;,·it)· (Chllgh and Seth. 2004: Dcml. "','ild, and \Va8n~r, 2(04). CI I.s arC also able l\> 
pr0duce cytokin~' such as IFN-"( and TI\F-o: \\hich have antiviral pro~ rt i~, aoo ar~ 
involved in blocking IllY-I entry (Cocchi et al.. 2(00) . Additionally. th~ Ihl cell 
responses that are ciicited are in>ol\·ed in prcserving an d l"cc!ivc CTL response (Chugh 
an<J Seth, 2(04). 
F>.og~nous antig~n' arc lL,ually processed alld transpol1~d to MIIC class II ntoiccllles 
(activates Th2 cells) whik endogenous antigens are displayed b} MHC class I molcc·ules 
(ac!ivates T"I c~lI~ an<J CTL rcspons~s) (D~ml d at.. 2(05). In general. (jag VLPs were 
thollght to be pr(lce,,~<J and compicxed with MIIC class II moiccules oilly. as VLPs are 











shO\\n cross-presentation of VLPs and other exogenous antigens, \']a the \1IIC class I 
patlmay in DCs. suggesting that the MHC class I and" pathways are more Ilexible than 
\vhat \vas thought (Ouan ct ai., 2005). Hencc. (jag VLPs are able to stimulate strong eTL 
and I!, cell responses ill l'i\'O because they can be processed and displayed by both MHC 
class I and II molecules. and they contain many T cell epitopes (Deml et ai., 20(5). 
Furthermore. new studies have shown that Gag VLPs are able to elicit a broad, cross-
clade ('11. response due to conserved target CrL epitopes, further demonstrating the 
promising potential of Gag as a vaccine candidate (Deml et al.. 2005: Oeml. Wild. and 
\\'agner. 2()()..J.). 
Induction of thc humoral immune response requires TI12 ccils to recogni/e an antigen-
VlllC class II molecule and secrete cytokines (Fig. 1.4) that activate B cell proliferation 
to form antibody-secreting plasma cells and memory B cells (sent to the lymphoid tissue) 
(Flint et al.. 1(99). 
(iag-only \'LPs are able to induce the production of anti-Gag antibodies. but they arc 
unable to elicit a NAb response. as has been shown in immunogenicity studies with 
rabbits and non-human primates (Deml et ai., 20()5). The function of anti-Gag antibodies 
has yet to bc determined, but there appears to be a correlation between the decrease of 
anti-(jag antibodies and the progression of A IDS (Chugh and Seth, 20(4). NAb 
stimulation is particularly important in fighting an HIV infection because it is thought to 
prmide protection against the viral infection and remove cell-frec virions from the host 
blood ('Yao et ai.. 20(3), Ho\vever, the efficiency of the Nabs' effect against IIIV is still 
unconJi rmed (Yoshiza\\ a et aI., 200 I). While some studies have demonstrated 
accelerated clearance of HIV virions in the blood of non-human primates when NAbs arc 
prcscnt. others have shown NAbs to be ineffective due to rapid viral escape, 
\:c\C!'theless. \accines that only induce eTL responses are not dtccti\e enough to 
prnent \iral escape either (Mceiettigan et al.. 200.3), Thus a combination of both ('IL 










1.6.2 Enhancement of the immune response 
,\Ithough there have been several attempts to develop the ideal IIIV \accine. there have 
been a number of drawbacks due to ineffective immune responses and the ability of IIIV 
tll a\oid elimination by the immune system. To enhance the initial immune response 
elicited by (iag antigens. a fC\\ strategies have been explored . 
. \djLl\ants ha\'e been used in conjunction \vith some potential HIV vaccines to improve 
the immune system induction of Gag VLPs and that of other sub-unit vaccines 
(HUonagurll ct al.. 2007: Doan et al.. 2005). One of the more successful adjuvants has 
been the cholera toxin (CT). which has enhanced immune responses quite dramatically in 
animal models. Ilowever. CT has a high level of toxicity and cannot be used in humans 
(( iuo et al.. 2()O~). Several other adjuvants are now being investigated to augment 
Immune responses. including hemagglutinin (the intluenza \irus surface glycoprotein). 
pro-intlammatory cytokines and co-stimulatory molecules (Young and Ross. 20(3). 
I p,.\ sequence modifications such as codon optimisation and removal of cis-acting 
inhibitory sequences has also been suggested as a method to elevate the immune response 
elicited by (jag. through increasing the level of protein expression (Leung et al.. 2004: 
Y llung and Ross. 20(3). Genes that have been codon optimised for mammalian 
expression systems havc demonstrated enhanced protein expression and stronger immune 
respllnses (/tlr Megede et al.. 2000. Leung et al.. 2(04). 
\'aeeine immuniLation strategies have proven to affect the immune response elicited as 
\\ell. Studies ha\e found that prime-boost strategies are the most effective in stimulating 
strong cellular and humoral responses (Amara et al.. 20(5). Thesc make usc of DNA to 
prime the immune response. and a live-attenuated viral \'ector to boost the initial response 
(Smith ct al.. 2()04). Alternatively. subunit or VLP vaccines could be used as boosting 
ellmpllnents. Some of the most common prime-boost systems are based on the use of 
recombinant pox \iruses such as MV A as a booster (Gherardi et al.. 2()04). A recent study 
using (jag-Pol-Em DNA (to prime) and \1\,\ Itll bu()st) has shlmn that this is a very 











hcn tllllugh somc \aCCllles have successfully induced potent immune responses in 
animal ll1odels. the de\elopment of CTL escape mutants remains a major problem 
(.\lcami et al.. 20()5). These escape mutants are the result of mutations in critical viral 
residues. \\hich can mask the virus so that it is virtually undetectable to the immune 
system. To ()\ercome this drawback. a vaccine nccds to target as many ('IL cpitopes as 
possible. in order to elicit a broad, efTective eTl response. Thus. as mentioned 
pre\ioLlsly. the use of foreign epitopes inserted, fused (found in type I YLPs) or attached 
(found in type I I YLPs) to the Gag YLP have been explored in some detail (Deml et aI., 
2()()5). Research has shmvn the use of a variety of different combinations making up 
recombinant YLP immLlnogens, many of \vhich stimulate an increased immune response 
compared to naked Gag YLPs. Foreign epitopes han~ included gp 160. V3 (the third 
\ariable of IllY-I gp 120) and CD4BR (CD4-binding region of HIY -I gp 120) to name a 
IC\\, :\on-structural proteins from the early phase of the HIY life cycle such as Tat, Nef 
and Re\ ha\e also been incorporated into Gag YLPs (A1cami et a1.. 2005). Buonaguro c/ 
iI/. (Buonaguro et a!.. 2(02) successfully produced HIY -I A YLPs which packaged gp 
12() and \\ ere able to elicit strong cellular and humoral immune responses. This 
delllonstrated the ability of chimaeric Gag YLPs to enhance an immune response quite 
signiticantly, 
,\nothcr aspect considered to be very important in combating HIY is the induction of a 
Illucosal imlllune response. Systemic immunity is considered to provide the primary 
source or protection against a viral infection (Flint et a1.. 1999). hO\\eyer. in the case of 
111\'. Illllcosal immunity is essential for preventing transmission and enhancing viral 
infection control (Doan et a1.. 2005; Yoshizawa et a1.. 2001). The mucosal immune 
response is stimulated by exposure of immunogens at mucosal sites (Gherardi et a!., 
2()()4 ). Lymphoid tissues exist below the mucosal membranes in the digestive, 
respiratory and genito-urinary tracts (aka the mucosa-associated lymphoid tissue system-
\1.\LT), This system contains cells which carry 8 and CD4 T-Iymphocytcs (Flint et al.. 
I ()l)l); Ciherardi et a!.. 20(4). These lymphocytes secrete the antibody Ig A (responsible 
for pre\enting \iral attachment and also believed to neutralise HIY-I) (Guo ct al.. 20(3) 











\\here an immune response can be elicited (Gherardi et al.. 20(4). Although the immune 
respunses elicited are weaker than systemic responses. mucosal \accination provides 
additional protection and also allows the vaccine candidate to O\ercome drawbacks of 
intra\enllUS immuni/atioll (such as pre-existing systemic immunity or sclective systemic 
Illllllunllsuppression). The site of mucosal immunization appears to playa large role in 
the extent of protection provided. Intranasal. intraperitoneaL intrarcctal and intravaginal 
immuni7ations have been investigated. although intranasal immunization in mice has 
been found to be the best way to induce genital antibody responses (Gherardi et al.. 
2004 ). 
1.7 Drawbacks of Gag VLPs in vaccines 
In spite or the extensi\e research currently exploring the use of Gag VLPs for vaccine 
purposes. there are some disadvantages of VLPs which need to be considered (Doan et 
al.. 20U)). To begin with. the production of purified. emcloped VLPs has been a problem 
because it is difficult to find an expression system that is able to produce these complex 
particles \\ith all the correct specifications (i.e. purity. yields. post-translational 
modilications). While the systems mentioned have performed more than adequately. each 
has its dra\\back. Also of some concern. is that Gag VLPs are able to associate with and 
incorporate random RNA material (in the absence of gcnomic RNA) from thc cells they 
are c:\pressed in (Khorchid et al.. 20(2). This is limited quite successfully by the removal 
or the ¢-sitc upstream of gag. which prevents nucleic acid binding to NC and reduces 
R!\.\ content or VLPs by approximately 95 (1<) (Persson et al.. 19(8). However. it is 
something to be aware of when using these VLPs as \accines for use in humans. In terms 
ur their potential as vaccines. VLPs have induced immune responses that are strong. but 
still \\eaker than those of replicating vectors. It is possible that due to the resemblance of 
the YLP structure to infectious virions. they might be inducing similar non-protective 
Immune responses. but this remains to be established. Hence. further research is 











1.8 Conclusions and study obiectives 
(hcralL thc ability of Gag antigens and particularly VLPs to stimulate the Immune 
systcm has allO\\ed for the exploration of various ways to optimize HIV-I vaCCll1e 
dcsign. Ho\\ C\cr. \\hile many attempts have had success in small animal models. testing 
these \ accines in humans could still render disappointing results due to differences in 
animal and human immune systems. Thus. further research is necessary to produce an 
cllecti\ e I [[\. -I \accine that ean induce broad. long-lived CTL and Til cell responses, and 
potent neutrali/ing and anti-HIV -I antibody responses (Deml et aL 200S). 
[n an attempt to make a novel HIV-I vaccine, previous work in our laboratories resulted 
III the dcn:lopmcnt oi' the multigene IIIV-I DNA vaccine candidate. pTIIr.grttnC 
(Burgers ct aL lOO()). This vaccine design was based on IIIV-I subtype C. the primary 
subtype i'oulld in sub-Saharan Africa. It encodes a polyprotein (1224 amino acids) 
consisting of the H IV -I proteins p6-truncated non-myristylated Gag. reverse transcriptase 
(R[). shul"lkd Tat and truncated NeL all of which were inactivated for safety purposes as 
described pre\iously (Burgers et al.. 2006). In mouse immunogenicity studies. 
p II [r.grttnC \\as able to elicit significantly broad. strong cellular immune responses 
against several of the IIIV proteins present, making it a promising \accine candidate 
(Burgers et al.. 20(6). In view of this and the heightened cellular immune responses 
induced in miCl~ \vhen II IV -I Gag VLPs were used to boost a pTHgagC DNA vaccine 
(JaITra) et aL 2(04). several chimaeric HIV VLP DNA constructs were designed as 
possible 'boosts' to complement the pTHr.grttnC DNA \accine (Halsey et al.). These 
\"LP constructs encoded Type I in-frame VLPs comprised of either full length PrSS"ag or 
ph-truncated (jag (PrSO,,!<Ii!) fused to a functionally inactivated TatNei' fusion protein, 
inacti\ated RT or a RT-Tat-Nef fusion protein. 
Initially. the respective chimaeric VLPs were detectable when expressed in insect cells, 
hut \\crc not produced in sufficient quantities to properly explore their immunogenic 
charactcristics. and thus their ability to elicit an effective anti-HIV immune response. in 
mouse studies. The objectives of this study were to optimise the production of selected 











ability of these \'LPs to boost an immune response in mice, Two of the ehimaeric VLP 
constructs created \\cre selected for immunogenicity testing in mice. These constructs 
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Due to the gnl\\l11g utili/ation of IllY -I YLPs 111 vaccl11e strategies. there has been a 
!,!reat need to express YLPs in large amounts. Recent research has examined several 
expression systems: hO\\ever. the baeulovirus-insect cell system has prO\ed to be the 
most generally useful (Doan et al.. 2(05). 
2.1.1 Bacuilnirus Expression Vector System (BEVS) 
RaculO\iruses are a diverse group of double-stranded DNA viruses that intCct insects. 
particularly of the order I~cpid()p/cra (.Iorio. Tran. and Kamen. 2006; O'Reilly. 1994). The 
haculovirus virion consists of a rod-like protein capsid. approximately 200-400 nm in 
length. encasing a core. The core comprises of the condensed genome (RO- 200 kbp) 
associated \\ith the protein. YPI2 (O'Reilly. 1994). The capsid and core are collectively 
retCrred to as a nucleocapsid. and acquires an envelope once it buds from the plasma 
membrane of infected insect cells. 
When they \\ere first discovered. baeuloviruses \\ere found to be \lTV useful as 
biopesticides. although in recent years they have been far more useful as versatile 
expression vectors (.Iorio. Tran. and Kamen. 20(6). Two of the most commonly used 
baculO\irus \eetors include Autograpllo cali/arnica M (multiply-embedded) nuclear 
polyhedrosis \'irus (AcMNPY) and Bonzh"x nzori nuclear polyhedrosis virus (BmNPY). 
1 hey have been used to express a number of recombinant proteins in insect cells. given 
their host specificity. potential for scaling up protein production. and high-level 
expression of complex proteins (Hunt, 2005; Kost. Condreay. and Janis. 2(0)). 
lhe Raculo\irus Expression Vector System (BEYS) uses recombinant baculovirus to 
express heterologous proteins via the infection of insect cells (GibcoBRL 2001: Hunt. 
2()())), A recombinant baculovirus is created by replacing the non-essential polyhedron 
gene in \vildtype baculovirus vvith a gene of interest. The most widely used system to 
create the recombinant baculovirus is the commercial Bac-to-Bac I \1 system. which uses 











Fco/i cells (method detailed in Appendix A I). Upon infection of insect cells by the 
recombinant baculo\'irus, the gene of interest is expressed instead of the polyhedron gene, 
thus creating recombinant baculovirus virions (late phase of infection) and large amounts 
nf the recom bi nant protei n (very late phase of infection). 
lhe 81·\'S has been particularly useful for the production of VLPs, given the complexity 
uf \TP formation. The system's ability to perform eukaryotic protein processing and 
post-translational modification (such as signal cleavage. phosphorylation. amidation and 
myristylation) has allowed research to investigate virion assembly processes in the 
absence of live \irus, and has allowed the production of numerous VLP antigens for 
immuni/ation purposes (Jlun!, 2005: Kost, Condreay. and Janis. 2(05). Some of these 
antigens include human papillomavirus VLPs, severe acute respiratory syndrome (SARS) 
VLPs and hepatitis C VlPs (Kost, ('ondreay, and Janis, 2005). 
In this study. the BEVS was used to produce large quantities of chimaeric 1I1V VLPs for 
illllllunogenieity studies. Recombinant baculovirus stocks \\ere amplified to 
al'ConlllHlLiate optimi/ation experiments, as well as bulk VlP production for the mouse 
imlllunological studies. 
2.1.2 Chimaeric Gag VLPs 
Ihe 1\\0 IIIV ehimaeric constructs chosen for optimization in this study were GagRT and 
(jag!'" (Fig. 2.1). They were chosen because Nee Gag and RT were all previously 
identilied as primary target regions for T-cell recognition in HIV-infected individuals in 
southern Africa (Masemola et aI., 2004). This means they contain eTl epitopes that 
\\ould be important to include in a multigene vaccine attempting to elicit a potent cellular 
immune response. In addition. RT, Tat and Nef are all non-structural proteins produced in 
the early phase of the \iral life cycle (luciw. 1(96). Thus. their usc in a prophylactic 
\accine could stimulate an immune response that contributes to eliminating IIIV in the 












."igu,", 2.1 - Cbim"o,i, (jog c~Il"n"'ts u«'d in thi , >lOOy_ (.j GagTN COn,,,,,,,l - ph"lIl'c Ilu.1 voW..- (><c 
APr<ndi, A:OJ ,,;tl1 hum . niLcd. m~ri"'~I .. <d Ga~TN (HM&agTN) in .. " (}'e ll ow :lIT",,), (h) G.gRI 
con,,,,,,,l - pF"-"ll." Du.l ,'cC!"," wi,h huonallizeJ, on,ri<1ylaled G,gRT (HMl."'~RT) in""i (blu< arrow), 
B la<;~ boxe> ,,,<.lie,.. . anl,I>jOlic re.,iSl.nce g""'_'. Amri(;illin lAmp) .lId Genlamy.ill (0m). 
Furthermore. each of the accessory proteins coosen to "reate (he chimaeric VLI', have an 
essential function for virJI propJgalion, ,0 targeting cells expressing tiler" could 
potentially cripple an HIV infeclion (Hel el uL, 2002). RT j, a ,-ital enzyme "rtile 11iV 
ILli.: cycle u,cd {() generate IllY DNA from the RNA genome (Luciw, 19%). It di,piays 
reiuli,'d)' low >eqllCncc 'Miability and strong immunogen i~ ity Juring nutmal Iniectioll>. 
m~king il ~n LmpmtalH ~llIigcn to con,idcr j'lr viml conwinmcill (Pacheco el ul.. 2(00). 
"ef is an J""e>wry protein thJt J<>wnregulate, CD4 and MHC class I c:l.pression of 
inlected cell5. influen"es T-cell ;lCtivJtion Jnd enh~nc~, virion Lnlecl,,-ily (Hd Cl al.. 
2002; SCrlnu Cl al.. 2005]. It is kno\\n to indoce strong CTL response>. despite it> 
"'~lLcnec vmiahility. lilcrcforc making ;1 a very useful lmgcl for vaccine purpose~ (Betts. 
yu,im, unJ Koup. 2(02). On lhc other hand. Tal is ill\olvcd in tile upregulJtion of 
('hemoline receptor expre>sion ~nJ TNF-[1 o,-cl1'roJlIction ulllong many othcr ""pectcd 
functions (Scriba el al.. 2(05). It 11ft> ft beller "onserv~d ~quen~e than the nefg~nc, hUI 
d,.:, not cOlHain Cp,lOpc, that slimulalc dorninam imlllune rCSp<:>ilses (RamnkrisfMw el ~l .. 
2()()4. Scrinu el al.. 2005). Hcnce. the Tal and '\Ief protein, arc fused togcthcr in lhc 
vu~~ine LOn>trucl chosen, 10 complement ~:.>Ch olner. 
Thc ollC major dru" buck of w,ill g :.>Ccc"ory prolc ,ns slIch as IIlc,c tor, ucc inc purPO'>CS is 
the i~>uc oj" saldy, as the u,e oj" Ihe'>C protein, in pas( ,tlidic, hlls proven IClilul (Hd ct al.. 











:.11.). Hriefly. the RT active site was mutated (YMDDL -:> YMA.\'L) to induce 
Illal"ti\atioll. three essential gene regions of Tat \\en~ shuffled in such a way as to 
prcc>el"\ e :.111 potential epitopes but inhibit functionality. and Nef \\as inactivated by the 
remo\al of3() base pairs (bp) at the 5'-end. 
2.1.3 Quantification methods of recombinant baculO\irus 
I'or ma>;imum and enicient protein production using HEVS. it is important to optimizc 
the system accordingly (Janakiraman et al.. 2(06). To do this. it is necessary to know the 
conccntration of infectious recombinant baculovirus particles in \irus stocks. Two of the 
most common methods to quantify viral titres were chosen for this study. namely plaque 
assays and iissue Culture Infectious Dose 50 (TCID~II) assays. 
Plaque assays imolve infecting insect cells with the recombinant baculovirus and then 
monitoring the lysis activity (demonstrated by the formation of plaques) of those cells 
infected (O'Reilly. 1994). By counting the number of plaques for a given virus dilution, 
the concentration of the initial viral stock can be determined. On the other hand. Tell):i,l 
assays (also kJ1(mn as end-point dilution assays) invoh'e the infection of several insect 
cultures using di fferent dilutions of virus. The viral titre is then estimated by determining 
\\ hich dilution of the \irus infccts 5mli) of the cultures initially inoculated. While both 
methods ha\ e demonstrated success. both have drawbacks. Thus. it \\ill be important to 
compare the assay results' to obtain a better indication of what the true viral titre is. 
2.1 A Chapter objectives 
Ihe aims ufthe work reported in this chapter were as foIIO\\s: 
(i) I u produce large quantities of recombinant baculovirus stocks express1l1g 
CiagRT and CiagTN for use in optimization experiments. 
(ii) 10 verify the content and integrity of the previously created recombinant 
Acl\1l\PV (rAcMNPV) constructs after amplification of baculovirus stocks 
using PCR and DNA sequencing. 










2.2 \1aterials and Methods 
2.2.1 Insect cell culture 
\jJod!J/J/('/'(/ ji"lIgipcrc/a (Sf) 21 cells (Invitrogen) were used for the production of all 
baculmirus stocks. They \vere grown in tissue culture (TC) -100 insect medium (Sigma) 
supplcmented \\ith: 10°'0 (\/v) foetal bovine serum (FBS, containing up to SO mg/ml 
serum proteins) ((iibco). SO flg/ml neomycin. 69.2 flgiml penicillin Ci and 100 flg/ml 
streptomycin. Cells were grown in monolayer culture in sterile tissue culture Ilasks. and 
kept at a constant temperature of 2rc. Cells were maintained by seeding mid-log cells at 
:=;~ I ()' cells ml e\ery ~-4 days. as detailed by the supplier (Imitrogen. 2002). 
2.2.1.1 \1casurement of cell viability 
Insect cell \ iability was measured at regular intervals to confirm that cells were 
maintaining a healthy doubling rate and were not under unnecessary stress. This was 
done by staining cells (90 ~d) with Tryptan Blue (I 0 ~tl). and placing them into a 
\i eubauer counting chamber. The number of total cells and dead cells (cells that absorbed 
the blue stain) \vas counted in the four squares surrounding the central chamber. and an 
a\erage count \vas obtained. The percentagc of living cells was determincd using thc 
1'0110\\ ing calculation: 
('\0. ortotal cells· no. ordead cells) x 100 
No of total cells 
(Xl cell \iabil ity 
2.2.2 Amplification of recombinant baculovirus stocks 
2.2.2.1 Plaque purification 
Recombinant bacmid DNA carrying chimaeric Gag constructs (GagRT and CJagTN) and 
the respecti\e recombinant baculovirus first and second supernatants. were kindly 
prm ided by 1\1r. R.l Ilaisey (MCB. UCI). The baculO\'irus vector used to create 
recombinants \\as AcMNPY (method described in Appendix A I). Plaque purification 











()'Reilly et al (O'Reilly. 1(94). This was done to isolate pure recombinant baculmirus for 
amplification puq)oses. 
2.2.2.2 rAc\INPVamplification 
Puritied virus from plaque purification ,vas used (SO() ~tl) to infect 2xlOil 5j21 cells in a 
sterile 2-ml TC well. Infected cells wcre incubated at 27 DC for 4 days before the 
supernatant \\as harvested (Passage I). This process was repeated to create Passage 2 
using 2 1111s of Passage I as the inCcetant, and infecting Ixl0' S(21 cells in sterile TC 
tlasks. Passage I and 2 \vere stored at 4 dc. 
2.2.3 \"eritication of recombinant baculovirus constructs 
2.2.,\.1 S[)S-P:\(JL and western blotting 
All butTers used for SDS-PAGE and western blots are detailed in Appendix B2. Sample 
loading butTer (5X) was added to samples of Passage I and 2 of the respective rAcMNPV 
stocks in a 1:5 ratio. The samples were then incubated at 90 DC for 5 min to lyse cells and 
denature protein. after \\hich they underwent sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SOS-PAGE) (at constant current) on a 10 % SDS-polyacrylamide gel 
(Sal11brook. Fritsch, and Maniatis, 19~N), in order to separate proteins on the basis of 
molecular \\eight. 
()nce separated. \\estern blotting \vas performed \\hereby proteins from the respective 
samples \\cre transtCrred from the SOS-polyacrylamide gel onto nylon membrane using a 
Trans Blot' semi-dry transfer cell (Bio-Rad) and Ix transfer buffer. The conditions used 
for transfer \\ere as follows: 400 mA, 15 V. 90 min. Membrane was then incubated in 
hlocking butTer for 30 min, and a 1 :2000 dilution of Gag p24 polyclonal primary 
antibody (Appendix D) (Reid) in blocking butTer overnight. It was subsequently washed 
three times for 15 min using washing buffer, then incubated in a I :50()() dilution of Goat 
anti-rabbit Ig (i secondary antibody (Appendix 0) in blocking bulTer for I hr. A second 
set of \\ashes followed this. and then Gag protein bands were visualized using Nitro blue 










i\1cmbrane \\as rinsed with \vater alter 30 min to stop visual de\Tlopment reaction. rhe 
positiweontrol used \\as I-IIV-I 8 Pr55~a"(Appendix D) 
2.2.J.2 L\e\\\:PY DNA extraction 
Passage.2 (5()O ~ll) and DNA extraction buffer (Appendix 84) were combined in equal 
amounts and incubated at 95°C for 10 min with agitation. The mixture was then 
incubated on ice for 2 min before being centrifuged at 2000 x g for I () min. Resulting 
supernatant \\as removed. treated with 100 ,llgiml of RNAse A. precipitated \\ith o.() 
\olumes of ice-cold isopropanol and further centrifuged at 2000 x g for 10 min. Sterile 
\\atn (I()() pI) \\as used to resuspend the pellet. and the resulting suspension was heated 
to CJS 0(' for S min. The sample was re-precipitated with 2 volumes of 95 % of ethanol 
and ().I \olume of sodium acetate. and incubated at -20°C for 2 hrs. It was thcn 
centrifuged at 2000 x g for 10 min. and the pellet finally rcsuspended in 10 ~tl elution 
buller. 
2.2.J.3 Polymerase Chain Reaction (PCR) 
peR \\as used to eontirm that the genes of interest were present in the respective 
constructs. Primers \\cre designed to amplify the gag gene. fused (a{lIclUII) gene and the 
r{ gene in the respective constructs (Table 2.1). 
Table 2.1 Primers used tlw thc PCR amplitication of/III/gage {({{lIeland rt genes 
- - ---
Name of Sequence Orientation 
prImer 
II\I(j\(jl S' A TGGACGGCCCCAAGGTGAAGC 3' 
1l\I(j-\GR S' AIT(TTGGCTGA(j(j(jGGTCG( 3' Rc\ ersc 
(i\(iT,\1 S' CAICiGTCATCAejCTAC(i-,' 
(i\(iT,\R :'" ICl\(jTCCTTGTAGTACTCGCi 3' Rc\ erse 
(i\(iRTF S' CATGGGTGCTCGCGCA TCTATC -,' 
(i.\GRTR S' CiATTCGAAAGCGGCCGCTGTTC-,' Re\ crsc 
lhree PCRs \\cre carricd out with the primcr pairs I-IMGAGF!I IMGAGR (gag gene). 











5() fll contained 5 fll extracted rAcMNPV DNA. 10 pmol of the necessary primers. lOX 
laq polymerase buffer. O.2S mM dNTPs. 0.5 units SuperTherm Taq polymerase 
(Southern (ross Biotechnology) and sterile distilled 11 20. The HMCiag and RT reactions 
required 1.5 m:\1 Mg( '1 2• while the TN reactions required 2.0 mM MgCI> The PCR 
:lmplilic:ltion cycle profile consisted or 1 cycle 01'94 "C for 3 min. 30 cycles 01'94 °C (30 
sec each). 55°C (except for TN .. used 50°C) (0.5 min each). 72 °C (40 sec each) and 1 
cycle of 72 "C (5 min). Origin:ll recombinant bacmid DNAs \\Cre used as the positive 
P( OR controls for each reaction to confirm that the experimental PCR products were the 
correct si/e (kindly pro\'ided by Mr. R.J. Halsey. MCB. UCT). The negative control 
contained sterile \vater in place of the template DNA. Thc resulting PCR products were 
run on a ().~ () () :lgarose gel at 100 V for I hr. 
2.2._~.4 Subcloning 
The P( OR products \\ere gel extracted (Qiagen gel extraction kit) and cloned into pGem "-
I Las\' vectors (Promega) according to the manufacturer's instructions (Promega. 1996-
1 l)l)l)). Ihe resulting plasmids were then transformed into competent E.coli DH5o: cells 
and gJ"(m n on Luria-Bertani agar (LA) medium \vith ampicillin. X-gal and isopropyl-
thiogabctoside (IPTG) (Appendix B 1). Blue-white colony selection \yas Llsed to identify 
recombinant p(iEM-T Easy clones. Clones were confirmed to be carrying the gene of 
interest via restriction endonuclease (R.E.) digestion using EcoRI. Selected clones \vere 
sequenced (l'CT sequencing unit) using M 13 forward and reverse primers to verify that 
the genes or interest \\ere intact after rAcMNPV amplification. 
2.2A Quantification of recombinant baculovirus stock 
2.2.4.1 Plaque Assays 
lnder sterile cunditions. Sl21 cells (cell density: 1.5xl0(, cells1ml) were seeded into the 
desired Ilumber of TC ()-well plates (2 ml each). and \Vere left to attach for 4S min. A 
luglll dilution series of Passage 2 (I O-.J I cr')) \yas prepared using TC-I O() medium. The 
medium \\as removed from each well and replaced sequentially with I ml or the diluted 











the inkctant \\as removed, and wells were overlaid \vith 3 ml Plaquing mIx [Graces 
Insect Plaquing medium (Ciibco). 4 %l SeaPlaque Agarose (Adcock Ingram) and \vater in 
a 2:1:1 ratin]. Cells were stained 4 days post infection (dpi) with 100 flgiml Neutral red 
dye (Sigma) for 5 hrs. The dye was then removed and the cells incubated ror another day 
at 27 (. bcrore plaques \\ere counted. 
2.2.-L2 TCI[)';II assays 
l'ndcr .-;tcrile conditions. Sf21 cells (cell density: 1.5xlO<' cells/ml) were seeded in each 
\\ clioI' a tlat-bottomed l)() well IC plate using a Pasteur pipette, and were left to settle for 
-1-5 min. A logl!! dilution series of Passage 2 ()(r~ - 1O-1~) \vas prepared using TC-IO() 
medium. and each dilution \\as designated a rO\v (8 wells) of the Te plate. Fifty ~t1 of the 
appropriate dilution was then added to each well in the respective ro\\'o One row was 
designated the negative control (TC 100 medium added instead of infectant). After 10 
da\s. each \\ ell \\as studied to determine ir it was infected or not. The TCIO.;!) of the 
assay \\as calculated using the Karber formula (O'Reilly, 1994), and inrectivity of the 
\iral stock \\as calculated using the follmving equation: 
Inkcti\ity (pfu ml) = 0.69 X TCID s() (Dee and Shuler. 1997). 
2.3 Results 
2.3.1 Verification of recombinant bacuIovirus constructs 
Recombinant baculovirus stocks for the chimaeric VLP constructs, GagRT and GagTN, 
\\cre amplified ror optimization experiment purposes. Approximately 100 ml of each 
\irus stock \\as produced and stored at 4 dc. Western blots were used to confilm that the 
appropriate chimaeric proteins were produced by the respective baculovirus stocks (Fig. 
2.2). 80th (jagRT and GagTN proteins were detected in the respective stocks, and 
appeared in greater quantities in the amplified stocks than in the initial stocks. as would 
be expected. It is important to note. that as has been seen in pre\'ious work, both 
chimaeric \'LPs had a tendency to migrate slower than what would be expected for their 











aLl. This is poss ibly re lated 10 theil' particulate strudure. "hi~h ma\ onh denalllr~ 
partially after boiling. 
CI.,.d,ed Gag products. pN and p41 proteins were also present in the , tocks. suggesting 
Ihat there" as some j{)rm or proteo lytic pmc~s,ing of the ch i maeric VLPs. This is further 
wP lX' ncd by pr~\'ious s1\ldics which showed Gag cleavage product> su~h as p49 ('vIA-
CA-p2-NC). p41 (MA-CA). p25 (CA-r2) and p24 (CA) were present in ins.cct ce lts 
exp",,,ing PrS5""" (Wagne, Cl aI. , 1996). It has b~~n suggested that proteolytic cleavage 
OCClLrs du~ 10 parl ia l degradat ion ,,,,curring insi d~ and ()u!si d~ the in,eel cells caused b~' 
inse<:t and baculovinls proteas.cs (eru? ct al.. 1999). Although this is not idedi, lh~ 
chimacric prOl.eins w~r~ the most prominentl y detected in the respect ive samplcs, fu rt lJ.,,. 
'lLggesling thal prok olylic deavage was onl}' partial. 
,~ M , • tVC KT, TN, "T. Th, 
'" I ~)- ~ ( ; .. " ~ (;.,,'" 
" 
" ,, -
, - - - , ..- -
" - -
.-i~ " r. 2.2 W 0<10'" blot ' afte.. ... cambi nan( b,1Cu lo\ iru, ' tack, to he "<ed foe opt imimt ioll experimen" 
Memnrar"" were prohed "i,n p24"I""i fi c anti se rum , Arm", ( _ ) ilKiioate ,ne chimaoric pr<~e i n 
b~l"k Arru\\)"" d, ( ~ ilKiica' c '''pcmalon, band, oom.';.pund illg to (j"g p41 alld p24 r",poc1i,dy. 
,\bbre, ialiun;, M ' rKJl.C"lJI", ", e iglll marl"" f Pr5 S'" ( I I, . cor~rol),· i .. - "i ld,ype b""" lo, iru,· i,e 
control; RT, - GagRT inkct,n, hc·~>rC ,m pl ili co,io l1: Th. - G'gT'-' inf"cton' net",e amp lili c"!;,,,,, Rl, -
(j"~RT illfeC"lJLlll an", amp lil icaliull: Tr-. l_ (jogT\ iIlf.C"UlIl! after omp lilical iull, ~ ~I of · i.e c'Or~rol, olld 
401,1 of .11 OIhu <ample, w., lo:>dorl;n eoch 1:>11 0_ 
It is interesti ng: to nO(e that toc in(cnsity of (he GagR I band is mllCh less than tha( of the 
Gag!"1'\. !"h is suggest" that the inscc( cdls seem 10 produce less GagK I than (jag'l N.1l is 











cun~trllcts. a~ CiagRT (lOS kD) is larger than GagTN (02 kD). h()\\cyer further 
nperimentation is needed to verify this. 
It \\as necessary to confirm that the integrity of the recombinant gene sequences had 
remai ned intact after bacu Imi rus stock amp Ii tication was done. To veri fy the integrity 0 f 
the recombinant constructs in the amplified stocks. PCR and sequencing ufthe respectiYe 
gene~ \\as performed. Due to the large size of the full recombinant genes (GagRT - 2.SS4 
kb. (iagTl\ 2.443 kb). sequence verification had to he done on thc separate components 
of the recomhinant genes rather than the full genes. Thus. the PCR \\as performed using 
primers complimentary to the end DNA sequences of gag. n. and III genes respectively 
(Iahk 2.1 ). 
As e:\pected. the PCR results confirmed that both constructs contained a gog gene of 
appro"imately I.~ kb (Figure 2.3a). The GagRT construct contained an RT fragment of 
appro:\imately 1.3 kb and the GagTN construct contained a TN fragment of 
appro:\imately 0.9 kh (Figure 2.3b). No amplitication occurred when using the 
bantimirlls in!'cctant stocks directly (without e:\tracting DNA). This appears to be a 
di tlintit !'cat. and possibly requires the PCR to be optimi7ed further. After PCR 
\erilication. the resulting PCR products were purified using a gel extraction kit (Qiagen) 
and cloned into pGem"-T Easy vectors (Promega) in order to sequence the genes of 
interest. The sequencing results (Appendix C) veri tied that the correct gene sequences 
\\ere prescnt. \\ith no mutations or truncations obsened. 
Once the integrities of the constructs were verified. the recombinant baculovirus stocks 
\\ere quantified to determine the viral titre. This was done for two rcasons. First. 
amplification of recombinant baclliovirlls stocks can result in the accumulation of mutant 
yirlls or defectin? yirion particles (O'Reilly. 1904). This decreases the infecti\ity of the 
haclIlu\irlls stock as well as its ahility to express the recombinant protein in insect cells. 
Ilws. mcasuring the yiral titre provides a good indication of the concentration of 










thc expression sy.'tem, thc MOl or the rccombinant viral stocks has to be ca lcu lated, alld 
this r~quir~s knowledge or(he slOck viral titre, 
" , 3 4 5 6 , " 9 10 II I , ] 4 5 , , " .. .. -J.O . - -" • -". -• • u -
" . - - -- - - -.. -... ("J - -
.·i~lIr~ 2.3 - peR re;"hs coo,firmj.,~ Il,e ~.,,:< of ;<:0;<:. rI ood m genes in tl.e Go"RT ood GagT'-i 
con<;lruct, of rocombino'" h.c"loviru, >loch I I ~( of "'e peR roo<:,ioo, were 10. JeJ onto , O,~ ~.; 
Og'TO>e geL (,) peR .mpli"e,!i"" or Il'e t~g getle: L.o." 1- M. 2- e.,lr.o<ted L>1';,\ froon Go~RT 
r'\c\t'\PV amp1ifi<d '''>ok, .1_ GagRT b~cmid D"A (p",i'iv< control). 4· (".o"RT rAc~I"PV 'locK. 5-
>lerile woleT (negotiv< control). 6- e-x!racteu DNA hom (" •• "T'-' rAc~INPV amplified Sloel... 7- GoglN 
bacmid D1--,\ (lX'sili_e coo,tre>il. 8- G.~·lN r,\c\tNPV W>oK. (b) l'CR .mpljf"';l/joo of .he n and /II 
~en« '"'!"'ctiv<l)" Lones: (. M, 2· G. gRT rAc~t"PV "ock 3· e",,,,,-".eu Dl\A rrom RJ. ll.bcy·' 
G.gRT rAcM,",P\' "oc' (po,ili ,e com".). 4_ e"!r,,,,'eu DN,'" rn)m G. gR ( rAdt1-- PV ,"'plilicd ;loci. .. 5-
GagR (' b""mid DN,\ (p<",ilive cunlrul). 6- ;.te~le ,,"ter with R ( rrimer, (tleg;tlh'e COnlm1), 7_ GogTN 
rAcMN PV "coc'. g_ e"TOcted D:>'A Ii-olll RJ. H~k"l", (" •• gTN rAcMl\PV <lock (po,['i,'e conln)I), 9· 
<xlra<:'oJ Dl\A ti-om Ga"T'-' rA,~t'"'P\, .mplil1cd >locK. 10- "crilc ("'"gRI bac""id DN.-' (posith'e 
,00"01), 11- "'",CT wilb TN primer> In.:!!a!"e controll, M - 11)p.:rl,dder I lJNA MW markeT: kb -
kilobo;< 
2.3.2 Quu ntificution ur rffom hi nun I \mcu lovi ~ u" .,Iucl.!; 
III 11,,-, ,tlldy, 1101h pbqlle ~ssays aod TClD",. as,a~', w,:rc ,,-'>Cd 10 delennine viraiti lre, 
Rolh assa~'" "cre dorIC' ill duplicate (Table 2.2), The resulL' Ii-om the two ~,"~ys wer~ not 
in agreement with eaeh other. While the plaque a'says suggested that the ti/res were 
relativciy low, the Tl'JD50 assays showed titres 10-100 fold greater than the plaque 
~s,"\y', 10 addilion. the pbque as.'><Iy rcwlts slJ<,,,"cd the average GagRT litre to he brger 
Ihan the ~verage GagTN litre, while the opposilc wa.' found in the TClD",assay. These 
di'>C-repan~ies in the viml tilre' predi~led by playue as'><lYS. while problemati<.·, are not 
ullcommon. Previous r~search has shown lhal pl'''lue assays do t~J\d to underestimate the 
true viral (itre. providing fdbe inlilnnati(lIl alJ<,ul vi",1 stock infectivity (Janakiraman el 
(11.,2006). 
~ UKh 












(ii\cn that thc cxpected viral titre aner amplification is about 10<) pfuml (O'Reilly. 1(94). 
hoth assays sh()\\ccl that the viral titres of the constructs \vere low (bct\\een )(/'-10; 
P ru ml for (iagRT and 1(/'-1 ti pfu/m I for (iagTN). HO\\e\er. the Ie ID"1i assays appeared 
to be more reliable in determining the viral titres because they pnnided reproducible 
results that \\ ere closer to the expected titre values. 
Tahle 2.2 The a\erage viral titre for rAcMNPV stocks (for constructs GagRT and 
(iagTl\). as determined using plaque andTClDslJ assays. 
Assay type Viral titre (pfu/ml) 
GagRT GagT:\" 
Plilquc as~ayL ______ S.80x 10(' 4.00x lOb ------ - ---- --- --------
Plaque assay 2 4.IOx IO() S.70x 10(' 
AHrl!ge 4.95xl06 
i 
4.85x 1 06 
----------- -------- --- - ---- -- --------
1.40x107 
-
ICID,,(( assay I 8.70 x 10 
I (lD"" ass~y 2 1.80x1O' 
! 1.30y](/ ! 
-- -- ---- -- -------- -- I 
AYerage i 1.60x 10
7 
i 1.09x 1 OS 
2.4 Discllssion 
In this chapter. the integrity of gag,.! and gagrn genes \\ere verified by peR and 
sequencing. sufficient recombinant baculovirus stocks were produced for optimi7ation 
e\.pcriments to follow. and the viral titres of these stocks were determined. 
It \\ as important to confirm that the gene and protein sequences of GagRT and GagTN 
\\ere not mutated in the process of amplifying recombinant bacukwirus stocks. as a 
Illutation or deletion could have resulted in no or poor VLP formation (Wang. Lai. and 
I i. ]l)t)K). 80th the peR and sequence data indicatcd that there \\as no altcration of the 
rccombinant gene sequences. There was some proteolytic processing of the chimacric 
\TPs though. as suggested by the presence of p41 and p24 cleavage products on the 











\\ JS extensin:. 1100\e\'er. this does not appear to he the case here. as the chimaeric protein 
hJnd" \\ erL' strongly detected. Previous research has suggested that sllch protease activity 
CJn he minimized through expression system optimization. thus proteolytic cleavJge 
should not he J major problem in the production or the chimaeric VI.Ps (Cruz et al.. 
1991)) . 
Ihe Jl11plification of the recombinant baculO\irus stocks was performed to carry Ollt 
optimization cxpcriments. This is usually a straightforward procedure in the baculovirus-
insed expression system. \\hich has been kmmn to yield recombinant viral titres as high 
JS 1 x1 O'i pfu ml altcr amplification (.Iorio. Tran. and Kamen. 200(): O'Reilly. 1994: 
SJrafanm and Saenko. 20(4). However. although both GagRT and Gag TN rAcMN PV 
stocks \\ ere amplified to a certain extent. their titres (1.60 x I O~ pfu'ml and 1.()l) x I ()~ 
pfu ml respectively) were lower than the expected I x I 0') pfwmJ. even after repeated 
Jttel11pts at amplification. Many factors could have caused this. such as the eell line and 
cell passage number used. baculovirus infectivity. or inaccurate titre estimations. 
Looking at the cell line chosen for the amplification. Sj21 cells have been used in the 
production of a variety oj' proteins. They are often used in transfections. plaquc isolation 
and to produce high-titre stocks (Invitrogen. 2002: O'Reilly. 1(94). In the experiments of 
this study. they displayed high viability and growth rate during the amplification process. 
and are unlikely to be the cause of the poor amplification. lIowever. it is possible that the 
passage number could have had a negative effect on the ability of the cells to hecome 
infected and produce progcny virions. Studies have shown that in the late passages of 
insect cells. the cells lose their viability and grow at a slower rate (Imitrogen, 20(2). 
\larniak Cl il! (Maruniak. Ciareia-Canedo, and Rodrigues. 1(94) showed that passage 
number \\as particularly important for plaque assays when he demonstrated that S}9 cells 
at a Im\ passage number produced a higher viral titre than those a higher passage number. 
(ii\cn the similarities bct\veen ,')j9 and S/21 cells. it is possible that an inkction at a late 
passage could result in poorer viral yields than usual in S/21 cells too. The cells used for 
the amplification procedures in these experiments were at passage 27. while those 










;]s they h;]\ e heen knmvn to survive over 100 passages. Nonetheless. had the cells been 
inkcted ;]t ;]n earlier passage. the results may have differed. This will be an important 
\ ari;]hlc to e\.plore in future studies. 
\nother IJctm \\hich may have inlluenced the values ohsened fl)r \iral titre is the 
methods that \vere used for viral titre quantitication. Several methods ha\t~ heen designed 
to quanti 1\ the intectivity of recombinant baculovirus stocks. howe\cr each has its 
dra\\backs (.Ianakiraman et a!.. 20(6). 
Initially. plaque assays were used to quantitate the viral titrcs for the recombinant stocks. 
Although plaque assays are relatively less arduous than most methods. in this study there 
\\ere many factors that had an effect on plaque formation such as precipitation of the dye. 
temperature and \iscosity of the agarose. and cell density within the wells. If any of these 
l~lCtors \\ere not e\.act. plaque (ormation would be deformed or absent. The plaque assays 
\\ere also attempted a number of times before reproducible results could be obtained. In 
addition. the assays demonstrated low viral titres for both GagRT and GagTl'\ stocks. 
This could ha\e been due to the amplification being unsuccessful. or due to an 
underestimation of the true titre, as has been demonstrated by plaque assays prcviously 
(.Ianakiraman et al.. 20U()). 
In \ ie\\ of this. it \\as necessary to do a second assay. namely. a TCID:i1i assay, to 
determine \\ hich possibility \vas true. Unlike the plaque assays. the ICID:'II assay was a 
longer and more tedious method. and result determination is a subjective process 
(Janakiraman et al.. 20(6). However, results obtained in these experiments were 
reproduced \\ithout difficulty and were closer to the expected values than the plaque 
assay results. suggesting that thc amplification, although not completely successful. did 
\\mk. In \ie\\ of this. the results of the TCID:'1i assays were used for the optimization 
e\.perimcnts that rollow. In future. it may be of interest to look into alternati\e methods to 












On the \\ho\c. the rAcMNPV bulk stocks that were produced in this study \\cre found to 
carry the rull gene insert Cor both GagRT and GagTN. and stocks \\erc produced in 
sumcient quantities to continue with optimi/ation experiments. e\'en though the viral 
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I'he e.'\pression of recombinant VLPs can be affected by several factors. Some of the 
major factors that have been identified when using an insect cell expression system 
include insect cell line employed. cell density. MOL infection time. medium type. 
temperature. and shaking speed. Factors such as temperature and shaking speed are 
specitic to the maintenance of healthy insect cells and are generally kept constant. 
1100\e\er. the other factors mentioned above are dependent on the type of recombinant 
protein being expresscd. To produce high chimaeric VLP yields for immunogenicity 
studies. it \\as necessary to explore the most favourable conditions for VLP production. 
3.1.1 Factors affecting chimaeric VLP production 
In this study. four factors \vere investigated as to their effects on VLP e.'\))]"ession. One of 
these factors \vas the insect cell line used by BEVS. There are currently a number of 
possible insect cell lines that are being utilized for recombinant protein production: 
h()\\e\er. there can be a large variation in recombinant gene e.'\pression levels in different 
cell lines (Ilink et a!.. 1991). This makes predicting which cell line would be ideal felr 
production of a gl\en recombinant protein dirticult. and empirical evidence is thus 
neccssary. 
1\\0 specIes of insects are most frequently used. namely Spodoptcra frugipcrda (fall 
army \\orIn) and Tric/7op!llsia IIi (cabbage looper) (O'Reilly. 19(4). Within the S. 
(i'lIgijJef"{!({ species. the two cell lines. ,')j9 and 512 L have been identified as adequate 
hosts to AcMNPV vectors. These cell lines were the original cell lines used for 
baculmirus work. and were derived from the pupal ovarian tissue of the worm. Both Sj9 
and S(21 cells ha\e similar cell shape. size and doubling time. Ilowe\'er. S/9 cells appear 
to be preferable for large scale recombinant protein e.'\pression. sOllletimes producing as 
much as double the quantity produced in S/21 cells (O'Reilly. 1(94). In addition. S(9 cells 
are also able to gnm in monolayer and suspension culture. while S(21 cells tend to clulllp 
in suspension (in serum-riTe medium). growing best in monolayers. This means that 











Ihe hie/lOp/usia IIi (Tlli) species is also exploited by BEVS as a potential host. These 
celb ha\e a larger cell diamcier and a faster doubling time than S(9 cells. so the optimal 
time for recombinant-protein harvesting is likely to be less than that for S(9 cells. They 
are also preferred for recombinant protein expression. especially secreted proteins 
(\1:lruniak. Garcia-Canedo. and Rodrigues. 19(4). While High-FivcTI\J cells are the most 
popularly utili/cd Tlli cell line. a ncw cell line called Tlli ProTI\J cells has recently been 
pmduced I i.)!' the purposes of more erticient recombinant protein expression. This cell line 
\\ as used in this study. alongside Sj9 cells. 
The second factor that was of interest to explore was the cell density used in the 
rAc\1~P\, infections. Cell density has previously been shown to be a dominant 
inlluencing factor of recomhinant protein production. inhibiting production \\hen the 
density is tuo high (Wickham et aL 1992). Insect cells generally require ample space, 
Jdequate aeration and fresh medium in order to survive. Jnd are therefore healthier at a 
100\er cell density (O'Reilly. 1(94). At the same time. a greater numher of healthy cells 
a\ailahle and susceptible to a rAcMNPV infection could potentially lead to more 
recumbil1Jnt protein being produced. Thus. a fine balance must be found in order to 
l11aximi/e \ ields. 
Ihe third factor that was evaluated. MOl, was an important factor to explore because it 
required a halance to be found between producing high protein yields and using the 
minimum quantity of rAcMNPV infectant. MOl describes the ratio of infecting 
baculO\irus particles to the number of insect cells. Consequently. if the MOl is high, one 
assumes that recombinant protein production would also be high. Ilowever. high MOl 
\alues can be problematic for two reasons. Firstly. BLVS is a lytic expression system. 
leading to the e\entual lysis of infected cells. This means that a MOl that is too high 
could be potentially detrimental to the system. killing cells before they have produced 
adequate amounts of recombinant protein. Secondly. using high MOl values requires 
greater quantities of injectant to he used. especially if the infection is done on a large 











~tlldies is large. it is important to determine the optimal quantity or inlCetant necessary to 
pmdllee mJ~illlum VLP yields using minimal inrectant qUJntities. and this is possible if 
the optilllJI MOl eJn be determined. 
Ihe linal I~lctor considered here was infection time. Infection time in insect cells can vary 
quite substJntially for recombinant proteins. depending on when the recombinant gene is 
e~pressed in the \iral life cycle, and the stability of the cell line used. Both GagRT and 
(jJgI;,\ genes are controlled by the polyhedron (pPoIH) promoter. and are expressed late 
in the \iral lire cycle (72-96 hour post infection). Thus. the longer the infection time. the 
mnre likely that protein processing is going to be less efficient as cells near their death 
(HLI . .20()5). In \ie\\ of this. it is important to rind the best time to han'est the chimaeric 
\'LPs in terllls or yield. while also maintaining the structural integrity of the VLPs. 
3.1.2 YLP formation 
The expression of the respective Gag chimaeras in insect cells results in the production of 
chimaeric VI.Ps and their eventual budding from the host cells. Thus. the majority of 
chilllJeric \'LPs are expected to be found intact in the cell culture supernatant. However. 
there hJS been e\'idence to indicate that Gag VLPs as \\ell as chimaeric VLPs also bud 
into cytoplasmic vesicles and therefore could remain \\ithin cells (Royer et aL 19(1). 
I Ience. both the cell lysate and cell supernatant \\ere analysed for the presence or 
chimaeric VLPs in this study. 
,\.1 . .2.1 (iJg elea\age products 
In Jdditiun to intact chimaeric VLPs. several studies have shO\\n that specific as well as 
non-specilic (jag cleavage products are also detected in extracted VLP samples. as seen 
in ('hapter .2 (Cruz et al.. 1999; Tobin et al.. 19(6). These products are Ii kely to occur due 
to proteolytic acti\ity which also appears to occur outside of the cells. as Gag products 
are detected in the cell culture supernatant. This is especially observable at later infection 
time puints \\here cell lysis (and thus the release of cellular proteases) is more frequent. 











()nl~ ellectin; \\ays to reduce extracellular proteolytic activity signiticantly (Cn17 et al., 
I ()l)t) ). 
3.1.3 Statistical analysis 
I \aluating \\hich conditions would be best suited for chimaeric YLP production is 
complicated by the ill\'estigation of several factors' effects as opposed to just two factors. 
The only \\ ay to determine optimal conditions effectively is to analyse the results using 
the statistical method. analysis of variance (ANOYA). AN OVA is used to analyze the 
\ariation occurring in a given experiment (Montgomery. 20(5). This variation can arise 
I'rom many sourees. depending on the experimental design, and thus ANOY A allows one 
to ident i 1\ the causes of variation and compare these sources using the relc\ant statistical 
tests. The tests in an ANOY A are based on an experimental I·'-ratio (the variation caused 
by an experimental treatment or effect. divided by the \ariation due to experimental 
error). The experimental F-ratio is compared to a null hypothesis I~-ratio (equal to 1), and 
if the nperimental F-ratio is large enough, that the possibility of it equalling 1.0 is 
smaller than a pre-assigned criteria (confidence level). the null hypothesis is rejected and 
the experimental factor's effect on the results is deemed signiticant. In other words, the 
hypothesised distribution is premised on the null hypothesis being true, but if the 
experimental I'-ratio does not fit into the hypothesised distribution, then there is evidence 
that the null hypothesis is false, and that suggests that the i1l\estigated factor significantly 
affects the results. It is important to note that ANOY A is only appropriate if the data 
being tested has a constant variance and can be fitted to a normal distribution. If this 
\ari:lI1ce is nut constant or the distribution is not normal, the statistical model has to be 
transformed by means of a natural log application in order to account for the anomalies. 
In this study. factorial ANOY A was used to determine the best YLP production 
conditions for the respective chimacric constructs. The factorial experiment design 
imoh ed the indi\idual \ariation of each chosen factor. while the other factors remained 
constant (\1ontgomery. 20(5). In this vvay. each factor's effect could be evaluated 
separately. and factor interactions could be determined. When factor-factor interactions 











heClllse the errcet 01' an interaction is dependant on t\\O conditions not one. Thus, the 
1Il1l1lCnCC or an indi\idual factor is overridden by the effect of an interaction. This 
c"periment design makes the most efficient use of the optimization data and was 
thererore \\ ell suited for determination of the optimal YLP production conditions. 
3.1 A Chapter objectives 
The aims of the work reported in this chapter \\ere as follows: 
(i) 10 optimize the production of chimaeric YLP production by evaluating the 
effect of four factors on chimaeric YLP expression. 
(ii) To determine the optimal conditions for the expression of GagRT and GagTN 
through statistical analysis of the data obtained ti'om optimization 
e"peri ments. 
3.2 \1aterials and Methods 
3.2.1 Insect cell lines 
Sf9 (1I1\itrogen) and Tili Pro™ cells (Expression Systems) were util ized for the 
optimi/ation nperiments. The Sf9 cells were grown in SF-900 II insect medium (Gibco), 
and the Fili ProTf\lcells were grown in ESF-AF medium (Expression systems). Both 
media \\ ere supplemented with 10 Mg/ml gentamycin (Sigma). Cells were grown in sterile 
tissue culture tlasks (Amersham), shaking at 120 rpm and kept at a constant temperature 
of n°e. They were maintained by sub-culturing mid-log cells to 5x 1 O~ cellslml every 3 
days. 
3.2.1.1 \1casurement of cell viability 
Insect cell \iability \\as measured at regular intervals to confirm that cells were 
maintaining a healthy doubling rate and were not under unnecessary stress. This was 











3.2.2 Recombinant infectant 
IhL' rAcl\;lNPV infectants, CiagRT and CiagTN. made as described in 2.2.2. \\ere used for 
:.111 optimi/ation cxpcriments. 
3.2.3 Optimization procedure 
Ihe optimi/ation experiments \vere performed by infecting 10 1111 cell cultures with the 
respectin: recombinant baculovirus infectant and incubating these cells at a constant 
temperature of 27 8C under shaking conditions (120 rpm). The four factors' parameters 
\\ ere \aried as detailed in Table 3.1. Once the cells \\Cre infected, 1 ml samples were 
l'ollected at the given time points (Table 3.1). and cell count and viability \\as evaluated 
to determine the crfect the infections were having on cells. The optimization samples 
\\ere then centrifuged at lOOn x g for 1 min using a bench top centrifuge, after which 
supernatant and cell pellet were separated. Both pellet and supernatant samples \vere 
stored at ..j.)C for further usc. 
Table 3.1 The four factors and corresponding parameters which were tested 1I1 the 
llptimi/ation experiments 
iF actors Parameters 
r---------------------r---------------------~ 
I 1. Insect cell line Sf9 cells 
2. Cell density (ce111ml) 
3. MOl 
4. Infection time of the 
respective rAcMNPV 
(hours post infection) 
Tlli ProTl\lcells 
- - --,,------- -
0.5 x10 
1.0 x101l 









The negati\e controls included cells that were infected with wild-type baculovirus (at a 










3.2.4 Protein analysis 
3.2.4.1 Western blots 
45 
Western blots were performed on all optimization samples as described in 2.2.3.1. The 
positive control used was HIV-I B Pr55gag (Appendix D) while the negative control was 
supernatant from cells infected with wild type baculovirus. 
3.2.4.2 Gag p24 ELISA 
Quantitative analysis of recombinant protein expressIon yields iii the supernatant 
optimization samples was performed using the Vironstika:& HIV-I Antigen Microelisa 
system kit (Biomerieux), which recognizes the HIV -I Gag p24 core antigen. The ELISA 
procedure was carried out as detailed in the manufacturer's instructions. ELISA 
absorbance readings were detected using the Bio-Tek:& Powerwave XS at a wavelength of 
450 nm. These results were then converted into concentration (pg/ml HIV p24) values 
using Kineticalc for Windows software (Bio-Tek® instruments Inc.). Each sample was 
tested in triplicate, and a mean value was used for further statistical analysis. 
3.2.5 Statistical analysis 
A Four-factor ANOVA was performed on the obtained Gag p24 ELISA results using 
R.2.3.1 software (R Development Core Team, 2006). Once data was obtained from the 
ANOV A analysis, its validity was tested by examining the residual values (The error as 
determined by summing the square of the group means) to determine the validity of the 
test. This was done by establishing if the data agreed with the basic assumptions of 
ANOV A; that is evaluating whether variance of the experiments was constant and 
whether the data fitted a normal distribution. Tukey tests (generic pair-wise T tests) were 
also performed to compare the parameters of significantly influencing factors and 












3.3.1 Cell \iability 
Ihe optimi/ation experiments involved varying the conditions and parameters detailed in 
lable ~.I. I hese parameters were initially selected using data from previous work done 
in our laboratory (pers. comm: Ms A. Lynch. UCT). I:ach experiment \\as performed 
t\\lCC for reproducibility purposes. Samples were taken at specific times. and the cell 
\iability of infected cell samples was evaluated by calculating the percentage of living 
cells present in samples. This allowed the monitoring of the effect that the respective 
infections \\ere having on the cells. In general. there was only a slight decline in cell 
\iability as ]\101 increased. however infection time appeared to affect cell viability quite 
considerably (Iig. ~.l and ~.2). As would be expected. cell viability generally decreased 
mer time Jnd cells appeared wrinkled and unhealthy at 120 hpi. This \vas probably as a 
result ofhoth the baculovirus infection and depiction of nutrients. 
3.3.2 Western blots 
\\'estern blot data \\as used to contirm the production of the chimaeric proteins, and 
indicated that recombinant protein expression occurred at all time points measured and 
\\as found in both pellet and supernatant samples (detected by a Gag p24 primary 
antibody). No (jag products were detected in the negative controls. Antibodies specific to 
RT and :\ef protcins were also used for confirmatory purposes. and also indicated 
corresponding chimaeric protein expression in the samples tested (data not shown). As 
\\as found in the previous chapter. both GagRT and CiagTN migrated to positions a little 
higher than their molecular \veight relative to the marker. 
In particular. the \\estern blot data for samples of cells infected with GagRT (Fig. 3.~ & 
~.4) or (jagTN (Fig. ~.5 & 3.6) (ccll density 2xlOh cells/ml) illustrated that there 
appeared to he more of the chimaeric proteins in the cell pellets than supernatant samples. 
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moi 0,1 moi 1.0 moj S.O moL 0.1 m. , .0 moi 5.0 
" 
, 5 , 5 , 5 - h'. M ,. 5 , 5 , 5 _ I\e 
- - - - ~ ~ - - --. - -• 
• 
(a) 
moi 0.1 moo '0 mol 5.0 mol 0 .1 moo '" moi 5.0 M , 5 , 5 , 5 - ". " , 5 , 5 , 5 .l\. 
• - - - --- - - -.- ;-r • 
~ .... ---• . ., • • • 
'5 l 
F~""" JA _I '''IOr).:.1 or til< "rtim;'ilir:., ",mrl •. 1 100 (; ",RT VLP, ]'If(H.iu,,,,1 in Sf'! ""II:; "' • cdl d ... ""ity of 2x la' ,dh<' "~. 
M""",,_< ,,"" I""""d v.ith IIiV rl4-' re, il,,- ","iIieW"L, S"mpk, """1~' ,,,1 .. 43 I-<>m, po>! infwioo (1)p;I, (oj. 72 hpj (b)' 
'1<\ "ri (e), 1m I!pi (<I). A\>bn.~ jUli""" M - "",Ic~-"l., wci~ m",kcr. j - G"I'RT ml\o""",. _ " '0 - wildt) pc b"""JoL' i,"~ + -
TIl\'_ I B PT5lg!O~. P - ",II roelle1. S - cu),,~, '''''''''''''"." AITO"-' ( _ ) in<licMc whore O"~R I (1118 WI mig''''c< to 
Am.m h .. ",,,, , ~ ) i"<Iie"",,, I>:,e P,5S"'" ""!IT"," 10. 
moiO. l moi 1.0 ",oj 5.0 moi 5.0 moi 1.0 mol 0. 1 
kD. • , 5 , 5 , 5 • 1\ e M • , 5 , 5 , 5 - iw M 
_L" .. --- -oo - - .,,,, - - .... .'0 • -· - oo-
00 
(~l ,bl 
mui 0.1 -, '" moi 5.0 n .... i _1.0 ",oj '" m"; 0.1 • , 5 , 5 , 5 _ "e " • 
, 5 , 5 , 5 , • Ive " 
... - - - - .-- --oo -
. -
(el (JI 
~·i~" ... J.~ h " "pb (,ftlle 0l' i mi'~ic:o' ,urnpk> fOf 0,.,1», \'LP, proJuroi in -'ifi ",11< '" a "II .... ""ill nr 2, I If ""Ibi ml 
Mm""""'" ,we 1"_ "ilh Ill\, r2'-'1""il" .. "i""",m. S"mllk. :m>1;-.cd "' 48 I<lu" po>l ;nh,"," I",'i), I~). 71 hl'i (~), % 
hp' 10). 12(1 ",. (dl. Ai>lx<\i"''''''' M mnlx:ul..- v.cighl marler_ 1- ()~ I'N.. " ." - wildt)I'" ~"Io,;,,~. ~ III\'- Ill 
I~~~f"f. P -- ,-< II ["II"" S cu llUt" '"f"m",lWlI. AlTOw. ( _ ) ;oo;<OIC "her< Oaf !''! (~l W) mig",'" '>. ~"",,h,"'" 1<1 
















moi 0.1 moi 1.0 moi 5,0 mo; 0.1 mop 1.0 mop 5 .0 
kD. ~l - j". , , , , , , S I' _i\< \1 







... - - - --- -.. 
~ .. 
moiO.l rna< 1.0 mol 5.0 
" 
, , , , , , -IVO ----- • -• 








010; 0.1 , , 
_ _ M _ _ 
-. 
mo; 1.0 , , 
... 
me< 5.0 , , 






.-iaur. J.6 - Lx.mpb of Iii< optioni""l;"" >.",pl .. for GagTN VLP, proouccd in r. "i Pro"" cell, .1 a coil ocn>ily 
o f 2x I 00 cell ~,'mL Memo,,., ., we,. probe<l with HI\, p24., pecifi, ,."i seru"" S,~npl .. ;M1ail'sed at 48 iIo<", post 
inlecti"" (hpi), (OJ. 72 hpi (hJ_ % h(>i (c~ 120 hpj (d). MHlTe\' iati""" ~t - mo l",," I"T " eight marke r, 1- (iagTN, 
i,e - "lId,y!>," biKUioyiru>. ~ I !IV-Ill P,'5gal\. P cel l pellcl . S culture . upcrtllll.nt. Arruw, ( +- ) indicale 
where GagT'\ (92 ~D) mig"'w, to. ArTO"hcad, (0- ) indic~tc ",""" Pr55'" migrates to 
As wus the "ase in the pr~vi"us Chal'l~r, it was not lmexpected to find (jag cleavage 
producls w hen ,,"pressing Gag-d~rived V L Ps. Ilo,,"evo;-r. for the purposes of thi s s!tldy. it 
is not ideal. panicularly when it leads to a decline or ehimaerie protein yields. This ,eemS 
to be thc case for the 120 hpi samples. eSp"cmlly;n the Tn; PrOT'" ~e ll samples (Fig, 3.3 
and 3.6). 
3.3.3 Gal! p24 ELISA and ANO\"A 
The ELlSA was used as a means or me3suring r~comhinanl protein eXpr~SSlon 
quamitatively. and was donc in lriplicate to dd=in~ " mean , ·" Iue for G~g protein 
expr~ssed in each sample (Appmdi., E). B"lh p"11~1 and 'Up"mutan! <;;Implcs were 
assayed for the presence or Gag 1'24, lw,,~ver. l'dlular mutter in the pellc! samples 
il1lCrti:red with the ELlSA detection rndhod. Bel'''us~ oflhis. a' we ll as th~ foctthat only 











(.\ppcndix I') obtained for supernatant samples were focusscd on. The experimcnts 
shlmed that a maximum of 406.12 ng/ml !-IIV p24 \\as detected in the GagRT 
optil11i/ation cxperiments. v,'hen S'(9 cclls were infected for 96 hours at a cell density of 
I x IOf, cells ml and a MOl of 1.0 (Appendix F. Table E I). The maximum for GagTN 
c\.pcrimcllh \\as 4()().51 ng!ml HIV p24. detected when Tlli Pro cells "erc infected for 
12() hours at a cell density of I x 1 Oil cells/ml and an MOl of 5.0 (Appendix E. Table [2). 
(ienerally. (iagTN was expressed in moderately higher quantities than CiagRT. This is 
poc;sibly bccause ur the smaller size of (jagTN. which makes it easier to produce and 
process "ithin cells. 
Four-factor ANOV A was performed on the resulting ELISA data to determine. 
statisticall:-. the best conditions for maximized VLP production. ANOV A also assisted in 
identil\ing the major factors and factor interactions that atTectcd protein expression. The 
lbw (shll\\n graphically in Figs 3.7 - 3.14) demonstrated that there were several 
c;il11ilarities in the \\ay in which the chosen tactors affected the production of GagRT and 
(iagT;\. Specitically. cell density affected chimaeric protcin expression appreciably. The 
highest cell density. 2x 1 0(' cell/ml. did not produce the largest yields of chimaeric VLPs 
as \\ ould be expected; instead an optimal cell density of Ix I 01> celhnl \\as identitied for 
both constructs (Figs 3.7. 3.8 for CiagRT and Figs 3. I I. 3.12 for GagTN). 
Interestingly. MOl seemed to have no great effect on the production of either construct 
(Iigs 3. l) ror (iagRT and rig. 3.13 for GagTN). Recombinant protein expression was 
expected to increase as MOl was increased to a certain extent. gi\'Cn that MOl defines 
intCcti\ity of the infectant However. there was little to no effect observed as MOl 
increased in the experiments of both constructs. For ,V9 cells. a MOl of 0.1 produced 
10\\ er yields. \\hile yields produced by a MOl of 1 and 5 displayed similar levels of VLP 
c\. press lOn. 
rhc CiagRT ANOV A results indicated that the factors which significantly alTected 
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factor intcmc(ions (which were implied by graph:. wilhin 11", ,mne figure that J i ll;,r~d in 
,hup"J occurred OCl\\""n cel l line mid L-cl l densi ty (rig. 3.7), atld cell litle and infection 
time (Fig. 3.10). Thi, m~an, lhal ce ll li ne ,nll llcnccd or was dependent on both cel l 
den, ;t)' and i llf~l'l i ()n time. Th~ Tn; ProT'" "el l line Seem to prodllce higher yi elds then 
the Sf! cell line for the lwo lower ce ll densilies and al l inledion times (Figs J 7 and J 10 
respect ively). There was a clear increuse in prot~ i n <,xpre>sion over lime us wou ld be 
l'>.pectcd. althollgh GagRT product ion bcgan to plateau at the hIgher time points (Figs 
3.g, 3.10), showing on ly a smal l variation in prote in Cll-press ion occurring al 'J6 ~nd 120 











lhe (iagT~ data \\as only slightly different to that of the GagRT data. The factors that 
seemed to han: an effect on chimacric protein expression \vere the same as that of 
(iagRT. hO\\ e\Tr there was only one factor interaction found. bet\\·een cell density and 
cell line (Fig. J.II). Unlike with GagRT. there was no ob\ious difference in protein 
production bet\\ een the two cell lines. although the best infection time \\as also 120 hpi 
(Figs 3.12. J. 14). As with GagRT. a plateau was observed at the higher time points. The 
\10] data illustrated that a MOl of S was the favoured parameter for protein expression. 
but again the effect of MOl on protein production was not considerable (Fig. 3.13). 
lhe AN OVA data \\as able to effectively identify the optimal conditions for chimaeric 
\TP production (Table 3.2). The optimal conditions were alike for the two constructs. 
probably because they are both Gag-based VLPs and are thus processed in similar ways 
in the cells. 
Table 3.2 lhe optimal conditions to express the VLP constructs. GagRT and GagTN. 
in insect cells. as determined by ANOVA analysis of Gag p24 ELISA data 
T.ni Pro™cells S{9 cells 
Cell density Time post Cell density Time post 
Construct (cells/ml) MOl infection (hr) (cells/ml) MOl infection (hr) 
GagRT Ix lOll Any 120 Ix lOb Any 96 
GagT:\ IxIO() S 120 IxlO
il S 120 
Because of the complexity and cumulative effects that were generated by comparing four 
factors to each other. to determine hovv statistically significant the identitied optimal 
conditions \\ ere. \vas not possible. Thus. to establish how significantly di ffcrent protein 
expression was under the chosen parameters. estimated ditJerenees of the group means 
and pair-\\ise T-tests \\cre performed on the data. under the assumption that all other 
factors \\ere kept constant. This type of analysis is based on the assumption that there arc 
no interactions between the factors. which we know to be false: nonetheless. it does 
pr()\ide a rough idea as to the magnitude of the signiticance of the optimal conditions 











signifIcantly diffen:llt to one another if the differcnce in their means resulted in the error 
bars crossing x=(). Fig. 3.15a showed that when comparing the 3 cell densities for GagRT 
to nne another. none of the bars crossed 0, and therefore each cell density was 
signillcantly difTerent to the other within a 95 (1<) confidence le\·el. The same could not be 
said fiJr the infectinn time comparisons (Fig. 3.15b), which showed that % hpi and 120 
hpi \alues \\ere not signitlcantly different in terms of protein expression. 
In the case of GagTN, the pair-wise T-tests showed that \\hile the two cell lines were 
significantly difTerent to one another (Fig 3.16a), almost all infection times were not 
signitlcantly different from each other (Fig. 3.16b). This suggests that using any of the 
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Figure 3.15 rhe results of pai r-\\ ise T-tests used to compare the group means of the gi \ en parameters in 
order to determine h011 significantly different these parameters are hom one another. (a.) Comparison of 
cell densities for (iagRT. (h.) Comparison of infection times for GagRT. All tests \leTT done \\ithin a 95 OJ, 
con lidence intl'rl al. II here f~lctors I\ere determined signiticantly eli fTerent to one another i I' the error bars 
I rt.'IJrl':'enting standard del iation between two means compared) did not cross O. 
It is important to note that once the ANOV A analysis \\as completed, tests were done to 












is required for an ANOV A analysis to he sound). It \\as found that the data had a non-
constant \ariance because the residual values did not produce a random scatter plot when 
plotted against the fitted values. as is desired (Fig. 3.17a for GagRT data and 3.l8a for 
(iagT:\ data). In addition. the data did not conf01111 to the expected linear normal Q-Q 
plot. instead forming a sigmoidal curve (Figs 3.17h and 3.18b). To remedy thc problem. 
the ra\\ data were transformed by applying a loge function to all data (Figs 3.17c & d for 
(iagRT data and Figs 3.l8c & d for GagTN data). As can be seen. the transformcd data 
demonstrates random scatter plots along y = O. and linear normal Q-Q plots. indicating 
agreement \\ith the AN OVA assumptions. This kind of transformation procedure is 
standard and deemed acceptable for statistical analysis. 
.~ 
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Figure 3.16 The results of pai r-wise T-tcsts used to compare the group means of the given parameters in order to 
detLTmine hO\I ~ignificantly different these parameters are from one another. (a.) Comparison of cell lines for 
(jagl '\. \\I1en.' () - J:lli I'ro[\I cells. I ~ Sj9 cells. (b.) Comparison of infection times for Gag'!:'\!. All tcsts were done 
\\ ithin a 9:""" confidence inten al. where t~lctors were determined significantly different to one another if the error 
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I he production or the ehimaeric VLPs for immunogenicity studies required the 
optimi/ation of \'LP production to obtain sufficient VLP quantities and ensure that the 
predominant recombinant product would be the appropriate chimaeric VLPs, The 
maximum yields obtained (as determined by measuring Gag p24 levels) from 
optimi/ation experiments were disappointing, with less than 0,5 ,Ltg/ml being obtained. 
Previous studies have shown that chimaeric VLP yields from insect cells can range from 
5-2() ,Llg ml (Vlodnm et aI., 1')94). Ilowever. these yields ,vere dependent on the position 
of the fused protein on Gag as well as the length of the fused protein (Luo et aL 1(92). 
Both RT and the fusion protein. TN. are relatively large insel1s (49 kD and 36 kD 
respecti\ely). making both the chimaeric proteins fairly large (108 kD and 92 kD 
respecti\ely).1 hus. e\en though the proteins were being expressed by the cells, they may 
have been problematic to process given their size. Luo et al (Luo et aL 1(92) found that 
the size or the fusion protein expressed was inversely proportional to VLP yields 
produced. This tinding is supported in this study by the greater quantities of GagTN 
produced in comparison to the larger construct GagRT. 
Alternatively. because recombinant protein expression occurred close to cell lysis/death 
(late in the viral lire cycle). protein processing was likely to be suboptimal because of 
'compromised post-translational machinery and secretory pathways' (Hu, 2005; 
lkonomou. Schneider. amI Agathos, 2003). [n this way. the time point of 120 hpi is 
probably not the best time to harvest intact VLPs. even though it was found to be optimal 
for both constructs \\hen they were produced in Tlli Pro I \1 cells. This was suggested by 
the cell viability data which showed that at 120 hpi. cells were unhealthy if not already 
dead. Furthermore. western blot data indicated that Gag cleavage products were more 
prominent at 120 hpi than at other time points, probably caused by the release of cellular 
proteases after cell death. Taking both these points into account. in addition to the fact 
that there is little to no significant difference in expression le\els between 96 and 120 hpi 
times for both constructs. it would be preferable to harvest VLPs at 96 hpi to obtain 











(ienerally. the optimal conditions that were determined by ANOVA showed several 
similarities I'or the t\\O chimaeric constructs (Table 3.2). although. the chosen factors did 
al'kct recombinant protein expression in some surprising ways. In particular. cell density 
seemed to int1uence protein expression quite significantly. especially given that one cell 
density (lxlO
h 
cells ml) was favoured in all experiments. In some studies. higher cell 
densities have led to better recombinant protein expression. but this was dependent of the 
ccll line used (.Iorio. Tran. and Kamen. 2006~ Maruniak. Garcia-Canedo. and Rodrigues, 
I ()l)..j.). Wickham et al hypothesised that high cell densities resulted in depiction of vital 
nutrients and or accumulation of toxic by-products (Wickham et al.. 1992). This appeared 
to be the case for both cell lines tested here. where the highest cell density generated 
poorer VLP yields. The cell density of I x I Oh cells/ml \vas the best option for chimaeric 
VLP production. providing enough space. aeration. and medium availability for the cells 
during the stressl'ultime of infection. 
llnexpectedly. MOl results showed that MOl had little effect on the production of either 
construct. In most cases. MOl is used to provide the means to control an inICction, as the 
higher the Mal (\\ithin reason). the more viral particles there are a\ailable to infect one 
cell. and therct'ore the better the infection and recombinant protein production efficiency. 
I hme\er. in these experiments, once a threshold MOl was reached (which appeared to be 
1.0). the MOl no longer had an effect on the amount of recombinant protein being 
produced. so that protein expression at MOl I and 5 did not differ extensively for either 
construct. It is possible that this was due to the range of MOl values investigated being 
too naITO\\. and perhaps using a MOl value of 10 might have produced better VLP yields. 
This \\ill need to be investigated in future experiments. 
The optimization data indicated that the two cell lines used in this study produced similar 
expression le\els. according to the optimization data. This means that both cell lines are 
capable of producing chimaeric VLPs in comparable quantities. and as a result the cell 
line to be utilized for VLP production can be chosen based on factors such as availability 
and economic \aluc. rather than protein production ability. On the whole. even though 











scnsitin; to slight el1\ironmental changes. ,W9 cells wcre better at adapting to new media 
~l11d had greater longevity, and consequently arc more suitable for large-scale work. 
Ihus. the optimal conditions for large scale GagRT and GagTN VLP production were 
determined using the data from both the vvestern blots and the ANOV A. It was found that 
using the S,(C) cell line at a cell density of 1 x 10(' cells/1111. and infecting cells at an MOl of 
I.U for % hours. prmiclcd the highest yields of intact chimaeric VLPs. 
While the optimization experiments seemed to work successfully. one drawback of the 
experiments \\as the usc of a Gag p24 ELISA method to quantify VLP production. The 
ILISA measured (Jag p24 concentrations as opposed to direct VLP measurements, and 
the results \\ere thus intluenced by the prescnce of the Gag cleavage products in the 
samples. From the western blot data. it seemed as though the dominantly produced 
protcin \\as generally the chimaeric VLPs. thus they were assumed to be the main 
contributors to the detected Gag p24 in the ELiSAs done. Nonetheless. it is of interest to 
explore other methods of quantitication that could be more reliable. 
The optimization experiments provided insight into the dynamics of the recombinant 
hauil()\ irus inll:ctions. prming very useful in the determination of influencing factors 
and their clTect on the expression of GagRT and GagTN. It was now important to begin 
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.. U.I Purification of chimaeric VLPs 
('himaeric I IIV VLPs. CiagRT and GagTN, arc targeted to the cell membrane of the host 
cell by the (iag ~-terminal myristylation signal and bud tl'om the cells (Halsey et a!., 
20()S). In this \\ay. their secretion into the culture medium allows purification to be made 
simpler. as the VIPs can be isolated without contamination by cellular proteins. 
One of the most common methods employed to isolate H IV -I Gag VLPs fl'om clari fied 
culture supernatant is sucrose density gradient ultracentrifugation (SOCiU) (Doan et a!., 
2()():'\: Ciheysen et a!.. 1989: Jartl'ay et a!., 2004). This method is a fl1rm of rate zonal 
centrifugation and employs a sucrose step gradient. comprising of a range of sucrose 
densities. to separate proteins on the basis of their buoyant density (\Viser. 2(07). While 
there is some \arianee in the application of this purification method in the literature, it 
has been flHlI1d to result in the successful purification of VLPs fl'om both baculovirus and 
\accinia \irus expression systems (Ooan et aL 2005). However. it does have its 
dra\\ backs in terms of the level of VLP purity and sterility of VLP preparations (Bess et 
a!.. 1997: Dettenhofer and Yu. 1999). 
In \ie\\ of this. Optiprep" density and velocity gradient ultracentrifugation have recently 
emerged as a ne\\ and imprc)\ed method for HIV VLP purifications (Dettenhofer and Yu, 
]l)l)l): Ford. (jraham. and Rickwood, 1994). Optiprep" is a solution containing 60<i() of 
iodixan()1. It is a non-toxic. non-ionic density gradient medium that \\as initially designed 
as an X-ray contrast solution (Segura, Garnier, and Kamen, 2(06). Unlike sLlcrose, which 
increases in osmolality as density increases, iodoxanol is able to fl)rm iso-ismotic 
solutions at all densities. This provides better separation of proteins and maintenance of 
protein integrity (Dettenhofer and Yu. 1999). 
In this study. SDCiU and Optiprep" density gradient ultracentrifugation (OOGU) was 
compared in terms of their ability purify large amounts of intact. chimaeric VLPs. In 











I h\..· i\Il' method has plT\iously been used to successfully purify viral particles, but it has 
\et to be used for IIIV VLP purifications (Segura, Garnier, and Kamen, 20(6). It imolves 
the use of membrane filtration columns to clarify and concentrate the culture supernatant, 
so that VLPs ean be isolated from the resulting filtrate using ultracentrifugation. 
Although this method is less relined than the other methods, purified Gag-only particle 
yields were greater \\hen isolated using the MLJ method compared to the other methods 
described (pers.comm: Ms ;\. Lynch. UCT), and it was of interest to determine if this 
\\as true for the ehimaeric VLPs. 
4.1.2 E'aiuation of VLP integrity 
As mentioned pre\iously, chimaeric IlIV Gag constructs carryll1g additional epitopes 
such as gp 160 or ~eL are able to form VLPs (Deml et aL 2005). These VLPs arc 
generally stable and only slightly larger than the average Gag-only VLP; however. there 
is a si/e limitation that influences the formation of chimaeric HIV VLPs. Until recently, 
the si/e limit of the inserted epitope was believed to be approximately 200 amino acids 
(aa) (Deml et al.. 2(05). but recent work done in our laboratories has shown that this 
limitation can be extended to as much as 778 amino acids (Halsey et aLl. 
Ihe ehimaerie VLPs in this study, GagTN and GagRT, contain extra polypeptide fusions 
of .:122 and 450 aa respectively, and have been previously shown to form intact VLPs 
(I [alsey et al.. 200R). However. given the requirement that these proteins be in particulate 
form to stimulate a potent immune response (Ellenberger et al.. 2(05). it was important to 
\eri fy that both constructs expressed in insect cells form VLPs. and that these VLPs 
remained intact after purification. This is mainly because the immune response elicited 
by (jag in earlier mouse experiments was primarily attributed to the particulate nature of 
Pr55"·'''. Thus. for GagRT and GagTN VLPs to elicit a similar or enhanced immune 
response. they must be in particulate form. Additionally. it was necessary to confirm that 
the VLPs budded out of the cells as expected, as they were extracted fl'om the culture 











·tt . .3 Chapter ohjectiHs 
Ihe aims of the \\ork reported in this chapter were as follo\\s: 
(i) 10 confirm intact VI J>s are budding at the cell membrane of the insect cells 
expressing GagRT and GagTN. 
(ii) To evaluate \vhich is the best purification method for obtaining stable, intact. 
chimaeric VLPs in large quantities. 
4.2 Vlaterials and :v1ethods 
.... 2.1 YLP Purifications 
-1-.2.1.1 Sucrose density gradient ultracentrifugation (SDGU) 
Ihe appropriate optimal conditions (Table ].2) were utilized to express the respective 
chimaeric VLPs in Sf9 cells (250 ml). At 96 hpi. infected cell culture was transferred to 
sterile 2:"-1ll1 bottles (Sterilin) and centrifuged at 1000 x g far 20 min at room temperature 
to remO\e cellular matter. The supernatant was removed. layered onto a sucrose cushion 
comprised of]() (~;) sucrose (7 ml) and 70 <;i) sucrose (2 ml) (both made up using I x PBS). 
It \\as then ultraeentri fuged at 120 000 x g in a Beckman SW 28 rotor for 90 min at 4 0(', 
and the resulting protein band at the 20 'Yr) / 70 % sucrose interface was aspirated using a 
syringe. The resulting aspirate was pipetted on top of a step gradient consisting of 20, 30, 
-1-0 and 50 '! () sucrose. and ultracentrifuged at 120000 x g in a Beckman SW 28 rotor far 
()() min at 4 "c. Once this centrifugation was complete, protein bands that were visible in 
the gradient \\ere carefully removed using a syringe. The extracted bands \vere diluted up 
to -1-0 Illi in Ix PBS (pH 7.4) and underwent a tinal centrifugation. performed at 110000 x 
.. ~ for 60 min in a Heckman SW 55 Ti rotor at 4°C. The resulting pellet \vas resuspended 
in 500 ~ll PHS and stored at 4 0c. The negative control comprised of Sf9 cell culture 
infected \\ith wild-type baculovirus and treated as described abO\e . 
.J.::. J. /. / SIIC!"(}SC gmc/icill/j'(/ctiollatioll 
10 contirm that the chimaeric VLPs were present in the visible aspirated bands on the 
sucrose gradient and to further characterize them. the gradient containing the protein 











\\as determined using a pocket PAL-3 refractometer (Atago). Aliquots were tested for the 
presence of ehimaerie VLPs using western blot and Gag p24 [LISA analysis 
(Vironllstib ). 
-\..::!.I.::! Optiprep R density gradient ultracentrifugation (OGDU) 
\s \\ith the SDGl '. infected cell cultures (250 ml per construct) were centrifuged after 96 
hpi at I (JOO x g for 20 min at room temperature. The cell pellet was discarded and the 
supernatant \\as ultracentrifuged at 120000 x g in a Beckman S\V 28 rotor for 90 min at 
-\.(. The ne\\ pellet was then resuspended in 500 pI PBS. pipetted on top of a step 
gradient consisting of 10. 20. 30, 40 and 50 (ij) Optiprep:l~ (made using I x PBS), and 
ultracentrifuged at 155 000 x g for 180 min at 4 0c. Once this centrifugation was 
complete. protein bands were visible at their buoyant densities on the gradient (differed 
depending on the construct). and were carefully removed using a sterile syringe. The 
extracted hands \\ere treated as described for SDGU (4.2.1.1.). The negative control 
comprised of Sj9 cell culture infected with wild-type baculmirus and treated as described 
abo\e. 
-\,.2.1.3 :V1icro- l 'Itrafiltration (MU) 
As \\ith the SOGll. infected cell cultures (250 ml per construct) was centrifuged after 9CJ 
hpi at I ()()() x g for 20 min at room temperature. The supernatant was removed and 
microl'iltered using a 0.45 ~lm CFP-4-E-4MA polysulfone membrane capsule filtration 
de\ice (Amersham) under constant pressure (0.75 Bar) and tip speed (375 rpm). This step 
\\as necessary to remove excess baculovirus and cellular debris fl'om the supernatant. The 
resulting clarified liltrate was subjected to ultrafiltration using a UPP-300-C-4MA 
polyethersulfone membrane tilter (MWCO=300 kOa; Amersham) under a constant 
pressure (0.75 Bar) and tip speed (365 rpm). This liltration step concentrated the filtrate 
to I I (J of the initial supernatant volume. It was then diluted in I xPBS and centrifuged 
120 (J()() x g in a Beckman SW 28 rotor for 60 min at 4 °C to pellet VLPs. The pellct was 
resuspended in :W() ~t1 PBS and stored at 4 "C. Both tilters \\ere sterilized "ith two 0.1 M 










their usc. The negative control comprised of Sf9 cell culture infected with wild-type 
baculmirus and treated as described above . 
.... 2.2 Protein analysis 
.. 1-.2.2.1 Coomassie-stained SDS-PAGE 
All extracted VLP samples were run on SDS-PAGE gels as described in 2.2.3.1. The gels 
\vere incubated mcrnight in 10 ml Coomassie brilliant blue stain (Sambrook. Fritsch. and 
\1aniatis. I ()~0) under shaking conditions (SO rpm) at room temperature. The gels were 
then destained the next day by incubation in Coomassie destain for 5 hrs. or until protein 
bands \vcre detected visually. 
4.2.2.2 Western blots 
Western blots \\ere performed on all samples as detailed in 2.2.3.1. 
4.2.2.2 (iag p24 LI .ISA 
All ELISA analysis was performed as described in 3.2.3.2. 
-t.2.3 T,"ansmission Electron Microscopy (TE:VI) analysis 
.. 1-.2.3.1 Negative staining 
Lxtracted VLP samples of interest were adsorbed to glovv discharged. carbon-coated 
copper grids for 15-20 min. followed by two water washes and finally staining with 2 (Yt) 
uranyl acetate for t)() sec. Grids were then viewed using a Zeiss S 11 09 electron 
Illlcroscope. 
4.2.3.2 Cross-section TEM 
10 visllali/e VLPs budding from insect cells. cross sections ofSj9 cells (infected vvith the 
respective rAcMNPV stocks under optimal conditions - Table 3.2.) \vere prepared. At 72 
hpi. cells \\ere centrifuged at 1000 x g for 5 min. resuspended in 2.5 % (w/v) 
glutaraldehyde and stored overnight in the dark at 4°C (to fix cells). Fixed cells were 
gently resuspended in I ml I xPBS (pH 7.4) and pelleted at 1000 x g for 5 min. They were 











\\ith I 00 (\\ \) osmium tetroxide (made in 2xPBS - pH 7.4) for I hr. followed by two 
I xPBS and t\\O ddll:,O washes. Subsequently, samples \,ere dehydrated using several 5-
min ethanol \\ashes of increasing concentration (30. 50. 70. gO. 90. 95, Ion %). The 
samples \\ ere further dehydrated by resuspension in acetone, then embedded in Spurr's 
resin (Spurr. 19(9). and baked at 60°C (for setting purposes). Sections of approximately 
10() nm thickness were prepared with a glass knife using a Leica Reichert Ultracuts 
microtome and mounted on copper grids. These sections were stained with 2 (I(l uranyl 
acetate for 10 min at ambient temperature. rinsed 5 times with ddH:,O. post-stained with 
Reynolds' lead citrate for I () min. re-rinsed with ddH:,O. and air dried. Grids \vere viewed 
llsing a Zeiss S II ()l) electron microscope. A negative control was prepared by infecting 
cdls \\ith \\ild-type baculovirus, instead of the rAcMNPV stocks. 
4.3 Results 
-J,3.1 YLP budding 
Cross sections of SIC) cells infected with the respective rAcMNPV \vere examined using 
111\1 analysis. Chimaeric VLP t()rmation and budding from the cell membrane was 
confirmed (Fig. 4.1 a-d). as VLP structures were morphologically similar to previously 
characterized Gag VIPs (Halscy et al., 2008; Jaffray et al.. 20(4). The VLPs were f()Lmd 
to be at eli ITerent stages of the budding process in the cells examined, with some VLPs 
being fully budded and others protruding slightly from the cell membrane. All VIP 
strLlctures \\ere rOLlnd in shape. and demonstrated a large variation in the size. with 
(jagTN VIP diameters ranging Il'om 120-185 nm, and GagRT VLPs demonstrating a 
range of approximately 135-220 nm. As was expected, the majority of observed 
chimaeric VIPs \\ere larger than what has been documented for \vild type Gag VLPs 
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has indic"aled !i1allhes,: ,(rudureS are vcry like!} to be cellular microvesicles, given their 
variety in ,i~", m"rphol()g~' anc! elcdron density (Ile,s ct al.. 1<,1<,17). 
4.3.2 SI)(;U puifica . iun 
The tirs! puritica!inn method investigated. SDGU purification. involved centrifuging 
infe~leJ n'lI supernatam at high speeds onto a 70 % sucrose cushion 10 obtain a protein 
hand. Thi8 hand "as then pla~ed onto a sucro>e dem,ity gradient and ultraccntrifugcd for 
a given lime, resulling in the tilrmation or protein bands at \ocir respective buoyant 
densities (differed depending on the protein' isolated) on [he grad ient. The bancls were 
removed !I'om the gradient and ana l)'sed for the rre'''n~e ,,1"VLP8. 
BOlh chimacric VLP puri i!calions resulted in the presence of more lhan OIle band on the 
Jen,il), gmc!ienl, e~en alier >cveml repeatec! purillcation, (Fig, 4.2). '1 he GagTN ,amples 
con,i,tently pmc!oced three blind" "hile (jagR r ,muple, pmdlO<:ec! t"o bands. l"hi, \,'.1, 
une.xpech:d. a~ previOU8 (jag-onl)' YLP puriIiL~tiol1' had re,ullec! tn one prolein b"'1d 
only at a density of about 1,15-1, I 7 giml of S)Icrose ( i lammonds et al_ . 2007)_ (jivcn thi, 
occurrence, it wa, nece"ary to isolate all bands and analySt: them using \\estern bioI:> and 
TEM, >0 that we could establi,h which band contained intact. chimac!'ic VLP,. In 





Fi~"ro 4.2 Suor"". dOll';')' gradi."" (20_.1 0 ~;) ",,",a;ning ;nfect.d cell ; upern",ont pell"" after 
LlI"""'nlrifug"liun, (.) Sf! cdl, were illiected prior 10 plLrilic~iOll with llag.Th rAcMl\PV (a) m C;:I£K I 
rAc~l\' P\, (b)., p<r ,h. det"m;',.d e>p<imizod "",\(Iit'",,,_ Arrow' indicaLe ,h. prot.in bond, thaL were 










I'he C()(>massie- ,!ai11~d S[)S-PACiE gds illustrated lhm nOnC o l'the iso lated bands \Iere 
pure. a, '>Cveml Nher prolein products were <;till pre","t in tm, samp l ~, (Fig, 4.3). 
Furthermore, the eh imaerie VLP, did 1101 appea r to f>., the mo,t promiroenl prot~il1 many 
of the bal1ds isolated. with 0I1 ly ~ fai nt detection of Ix>th eh imacric VLP,_ 
,fl" 
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(al (log TN VLl' band sample, extracted ITom lOC' 'uc"''''' d<n, il)' lV,dien" (b) (lagRT VLP band ,ample' 
<"lracted rro", lh<' >l""'''' de,,,ity gr3d i .. ,. . Abl,,"yiati,,,,: M - marl.<r, I - ,,,,,,,,,eliy. b."uioy i"" 
infectant; Til - "'" b.nd i<ol.ted; \tB - middlo b~nd isolated; BB - bottom b.nd i,ul.led, Arrow he-.,i> 
indicalc the miWaliu" pc, iliu" ufthe re>P<"'liv. c'hi "'aeric VLPs, 
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Figuco 4,4 - We,lem hh~ , of lhe re'['Cl" i,'e VLP '~mrb after ~l)(a;_ probed with G.g l'24 antiho<!y_ (~) 
GaRi''' V I ~P ba"d ,amp/"" e>.l,a<lro fmm [iI< >tiC'''''''' de,,,ily ~r"die,n, (lI) Gll/:RT VLP b."d >ample> 
ox""",ed m~~ tho 'ill"""< den,i'), grad ient. ),1 - mar • .,; I - 'e<[1<ctiw baculovin" inf.ct.n" W -
di,ca"kd ,upcm.,anL an., rmal centrifugOlion: ,p ~ , amplc uf cdl 1"-'lIe" TB - lOp band i",loted: ,\18 -
middle hand i,,-.latod; BK - boItmn b",'" i ,~I",.d, Arro"" ho",1> j"di,a10 lhe ",igrali"" p<»iliM ur the 
,,-,,['Ccti.-< chim..,ric VLP,_ 
The imrurity "rth ~ samples \Va, nmlirm~d Ily w~'l~m blols. a lthough the dala sh()w~d 
~11 isolated b~nds contained chimaeric VLI's to some degree, d~srile lh~ir OtwiD lLS 










rrom onc anothcr using the \vestern blots (Fig. 4.4a). with all three appearing to contain 
(jag I~ and se\eral other Gag products, The TEM data suggested that even though the 
top band or thc (jag IN sample seemed to contain larger quantities of VLPs. there were 
numerous unknO\\n structures also present (Fig. 4.5a), The middle and bottom bands 
(Fig. 4.5b & c) \\ere slightly cleaner samples. however intact VLPs wcre few and far 
bet\veen. 
Similarly. the \\estern blot of GagRT samples showed that GagRT was present in both 
bands (Fig. 4.4b), It was difficult to di fferentiate between the two GagRT bands using 
11:\1 (Fig A.h). as both appeared to contain VLPs along with other structures. The origin 
of these structures \\ as unknown. but could be cellular matter or contaminants I,'om the 
sucrose used to form the gradient. Given that each band isolated t\'om the gradient was 
comprised of se\eral proteins. it was necessary to attempt to further characterize each 
band. thereby establishing which band/s would be the best to utilize for mice studies. 
Ihlls. sucrose gradient t,'actionations were performed for the respective VLP 
puritications. \\here 40 f1'actions of I ml were collected. 
The bands I,'om the Gag TN puri tication were remo\'l~d in the t,'actions 6-10 (bottom 
band). 15-17 (middle band) and 19-22 (top band). while the GagRT purification bands 
\\cn~ rem()\ed in fractions 15-18 (bottom band) and 31-36 (top band), The sucrose 
dcnsity rangc or each band was determined (Table 4.1). and p24 ELISA was performed, 
The bottom bands of both constructs were closest to the density expected for Gag-only 
VLPs (1.15-1,17 giml) (Hammonds et al.. 2(07), The other bands occurred at lower 
densities. suggesting that their contents comprised more of the smaIL less dense proteins 
(such as (Jag p24 and p41) than the bottom band. Alternatively. the chimaeric VLPs 
could be Colding in such a way as to decrease their density, and therefore. despite their 
larger molecular \\eight. settle at a lower density than what was Pl'C\iously seen with 
(jag-only \,[Ps. 
The [LISA data (Fig, 4,7) verified that the visible protein band t,'actions isolated from 











the (iag: TN sumples corresponded to th~ !urges! q uanlLly 0 (- Gag p24 (Fig:. 4.7a), wili Ie the 
lOp (iagRT band contained the gre~tcsl p24 quantities (Fig. 4.7h).lntereslingl)', there "a~ 
a third region (fractions 25-29) in the (iagR I data thut contained high Ciag 1'24 
concentrations but did not form a visible band. It is possible thut the composition "I' the", 
tractions inclllded a large percentage or smaller (jag proteins (such as Gag p24), "hich 
\\ere llot parlicuiule and til liS unable to rdleet lIght sullkiently 10 form a visible band. 
(" ) 
(, ) 
ri~",. 4.3 - Eleelron miuoW"pil> oj' ","acled pn~ci[] ba",j,; from tile {;agT~ ~lXil, (al lop ba"d, (b) \lidJle 
oan,j: (e) Rott()ln o .. ,d ;",tatoo. VLP, "',,,,r,'ed in "II three ext racts were he'"oen 1!5 170 nm in di,meter 











Figu ro 4.6 - lltttro!l micrO£,"ph, of.w .... ".d I'"",.i" Iml>d' ITom ' he C.agRT ~1XiL1_ fa) T"f' b.nd; 
(oj Rottom ",",,,i. VT.P, ob"'r\ 00 in ali exlr~:(' weTe "'" "_'-'n ISO - 21 0 nm in di,rnc1cT. IJ.. 500 
nm f0.- la): bar - 1000 nm f<" (bj_ AITo", docric! "'""'pb ofVI ,Ps. 
Table 4.1 - Th~ Jensity range, or the flrnte in banJs isoialcd from thc sucrose densit)' 
gradient fradionution 
.. . . 
Construc t ElanJ isolatcd Ikositv ranne of . " Ikn,i~' range- of 
from grmlicnt fnl ctions (g!ml of fractions (0;" wl,- of 
SllCroSC) , sucrose) , _. , 
GagT :"I Rot tom I .146 - I _176 34.2 - 40.2 
.. •.. 
\l iJdle I . 137 I .142 31.9 32.5 
.. 
Top 1.1 I I .12 
( 
26.9 27.9 
GagRT Bottom I .146 \.\61 
, 34.2 - 36.6 
-- --
lop 1.0~ I 1<)_9 203 , 
- -
Bc.:auscthe EI-ISA data i, a me~surel1lent oj"Gag fl24 as opposed to Pr55"" . it is dilTicull 
to cOn<:lude which hanJI" ~omprised of" Inc majorit: of intoct VLP,,_ In \'iew of this, it 
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FlgUl~ 4.7 Gog p:'4 ELISA d.", of th<' r",ct i,,,,, ob la ined fmr" " ,L>Cm>< J on,ity 2radl<"f conTai nin& (a) 
(j"gT"-illj<cr<J cell ' "1'<"""1<,,,( 1",1",,: (b) (.ag ll l _infe'fed coli ' '' I'''J'tlatanT f"ll<t. f1J'ock"" it>dicote the 
numocr of h.cti()n, that includ<d in the ""I'-"Ii\'o protein band, . Abbn·" i,liu"" TB lOP bo nd: M II 











II b impol1am 10 not~ that the negative control (Sf! cdl, illl<e<:led with wilJtype 
bacuJovim'l abo di>pJayed a prOlein b.lnJ on tf><, sucrose gradielll (at approximaldy 
35.5 % sucrose) alier ultracentrifllgation. Thi> band wa, isoJateJ anJ analysed. II was 
r<,unJ 10 conlain baclIIO\ iru s parlicles amongst olher u nkllown stnlcturc> (HoM data not 
,howll) blLt le'led n~g31i y~ r<>r th~ pr"scnec or Gag on western blots. as was expected . 
• 1.3.3 OI)(;U IIUTificli lion 
Simi lar 10 "hat was s~"n with th~ SD<iU plrrillc3lion. thc OD<iU yieldcd morc than one 
balld Otl the d"nsity graJients oi"the r~sp~'\:ti,e VLP puritications (Fig. 4.8). The 0agTN 
s.lmplcs produced three band, and OagRT '-'Imple, produced two band,. Given lhal both 
Ihi> pU'ifLcation melhod and SfXil! employed dellsily graJi",," to isolate banJs, il was 
not surp,i;ing Ihat all the bolated b.lllds were fOlllld to carry the chimaeric Vl.Ps. a, was 





Fi~u..., ~.8 Oplir"p~ d<",h, 2"dients (20· ~O ~/.) coot . inin2 ;nf<cl<d cdr '"p."".l.m pelk[> .llc~ 
~lt,"ccntTijtigatin<l .. 2(, 000 'I'm r", 1.5 hr<. (oj roll, wor< inf""tod pri", tn I'u,ifica(inn with 00&'1 N 
rAcMNP\,., pt., lhe d,",c7I1lir"d <.>plimi<ed C()ooiliun,. ( bJ Cell, "cr~ infoctod ["'"in'- In puriiication ",ilh 
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Jt "as not possible I<l Jistingllish hdw",," lh~ balld, "xlraCled using TEM (Figs 4.9 and 
4.10 for GagTN and GagRT respetli,dy). a, all Ih" nallJ, COlltailled intact VI.I'" 
Hov,'Cve,. the electron micrographs did ililistratc Ihat th" OD<il! samples app"ar~J 
relatively pllre' than what wa, sccn with the SD<jL pUrilic3lion. "ilh ("w"r ,andom 










\\cstcrn hlot (Fig. 4.11) and SDS-PAGE data (Fig. 4.12). with fe\\er (jag cleavage 
products detected. Also. the chimaeric VLPs. GagTN and GagRT. \\ere the most 
prominent protein in their respective sets of samples. unlike the SDGl) samples . 
. \s \\ as the case \\ ith SDCiU. the negative control produced 1 band which tested negative 
for (jag. but did contain baculovirus particles (data not sho\\I1). 
-t.3...t 'It" purification 
The last of the purification methods investigated involved the use of membrane tilters to 
isolate VLPs from other extracellular proteins. Once the clarified culture supernatant had 
been isolated. it was filtered through a 0.45 ~lm membrane to remove excess cellular 
debris. The resulting filtrate was then filtered through a 300 kDa membrane column to 
concentrate VLPs. Finally. the sample was centrifuged and the VLP pellet resuspended in 
PHS. The VIP samples were analysed as done with the other purification methods. using 
SDS-PACiF. \\cstern blot. and TEM data. Coomassie-stained SDS-PAGE (Fig. 4.13) 
shO\\cd the extracted VLP samples to be of similar purity to the ODGU VLP samples. 
Although there \\as a fair amount of Gag cleavage products in both constructs' samples. 
this can probably be explained by the concentration of all products being higher in the 
\H: preparations. relative to the previous preparations analysed. Importantly, the 
clea\age products \\ere undetectable when the VLP samples \\ere diluted 1 in 10, while 
the chimaeric VLPs \vere still present at this dilution. confirming that these VLPs were 
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The western blot data (Fig. 4.14 and Fig 4.15) reiterated this point for both constructs, as 
well as implied that the presence of Gag cleavage products was less than what was found 
with the previous purification methods, because it was only faintly detected in samples. 
In general, this purification method was suspected to be slightly harsher than the previous 
two methods because of the pressure exerted on the VLPs as they were filtered through 
the respective membranes. Therefore, Nef and RT-specific western blots were also 
performed to verify that the protein being detected on the Gag p24 blot also contained the 
respective fusion protein, and that these proteins were not being cleaved off the chimaeric 
protein (Fig. 4.14b and Fig. 4.15b). It was clear from these blots that the chimaeric nature 
of the respective VLPs was maintained after purification. 
The TEM data (Fig. 4.16) showed that VLPs were being isolated in particulate form, and 
there appeared to be fewer random, unknown structures present, which were possibly 
removed during the ultrafiltration step. As was seen previously, the GagTN samples 
appeared to contain a larger quantity of chimaeric VLPs compared to GagRT VLP 
samples. This is probably related to the ability of the insect cells to express the respective 
proteins. Given that GagRT is slightly larger in molecular weight and size, it may be 
more difficult to produce. In addition, it might also fold in a higher energy conformation 
that renders it slightly less stable than the GagTN VLPs. TEM analysis was also done on 
the negative control to determine if similar structures were present (Fig. 4.17). Although 
there were some similar structures (spherical shapes were 88-110 nm in diameter), none 
were the same size as what would be expected for VLPs. Several of the smaller structures 
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Tahle 4.2 Ihe (iag p24 ELISA data for the three puri tication methods 
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-+.4 Discussion 
rhe nccessity to purify chimaeric VLPs before they arc used in mouse immunogenicity 
studies is t\\()-fold. Firstly, it is important that the immune responses elicited in mice are 
accuratcly attributed solely to the chimaeric VLPs. Secondly, if the VLPs are not 
c'-:tracted sterilely, the prescnce of endotoxins in the injected samples could cause the 
micc to sutTer from toxic shock and die prematurcly. Hence, the cxpression system used 
I'm VLP production and the method of purification is of great importance. 
As mentioned pre\-iollsly, an insect cell expression system provides a novel approach to 
producing VLPs and has been used to successfully produce HIV VLPs, I iuman 
papilloma\irus (IIP\') 1.1 VLPs (Le Cann et aI., 19(5), and Hepatitis L VLPs (Li et aI., 
2()()5). One of the rcasons for easy production and isolation of VLPs in insect cells is 
hecause VLPs can be targeted to bud out of the cells and into the culture supernatant. 











li'om inside cells is avoided. as VLPs can be isolated directly tj'om the supernatant (Hink 
et a!.. 1l)() 1 ). 
In this study. the chimaeric VLPs were myristylated. and therefore budded out of the 
insect cells altcr expression. as was demonstrated using rEM analysis. Although there 
\\ JS no definite \eri tication tl1Jt the budded structures \vere the Gag chimaeric VLPs. 
their Jbsence in the negative control. Jnd their similJrity to previously characterized 
VLPs \\as convincing evidence (Halsey et al.. 2008; Jaffray et al.. 2004; Sakuragi et a!.. 
2()()2). In addition. previous research on the CiagRT and CiagTN constructs in our 
laboratories used immunogold electron microscopy to sho\\ that similar structures as 
those depicted abme contained Gag components (Halsey et al.. 2008). 
Once budding \\as established. three methods of VLP purification \\ere explored to 
determine \\hich method \\as able to isolate the highest VLP yields \vhile still allowing 
chil11Jeric \'LP stJbility and integrity to be maintained. Two criteria \\ere used to 
e\ aluate the chosen methods. namely. the quality and quantity of VLP samples obtained 
in the respective puritications. 
The quality of VLP preparations (in terms of VLP morphology. VLP size. composition 
Jnd purity) \\JS examined using western blots. Coomassie-stained SDS-PAGE gels and 
ITM analysis. The data indicatcd that all purified VLP samples contained intact 
chimaeric VLPs. As expected. these were larger and more irregular-shaped than the Gag-
only VLPs (Jam'ay et a!.. 20(4). and varied widely in size. \vith GagTN VLPs having a 
diameter range of about 120 -185 nm, and GagRT VLPs having a rJnge of 135- 230 nm. 
This variation. while not ideal, was not unexpected for chimaeric VLPs. and has been 
seen prniously (Halsey et a!., 2008: Wagner et a!., 1994a) . 
. ".Ithough only one VLP band was expected to result from the density gradient 
ultracentrifugation purifications, there \vere multiple bands found for both constructs. 
Ihis \\as surprising. but could be explained by the formation of VLP aggregatcs or the 











di fTen:nt densities. The formation of multiple bands complicated matters becausc it was 
difficult to difkrentiate between the bands formed. even after fractionation 
characterization. To use either SDGU or ODGU for bulk purification purposes. it would 
be necessary to combine all bands to accurately determine the VLP yield obtained by the 
respective puri fication methods. givcn that all bands contained chimaeric protcins of the 
correct molecular \\eight. Howcver. combining the bands could potentially lo\\er the 
purity of the extracted sample. [n addition. the similar buoyant density of the band found 
in the negative control for SDGU suggcsts using this method to isolate pure VLPs would 
be a di ftieult task. 
[n terms of quality. the VLP samples obtained using the SDGU and ODGlJ purifications 
\\cre quite different. despite the similarity of these methods. The VLP samples from the 
SDCil' purification comprised of many more small Gag cleavage products than the 
ODCil! samples. as demonstrated by western blot and SDS-PAGE analysis. While the 
presence of (iag clea\age products was found in all preparations and would not be ideal 
for the mouse studies. it was important to note that the ODGU and MU methods 
displayed strong chimaeric VLP bands and only a tew prominent Gag cleavage products 
in the \\estern blots and SDS-PAGE data. This \Vas particularly noticeable for the diluted 
:v1l; samples. which demonstrated detectable chimaeric VLP bands on the Coomassie-
stained SDS-P/\CiF gels. which did not occur with the diluted samples of the othcr 
methods. [n addition. thc S[)(iU samples appeared to indicate that the respective 
chimaeric proteins \\ere not the most promincnt proteins isolated using this method. 
No definitive conclusions could be made from the TEM analysis of thc VLP samples; 
hO\\e\er. it \\as clear that there were several impurities found in the protein bands 
isolated via SD(il l . These were also found in the preparations from the ODCiU and MU, 
although not as frequently. Some of the structures found in the TEM analysis were 
baculo\irus-related. which is not unexpected. but there werc many unidentifiable 
structures that \\'ere possibly cellular matter (such as microvcsiclcs). impurities from the 











prmiuce high non-specific immune responses 111 experimental mice, therefore skewing 
results obtained in immunogenicity tests. 
lhe lju:.l1ltity of VLPs within the given preparations was assayed using Gag p24 ELISA, 
in conjunction with the Coomassie-stained SDS-PAGE data. Both methods ,vere uscd for 
this purposc to account for thc fact that the ELISA measured only a component of Gag 
(p24) as opposed to quantifying the whole VLPs present in the respective samples. In this 
\\ay, the !:LISA results could have been skewed by the presence of Gag cleavage 
products. and therefore needed to be used alongside the SDS-PAGE data, so as to 
confirm they \\ere reflecting what was being observed in the SDS-PAGEs. 
(ii\ en that multiple protcin bands wcre isolated II'om thc SDGLJ and ODeil) 
purifications. and that all bands contained chimaeric VLPs as well as other Gag products, 
it \vas ditlicult to make direct quantitative comparisons bet\veen mcthods without 
comhining the amounts obtained for individual bands for SDGU and ODGU. The data 
illustrated that thc MU yields were greater than the combined band yields of the othcr 
t\\ 0 methods. While the ELISA data was not a direct indication of the VLP yield, and 
\\ as obviously influenced hy the presence of Gag cleavage products, when used in 
addition to the Coomassie-stained SDS-PAGE data, it seemed likely that the MU 
purification method yieldcd the best VLP yields. 
In conclusion, although SDGU has becn used to extract HIV VLPs for previous mouse 
e\:periments in our laboratories as wcll as others, thc results suggest that SDGU was not a 
good option for purification of the chimaeric VLPs. Both thc quality and quantity of 
VLPs isolated using SDGU was poorer than what we found with ODGU. In terms of 
quality of VLPs, ODGt J and thc MU preparations wcre similar. as both methods yielded 
intact VLPs. \\ith fcw cleavage products and impuritics. However. the quantitative data 
favoured \!Il'. The yields produced by this method werc almost double that of the ODGU 
yields. \it: \\as also less labour-intensive than thc previous methods, making this 
purification method the better option for producing bulk VLP preparations for the mouse 
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5.1.1 Prime-Boost \accine strategy 
There is an abundance of evidence to suggest that an effective cellular immune response 
against HIV -I is able to control and suppress viraemia during primary and chronic IllY 
infl:ctions. in addition to providing long-lasting protection (Amara et aL 2005; Oeml et 
al.. 2()():": .Iam·ay et al.. 2()04). Although several HIV vaccine attempts have illustrated the 
ability to induce cellular immune responses. many have been weak and lacked longevity 
in non-human primates and humans (Paliard et a!.. 20(0). As mentioned previously. the 
use of a heterologous prime-boost vaccination is an effective method to enhance T-cell 
and humoral responses. The basic concept of a prime-boost vaccine is to prime an 
Immune response against one or more target antigens using one vector. and then to 
enhance the speci ficity of this response by exposing the immune system to the same 
target antigens delivered by another vector (Woodland. 2004). Most of the recent prime-
boost \accinations have made use of a DNA vaccine prime and a viral vector vaccine 
boost. although. other boosting candidates have included subunit protein vaccines and 
VI P \accines. VI Ys have been of particular interest because they have been shown to 
elicit signiticant immune responses. 
In this study. the chimaeric YLPs. GagRT and GagTN. were tested for their ability to act 
as \accine boost candidates. The presence of multiple antigens in these VLPs reduces the 
likelihood of CTL escape. which often occurs when there is a single. dominant epitope 
(Deml et al.. 2005; Ellenberger et al.. 2005). Furthermore. multi-protein vaccine 
candidates arc able to elicit broader and possibly more effective immune responses 
against IIlV (IJlenberger et aI., 2005; Nkolola et al.. 2(04). In particular, Tat, Ner and 
RT contain se\eral prominent CTL epitopes. Tat and Nef-specific 'I-cell responses have 
sh()\vn a correlation with non-progression of IllY and possible protection (Scriba et al.. 
20U:"). \\hile RT has induced potent Th 1 responses in mice. when administered in low 











S, I.2 pVRCgrllllC /} .~A \'accint' 
In lhi, ,[udy. the "prim,," component for ali \'3ccinal;on cxpcrim~n!s " as lh~ DNA 
vuccine. pVRCgrtlllC (Fig. 5.1). This vaccine is one o l'the 1\", plasmid, IhaL made up the 
SA/I V I DNA -C2 "acein". a ""conti generalion vac~il1e. cn:aled in th" Unh ~rsity of Cape 
To-,n SAAVllabma[orj"" It is lmsetl on the firs! generation vaccine. SAAVI Dl\"A-C 
(pTHgmnC), onl)' differing ill the lector backbone (lJurgers c( aI., 20(6). In pmli~ula r, 
lhe plasmid, "VRCgrt!nC. encodes a muitigcnc DNA ,accine in lh" fo rm "fan HIV- I 
,uhlyJlC C pol)'protein derived from ll u422 and [)u l SI HIV i;<>ime" All gene, "ere 
optimized to rellecI human codon u,age and 1ll(,.jilEeJ 1(" >akly plll-poses. The 
polyprolcin. grttnc. compri",d "I' f"m HIV protein" namely. p(HruncuKxl Gag (ldyr- ). 
i"aet ivmet! ,eve"e trLtn,criptase (R 1'). >lm flled Tat and inactivatcJ Nef (TN). 
rhe backbone of the pVRCgrttnC plasmid was a pVRC vector pmvit!ed by the Vacc ine 
Research Centre of the ~miona l In~titut~s of Health. flelhe, t!a. Mary l'-'llt!. US/I, This 
backhone eontainet! the kanam)'cil1 ""i,tal1ce gene as a Sl:kction marker. and a 
regulatory R regiol1 (ium the 5' long terminal rep"at (L TR) of human T-cel l leuk""mia 
viru, type I (II II .V-I). \\hich acted as a lran,rriplional ant! po'llr:m>eriplional enhUl1cer 
(Rlmuch et al., 2005). In general. CMViR !)l\"A "aceines e licit ,ubstant ia lly higher 
HIV-l sJ)CciflC cellu lar immune response, wmpared \\,ilh the analogous C\'IV-only 
puremul DNA vaccine:> in both mice and l'ynomnlgu, monkeys. hence its u,e in Ihis 
\'acr:ine (13arouch el aL. 2005). 
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5.1 .... Chaptet' ohjectins 
The aim~ of the \\ork reported in this chaptcr vvere as follows: 
(i) 1 () utilize the extracted chimacric VLPs as boost candidates III two DNA 
prime - VLP boost vaccine strategies in mouse studies. 
(ii) To evaluate the cellular immune response elicited by the chimaerie VLPs in 
mIce. 
(iii) To evaluate the humoral response induced by the prime-boost vaccination of 
mIce. 
(i\) 10 il1\estigate whether the use of two boost inoculations impro\cs this elicited 
immune response against HIV. 
5.2 Materials and Methods 
5.2.1 'Iicro-/l"Itrafiltration 
I he appropri:.lte optimal conditions Crable 3.2) were utilized to scale up production of the 
respective chimaeric VLPs in Sf9 cells (2500 ml). At 96 hpi. infected cell culture was 
transferred to sterile 25-ml bottles (SteriIin) and spun at 1000 x g for 20 min to isolate the 
culture supernatant. Micro-/ultrafiltration were used to extraet and purify VLPs from the 
culture supernatant. as described in 4.2.1.3. 
5.2.2 Protein analysis 
5.2.2.1 Quantitati\ e western blots 
10 lIuantit'y the amount of purified chimaeric VLPs obtained. a dilution series of the 
respeeti\e samples \\as run parallel to a dilution series of a positive control [recombinant 
(Jag p 17 Ip24-C protein of known quantity (ARP 695.2 - FIT Biotech Oyj Pic, Tartu, 
htonia)] on western blots (done as described in 2.2.3.1). The intensity of detected bands 
\\as measured Llsing densitometry software. Genesoft (SynGene. Synoptics Ltd.). and the 
intensity data from the positive control samples was used to plot a standard curve. This 











purified stock solutions. These westcrn blots \vcre pcrformcd twice to determine an 
:.1\ erage \alue for the quantity of VLPs isolated. 
:'.2.2.2 ('oomassie-stained SDS-PAGF 
Ihe purity of all \"LP samples werc analyscd using SDS-PAGE (done as described 111 
-+.2.2.1 ). 
5.2.2.,\ Negati\e staining TEM 
.\11 purilied VLP samples undcrwent TEM analysis as dcscribed in 4.2.3.1. in order to 
verify VLP structural integrity. 
5.2.4 Endotoxin tests 
Indotoxin tcsts \\cre pcrformcd using thc QCL-I OOOH Limulus Amcbocytc Lysate (LAL) 
kit (Cambrex Bio Seiencc Walkersville Inc.). Thc procedure \\as carried out as detailed 
in thc man u faeturer' s instructions. Samples wcre dcemed acccptabi c for mouse 
expcriments if endotoxin readings wcre equal to or below 0.125 Endotoxin LJnits/ml 
(fT ml). 
5.2.5 YaccinatioI1 of mice with the respective chimaeric YLPs 
5.2.5.1 Preparation of mice 
All mouse experiments were approved by the University of Cape Town Animal Ethics 
('oJl1mittee. Female 11_2" 8alblc mice \vere used in vaccination experiments (South 
Ali'ican Vaccine Produecrs Pty Ltd- Johannesburg. South Africa). and kept at the 
lini\ersity of Cape Town Animal Unit for approximately I () days before vaccination (to 
Jllm\ JliJptJtion to surroundings). They wcre maintained here for the dUrJtion of the 
experiments. 
5.2.5.2 Inoculation plan for experiments 
The vaccination protocols for the four mouse expcriments were performed by trained 
Jnimal technologists according to the schedule described in Tables 5.1. Thc "primc" 











(resuspended at Img ml saline) (Aldevron. Fargo. ND. USA) per mouse. This \vas done 
\ ia an injection of 50 I--d into the quadriceps muscle of each mouse. The "boost" 
component of the \'accination was the administration of purified chimaeric YLPs 
(resuspended in h PHS). Mice were bled prior to inoculation. and at the end of the 
e~perilllent. \\hich \\as 12 days after the boost inoculation. The spleens of the infected 
mice \\ere ha]'\'ested to determine the cellular immune response induced by the respective 
in oc ul at i on s. 
Table 5. J- The vaCCll1es and vaccination protocols for the mouse experiments 
(p\'RCgrttnC DNA prime - GagRT or GagTN YLP boost). 
Gn)Up Vaccine Inoculum Vaccine Inoculum 
# mice (prime) per mouse (boost) per mouse 
Day 0 (/lg) Day 28 ( /lg) 
I : p YRCgrttnC 100 -
.------L i 





3 pVRCgrttnC 100 Respective I 0.05 
YLPs 
-+ i p VRCgrttnC 100 Respecti\e 0.10 
! YLPs 
5 ': pYRCgrttnC 100 Respective 0.20 
YLPs 
() - Respective 0.05 
YLPs 
7 , - Respective 0.10 
YLPs 
S ' - Respective 0.20 
! YLPs 
(hen: \vere live mice per group. all of whom received the respective vaccines via 
intramuscular injection. Blood sera samples were taken before inoculation and sacrifice. 
All mice \\ere sacrificed on Day 40. and their spleens were rem(wed and processed as 











5.2.6 Immunogenicity testing 
).2.(1.1 Preparation of splenocytes for immunogenicity assays 
I he spleens of each group of mice within the gi\'en experiments were pooled. A single 
cell splenocyte suspension was generated by meshing the pooled spleens of each group 
through a metal sine using RPMI medium (Gibco). Suspensions were transferred to 50 
ml Sterilin I \1 tubes and centrifuged at 1500 rpm for 5 min. The resulting cell pellet was 
re-suspended in 50 ml 0 f RPM [ and the centri fuge \\as repeated. Resulti ng pellcts 
under\\ent two further washes, where fibrin clots were removed using a Pasteur pipette 
before the linal centri fuge. They were once again resuspended in 50 ml RPM I medium, 
cell count and \iahility was determined and the required number of cells for the 
imlllunogenicity assays was removed. These cells were centrifuged at 1000 x g for 5 min. 
The red blood cells (RBC) of samples were lysed using a RBC lysis buffer (Gibco) when 
the splenOC)1eS \\Cre used in IFN-, and IL-2 assays. 
('ells \\erc centrifuged agall1 at 1350 rpm for 7 mm. The pellets were resuspended in 
complete RPf'v1I medium (Appendix 85.1), and cells \vere re-counted, so that the required 
quantities of cells for the respective assays could be removed. 
).2.6.2 Determination of phenotype of splenocytes 
Cell surface markers (CD3, CD4, CD8, CDI9) on isolated splenocytes \\ere investigated 
using 110\\ cytometry. To prepare samples, 1 (% blocking solution (in tris-buffered saline) 
\\as added to 1 x 10(1 splenocytes, and incubated for 20 min in darkness. Cells were then 
\vashed with FACS buffer [PBS with 1 %) FCS + 0.1 (Yo NaN1] and centrifuged at 1500 
rpm for 5 min. The cell pellet was resuspended in residual FACS huffer, fluorescent 
antibodies specific to the respective cell surface receptors were added to samples, and 
they \\ere incubated for 30 min in darkness. Cells underwent another FACS butTer wash 
and centrifuge, follo\\t;d by the addition ofa FACS Lyse solution (BD Bioscience) and a 
further incubation of 10 min at room temperature. The final step involved another FACS 
buffer wash, after \\hich cells were resuspended in 900 ~Ll FACS buffer. Labelled cells 
\\ere acquired on a FACS Calibur flow cytometer (500 000 gated events acquired per 











S.2.h.:- LLispot assays 
I he isolated splenocytes \\ere used in IFN-, and IL-2 FLispot assays to evaluate whether 
specific I-cell immune response had been induced in mice. These \vere perf()nned using 
81) 8iosciences kits. \\here the protocols were carried out as detailed in the 
manutacturer's instructions. Briefly. plates were coated with capture antibody (IFN-, or 
11.-2 antibody at S ,Ltg/ml in PBS). scaled and incubated at 4 °C overnight. IL-2 plates 
\\ere pre-\\cl \\ith 7() % ethanol before the coating step. so that the spots created a 
sharper image \\ hen detected. The next day. wells \vere washed with blocking solution. 
and incubated in blocking solution for 2 hrs at room temperature. The blocking solution 
\\as then discarded and the respective stimulant peptides \\ere plated in the necessary 
\\ells. Ihe peptides antigens used as stimulants in these assays are detailed in Table 5.2. 
It is important to note that the Tat4 (NCYCKHCSYHCLVCFQTK) and Nef8 
(\,(iAASQI)LDKHCiALT) peptides (final concentration: 4 ~lg/ml) were not referenced 
peptides. The MHC restriction of the Tat 4 peptide was unknown. while Nef 8 was an H-
2Kd binding peptide with a possible CDR epitope in Net'. All peptides were prepared in 
R I () medium (Appendix B5.1). although the Tat4 stock contained 0.04 (10 DMSO (in final 
concentration ). 
A single cell suspensIOn of splenocytes was prepared as described in 5.2.5.1. and 
splenocytes \vere plated in triplicate at 5 x 10:i/well in a final volume of 200 Jll RIO 
culture medium. Concana\ilin A (Con A) (Sigma MO. USA) \vas used as a positive assay 
control. and plated in the respective wells after the cell suspension to a tinal 
concentration of 0.5 ,Ltg/m\. Plates were then incubated in darkness at 37 0(', in a 5 (Yt) 
(·Oc. humidified incubator. After 23 hrs. plates were washed 3 times with eH-IeO. then 3 
times \\ ith \\ash burter I. Detection antibody [biotinylated anti-mouse IFN-, or IL-2 
diluted 1 :250 in dilution buffer] was added to each well (1 00 ~l l/well) and plates were 
incubated for a further 2 hrs at room temperature. The detection antibody was then 
discarded and plates were washed 3 times with \vash bulTer I. Avidin horseradish 
peroxidase (Avidin-IIRP) (diluted 1:100 in dilution buffer) was added to the plates (100 











buller I and II as done before, and 100 ~t1/well of Nova Red substrate solution (Southel11 
('ross) \\as added, Spot development was monitored for 5-1 () min before reaction vvas 
stopped by \\ashing \\ ells with H::>O 5-6 times, Plates were air-dried at room temperature 
and stored in the dark until analysis. 
Plates \\ere scanned using an ELispot CTL Analyser (Series 3B) and spots \vere detected 
~ll1d counted using a computerized Immunospot Image Analyzer (Cellular Technology 
Ltd. ('Ie\eland. Ohio) with Immunospot software (v3.2). The mean number of spots was 
determined for triplicate \vells and adjusted for one million splenocytes to provide data as 
spot forming units (SFU) per million splenocytes. The background responses were 
identitied as the responses observed in the absence of peptide (stimulation with the 
medium only) or the presence of irrelevant peptide. For each group of mice, a response of 
2:to the mean background response + 2 standard deviations (SO) was considered as a cut-
off for a positi\e response. 
Table 5.2 Stimulants used 111 IFN-y and IL-2 ELispot assays (final concentration: 2 
,llg ml) 
~;~l-e-o-t~'-'I---------D-e-s-c-rl-'p-t-io-n---------'---A--m-i-n-o-a-c-'i-d---'---R--e-fe-r-e-n-c--es~ 
stimulant II seouence 
---------~·--------c------~--------~------·~~--~----+_------------~ 
R 1 () : Background control 
med i um 
-----~-. --,-------~,---------------~--------------~------------~ 
IrrelC\ant' H-2Kli binding peptide 
peptide I (Negative peptide control) 
(jag CDsI~I-2K'1 binding peptide: CD8 








! epitope in Gag 
: 
MIIC-II binding peptide: C04 
AMQMLKDTI (B urgers et aI., 
2006: Mata, 
1999) 
NPPIPVGDIYKR (1m, 2007: 
epitope in Gag WIIGLNK Mata, 1999) 
I
I MIIC-II binding peptide: CD4 FRDYVDRFFKT (1m, 2007: 
epitope in Gag LRAEQATQE Mata, 1999) 
I MHC-II binding peptide: C04 PKVKQWPLTEV I (Casimiro, 
I epitope in RT KIKALTAI 2002) 
ll-2K'I binding peptide: CD8 VYYDPSKDLIA (Casimiro, 
epitope in RT 20(2) 











5.2Jl.4 LA \' blot \\estern blot 
.\ commercial Ne\v LA V Blot I (BioRad) was used according the manufacturcrs 
instructions to determine the specificity or the antibodies in mouse serum, and thus 
e\ aluate the humoral immune response induced by the respccti\'(~ \·accines. Mouse serum 
\\as used at a 1:-l-0 dilution and antibody content detected with goat anti-mouse Ig (J 
conj ugated to al kal i ne phosphatase. 
5.3 Results 
5.3.1 Quantification of purified VLPs 
\'1 Y production \\as scaled up in order to generate the quantities necessary for mouse 
studies. T\\() batches \vere produced per VLP construct, so as to ensure there would be an 
adequate quantity or VIPs available for the immunogenicity experiments. Purification or 
the respective VI Ys \vas performed using micro-/ultrafiltration, and once puriried, VLPs 
\\ere stored in PHS at 4 0(', Samples were analysed on western blots to confirm that 
chimaeric VIPs had been purified and isolated intact (Fig. 5.2). Although Gag p24 
ELISA \\as Pl'C\iously used for quantitative purposes. it was found to underestimate the 
quantities or VIPs. possibly because disruption of the VLPs \vas not occurring optimally. 
I hercfore. \\estern blot densitometry was employed to quantify the Gag content of 
puritied VIP samples for mouse experiments. A dilution series of a Gag p 17/p24 positivc 
control of klllmn quantity was employcd to create a standard curve that was used to 
determine the (Jag eoncentration of chimaeric VLPs in the respective sample batches. As 
\\as obsened in previous chapters, a prominent, intact chimaeric protein band was 
detected for the respective samples on the western blots, as \vell as less prominent Gag 
clea\age products (Fig. 5.2). The TEM data suggested the samples were fairly 
heterogeneous. but this \\as expected. given the data obtained in Chapter 4. More 
importantly. the TLM data illustrated that VLPs were structurally intact (Fig. 5.3). 
Hatch 2 of the respective chimaeric VLP stocks were selected for the mouse studics 












10" er enJotmi n va l ue, (,~e A Pf"Jndi~ G). Batch 2 of tho: Gag TN VI.Ps contained about 
50 IIg "I' VIPs, culkdeJ fmm ::o.~ l i tr~' of infeck>J Sj9 cd ls. Balch 2 for GagRT VI.p, 
cuntaincd arpro~immcly 38 j.lg of VLPs, isolmed fnMn the same quantity uf cel ls. 
Quantificmion ofthe,c bmchcs j, givcn in ilppendix i'. 
5.3.2 Ana lys is ufpurificd VI,I' , 
To analyse purity of the VI I' ,amples. C(Mlmassie-slained SnS-pAGE was u,cJ. Thi, 
indicm~-d thatthc ,amplcs wcre fairly pure. as <:ellu lar and hacu lov irus proteins Were not 
prominent ly detected (Fig. SA). 
EnJoto;..in te,t rc,ults (.>\ ppendlx G) provided e, idencc of the steril ity of the respective 
,ample,. The recornmcnJed level of elll]oto;..in, allo"eJ /'" animal ,tudies lS one that is 
less than (If cqual to 0.125 endo toxin un its per ml (EU/ml) , Once Vl,p stocb ilad becn 
Jiluted a, was required for mouse inocu lations. the enJ(>toxin levels in the res.pective 
,amplcs "ere belo'W what was Jeemed un,afe for mi<:e. TIIC,e could therefore be u,ed in 
the vaccination experiments. 
GaglNllt GagK t II I G.~RT lIZ 
\t 96 t68240 0.1 0.010.001 o.t O.Ot O.OOt M 24 48 72 % 0.1 O.Ot 0 .1 o.Ot - - • - • -
- -- - - ---
(oj 'hl 
h~un; 5.Z- W.'te,n bl"" pri",od "'lh 11t\ (jag p2~ primary "n'ibu<J~ ''''rc u,oJ <u anal ~>c and 4"""l il:, 
purified VI.P "''''ric>, taj (",agTN VLP ,a"'rlo , ; (h) GagRT VLP ""'rto,. ,\bb",.iatioll<.' M - molocular 
w~igh' marler; + i,'c - (",ag pi 7i p24 ([>II ) pmili,'c co{,lml "I' known qu.ntit i", (ngl; B I - batch I , III -
batch 1; 0.1 - I in 10 dilution: 0,0 1 - I in tOO di lution' 0.001 - 1 in 1000 d;iLK;on, Arm" iI<.J, indic",-" 











fi~",'O 'U . Fleotr~n micmgrO(>h' of ~"T.':[Cxl chim"~ri" VLP, (0) G"gTN VLP ,,,"ple; Un .. - 200 "m (b) 
G.gRT VLI' "."pl" Fl., - 500 noll. Red arrow, d.l~ct .,a'"ple< ofVL~_ 
M , 2 3 
• - • 
(a) (b) 
f ie""c 5.4 - S I )S-~.'\(JE gel phologToph' ~fthe '"'I>Oct;'" VIY "0'1'1'10. "n,7 ex">clion "<In" ml,"1-
iuilml,I"",j",,- (~) G"gTh VLP "lJTlpk,_ Lone.: I·m<>le;.:u l.r weighl "".-kor; 2-G.gTN \ l p, [Jotch I, 3-
(iagTh VLP, Bolch 2. (b) G.gRT VLP .ampk'_ Lan,,, I-G"gR I VLP, [J.loh I: 2-GoRI \LJ><; [Jolch 2: 
J-blan.: 4- ".,Ieelll., "eight "'''''.r_ "'row head' iOOk"" the migralion di"ooce "r the re>[l'-"C, ivc 
ohim ... i, VI.I',. 
5.3.3 Immunogenicit), studies Hn"I~'sis 
The prime-boos! nlC~ille r~girn"ns \\~re pcrf() rrn~J a, d~!ailoo in Tah lc 5.1. The 
ex[>t'rimellis aimed to delermine whether lh~ ~himueri~ VLPs had r"l~nliallo induce an 
enhanced cellular immune response" hen ad mi nistered as a boost component of a prime_ 
h<~"t vaccine ~tr"le!;~'. It ~nlui led lhe use or" DN A v"c~ine rri me (p VRCgrllnC) and one 
VLr h<>osl (eilh~r GugT">J or GagRT VLrsj. adminislered 28 days al'tcr Ihe Initial 











The spleens of the mice were removed and pooled for each group. The spleens were then 
processed to evaluate the cellular immune response that was elicited by the \accines. Cell 
surface marker analysis of splenocytes was performed to establish cell phenotypes. The 
number of C])~. C[)..t. CD~. and CD 19 cells and ratios of CD3!CD4. CD31CDS and 
(])4CDS \\as determined for each group. [n order for the immune responses of groups 
of mice \\ithin a gi\cn experiment to be comparable. they needed to demonstrate similar 
lymphocyte ratios and T-cell numbers, as considerable differences could influence the 
interpretation of assay data to follow. As desired. the cell surface marker data indicated 
that group samples compared within each experiment had similar numbers and ratios of 
I-cells to each other (Appendix H). 
C[)4- and C])S-+ I cells in splenocytes pools secreting IFN-, and IL-2 during ill vitro 
restilllulation \\ith specific HIV -\ antigen peptides were measured in FLIspot assays. 
Ihis \\ as done to determine if specific cellular immune responses were elicited in the 
n:pcrimental mice. and if there was a prominent boost effect detected for mice that 
recei\cd VLP boosters. IFN-, and IL-2 were chosen because both are central to the 
de\(:lopment of an adaptive immune response, specifically a cellular response (Janeway, 
2()()5 ). 
5.3.3.1 G{/gJ:Y L\jJl.'rilllcnt 
In the experiment Llsing the GagTN VLP boost, IFN-, and IL-2 assay data demonstrated 
a similarity in the results obtained for the media and irrelevant peptide (Appendix I). 
Ihese responses \VeIT due to non-specific stimulation of the cells. and were low as 
expected. hO\\e\l;r they were greater for those groups that received VLP inoculations, 
than those that only received DNA inoculations. There was also a strong. consistent, 
positive response stimulated by ConA (not shO\vn) which \erified that the assays had 
\\urked. 
[he IF1\J-, data sh()\\ed that, as has been seen in previous studies. mice that received a 
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specitically (jag CDX and CD4 peptides (Fig. 5.5a) (Jaffray et al.. 20()4). While the 
responses for Group 2 (DNA primc/DNA boost) were moderately better than Group I, it 
\\as clear that the usc of a GagTN VLP boost in addition to a DNA prime (Groups 3-5) 
\\ as able to enhance the production of IFN-, quite considerably. 
Ciroup -J. (D\lA prime 100 ng VLP boost) developed the strongest IFN-, response, 
specitically for the Gag CDR peptide (SIR ± 12.2 sfu), both Gag CD4 peptides (416 ± 
12.2 sfu and 75 ± X.I sfu respectively) and the Tat4 peptide (298 ± 33.4 sfu) (Fig. 5.5a). 
The boost effect demonstrated by group 4 was particularly prominent for Gag CDS and 
(iag CD-J. ( 13) peptides, where a 90-lold and 40-fold increasc (respectively) vvas observed 
\\ hen comparing these responses to those obtained for Group I. This contirmed that the 
(jag response \\as a dominant one, as has been reported in other studies (Betts et a!.. 
1997: Lichterldd et a\., 2(05). 
(iroups that recei\cd VLP inoculations only (Groups 6-8) displayed relatively strong Gag 
('!)-J. responses. although these responses were still approximately 5-fold lower than those 
ubsenul tll!' Group -J.. In particular, Group 7 (received the same VLP dose as group 4 but 
no DNA prime) generated the poorest IFN-, responses amongst of the VLP-only groups, 
pro\'iding further evidence of the boost effect exhibited by Group 4. 
Like (jroup -J.. (jroups 3 and 5 (received 50 and 200 ng GagT\l VLP boosts respectively) 
also demonstrated a boost effect for the (Jag CD4 peptides (I RO ± 7.6 and 294 ± 26.9 sfu 
respecti\ely) and the Tat peptide (97 ± 40.1 and 103 ± 13.1 sfu respecti\ely). Group 5 
appeared to induce stronger responses than Group 3, and also induced a Gag CD8 
response. which \\as not displayed by Group 3. Overall, the data indicated that although a 
boost effect was de\cloped by all three groups. the optimum dosage for an effective boost 
Dr the cellular immune response was clearly 100 ng GagTN VLPs «jroup 4) in this 
e"periment. 
rhe 11.-2 data (Fig. 5.5b) \'erilied this to be true, as Group 4 also demonstrated a boost 











and thelat (12~ ~ 21.2 sfu) peptides. There was no significant Gag CD8 IL-2 response 
I'm (iroup -J. as \\as seen with the IFN-, data, which was not too surprising, given that 
(D-J.' I-cells arc mostly responsible It)\' IL-2 production. Similar to what \vas seen with 
the II'\-y data. Groups 6-S (received VLP-only inoculations) showed the de\clopment of 
strong Gag CD4 ( IJ) and Tat responses. Again. the DNA-only groups (Groups I and 2) 
demonstrated relati\(~ly poor IL-2 responses. corroborating that an enhanced immune 
response occurred \vhen mice were boosted \vith 100 ng of GagTN VLPs (Group 4). 
l infortunately. the Nef responses in both the IFN and IL-2 assays demonstrated large 
\ariations (as indicated by the SO values) and were therefore deemed unreliable. 
Ihe LA \' blot data indicated that there was no apparent humoral immune response 
elicited in the mice of any of the groups post vaccination (data not shown). 
5.3.3.~ GagNT EYjJc/,illlCl/! 
rhe dose of 100 ng also proved to be the optimal VLP dose in the GagRT expcriment. 
\\here Ciroup -J. (received DNA prime/]()O ng GagRT VLP boost) elicited the most 
effeeti\c IFN-, and 11-2 responses (Fig. 5.6a and b). The highest frequency of IFN-, 
producing cells from Group 4 were those recognising the Gag CD4 (13) peptide (271 ± 
2().~ sfu) and RT CD4 and CD8 peptides (306 ± 22 sfu and 406 ± 25 sfu respectively) 
(Fig. 5.6a). Ihese responses \vere much stronger than the DNA-only (Groups I and 2) or 
VIP-only ((iroup ()-S) responses. proving a boost effect did occur. The VLP dosc used 
for Cjroup -J. ( 100 ng) appeared to be the only one able to elicit a boost response. because 
although the results ohtained from Group 3 also displayed an increased response to Gag 
CD-J. ( 13) and RT CDS peptides, this did not appear to be considerably greater than what 
\\as detected for the VLP-only groups. Group 5 generally produced relatively poorer 
IF)\;-y responses compared to Groups 3 and 4. Interestingly. while Group 3 was also able 
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Ihe 11-2 assay results (Fig. 5.6b) l'ollO\ved the same trend as the IFN-, data. in that 
(iroup -+ demonstrated positive responses to both Gag CD4 peptides (I n ± 37 sfu and 47 
~. 55.7 sfu respecti\ely) and RT CD4 and C08 (219 ± 48.5 sfu and 40 ± 9.2 sfu 
respectin;ly). Similar to the (iagTN VLP IL-2 data. there \\as no signiticant response to 
cells stimulated \\ith (jag CD8. except for (iroup 8 (200 ng (iagRT VIP dose only). 
(iroups ()-8 appeared to be stimulated by Gag Cf)4 and RT CD8. but these IL-2 responses 
\\ne not as strong as what was seen for Group 4: once again reaffirming a heightened 
cellular immune response occurred for mice receiving a GagRT VLP boost of 100 ng. 
Although significant cellular responses were evidently induced by the \aceines. there was 
IlO apparellt antibody response to (Jag in the (iagRT VLP experiment. as \\as the case 
\\ ith the (JagT~ experiment (data not shown). 
5.4 Discussion 
Ihe importance or a cellular immune response against HIV has been highlighted in 
se\cral animal \accine trial studies (Amara et al.. 2005: Buonaguro et al.. 2006: Smith et 
al.. 2()()-+). in addition to the fact that long term non-progressor (LTNP) HIV patients have 
presened I IIV -I specific CD4+ T cells. C08+ T cells and memory T cells. all of which 
have been identified as a means to control viraemia (Pantaleo and Koup. 2004: Sadagopal 
et al.. 20())). Currently. one of the more successful means to elicit a superior cellular 
immunc response against HIV in animal models. is using a prime boost strategy, 
particularly \vith the usc of HIV VLPs as a boost component (Jaffray et a!.. 2004: Paliard 
et al.. 200()). 
The immunology experiments in this study explored the potential of the chimaeric VLPs. 
CjagRT and (jagT~. to induce and possibly enhance a cdlular immune response against 
111\-1. This \\as e\aluated by the enumeration of vaccine-specific IFN-, and IL-2 











Secretion or IFN-, is helieved to be indicative of the early stages of cellular immune 
response generation and theret'ore provides an idea of a vaccine's immunogenicity 
(Pantaleo and Knup. 2()()4). On the other hand, IL-2 is a typical indicator of antigen 
clearance and long-term memory T cells that demonstrate protection (Pantaleo and Koup. 
2()()4: Sadagopal et al.. 2(05). It is believed that eliciting T-cells able to co-produce these 
t\\O cytokines (also k11lHVn as polyfunctional T cells) results in viral clearance and low 
antigen load. as is observed in LNTPs. Thus. these cytokines \\ere used to indirectly 
gauge the type and specificity of the cellular immune response induced by the respective 
\"LP \accines. 
The IFN-, and IL-2 data clearly demonstrated a boosted cellular immune response 
occurring \\hen the respective VLPs were administered as a boost vaccine after 
inoculation \\ith the DNA prime. No such boost was observed when t\VO doses of DNA 
\\ as administered. or when only VLP inoculations were administered, verifying the 
sLlccess or using a heterologous prime boost strategy. as is demonstrated in the literature 
(Dale et al.. 2()()2: JafTray et al.. 2004). Furthermore, an optimal VLP dose of 100 ng was 
fOLlnd to induce the most potent immune responses in both chimaeric VLP boost 
experiments. Comparatively. this dose was lower than what has been published in other 
studies (BlIonagllro et al.. 2002: Iialsey et al.. 2008). but it \vas adequate to induce 
positi\e ('1)4+ and (,D~+ T-cell responses . 
. -\ strong ('[)4+ T cell response specific to Gag was most prominently elicited in the 
(jag[(-.; and (iagRT experiment for the group that received a DNA prime and VLP boost 
(IO() ng) (;roup 4). Although CD4+ T cells are the target of IIIV - L they playa key role 
in activation of both B cells and CD8+ T cells, and in controlling C"lL responses 
(Sadagopal et al.. 20(5). In addition, they have been linked to the control of H IV-I 
infection and replication (Jansen et a!., 2006: Kalams et al.. 1999). Thus. their induction 












I hc (iag ('J)S~I-ccll response elicited by Ciroup 4 in the GagTN experiment was also 
considerable. although a much weaker Gag CD8 response was detected in the GagRT 
cxperimcnt. This \\as unexpectcd given that previous research shO\ved significant CTL 
rcsponses \\ ere stimulated when Gag VLPs were used as vaccination candidates in rhesus 
macaques (Paliard et a!.. 20(0). Interestingly. there was a Gag CD8 response induced by 
the other t\\O groups that received prime-boost \accinations (VLP doses below and above 
that or (imup -1-) in the GagRT experiment. which suggests that the Gag CD8 IPN-r data 
for (iroup -1- might be anomalous. Alternatively, the neligiblc Gag CD8+ T-cell response 
could be duc to the ract that VLPs are exogenous antigens. and are therefore primarily 
presented to the immune system via MIIC class II molecules. which stimulates the 
acti\ation orTh cells. rather than CTLs (Oeml et a!.. 20(5). There are occasions of cross 
prcscntation \\ here exogenous antigens such as VLPs are processed and presented to the 
immune systcm \ia AP('s using MHe class I molecules. In these cases. CD8+ T-cells are 
stimulated but this process is believed to be inefficient and int1uenced by many factors 
including dosage and time (Maecker et a!.. 2(01). It will be important to further 
il1\cstigate the effect of dose on the elicited Gag COR response in future experiments, to 
contirm \\hether there \\as an error in the result here, or \\hether a larger quantity of 
\"LPs is required to impnne the Gag-specific CD8+ T-cell response. 
The significance or a vaccine eliciting anti-Gag antibodies has yet to be determined in 
terms of combating IIIV-I. but their disappearance has been linked to the progression to 
.\II)S in 111\"-1 infected individuals (Chugh and Seth. 20()4). The lack of induction of a 
(iag-speci tic humoral response by the VLPs in these experiments could be related to the 
dosc or \"LPs llsed in these experiments. as was the case for the poor CD8 response in the 
GagRT experiment. Earlier VLP vaccine studies have used much higher VLP doses to 
achie\e similar cellular immune responses as observed in this study, but they \vere also 
able to stimulate strong anti-Gag antibody responses (Buonaguro et a!.. 2(02). It is 
possible that by increasing the dose of VLPs. or possibly incorporating a second VLP 
boost into the \accine strategy. an improved humoral response could be induced. On the 
other hand. monitoring the mice over a longer period of time after the boost inoculation 










humoral re'iponses arc commonly generated some time alter vaccination (can be between 
-1-2 and 56 days alter the initial inoculation (Young and Ross. 2006: Zhao et aL 20(5)). 
I he multi-antigenic nature of the DNA and VLP vaccines in this study. allowed for the 
exploration of eliciting broader. cellular immune responses. Modifications to Gag have 
been kmmn to affect pal1icle formation and budding. as well as the immune responses 
that arc induced ('y'oung et aL 2006). This appeared to be true for the GagTN and GagRT 
experiments here. where a boost effect Vias observed for both Tat and RT peptides. In 
particular. potent CD4 and eD8 responses specific to RT were detected in the GagRT 
experiment. suggesting that a GagRT VLP boost was able to elicit an enhanced, broader 
immune response than using a IIIV-J DNA vaccine alone. The Tat data \vas slightly 
more questionable. as the Tat4 peptide used for ill \'itl'O stimulation in the ELispot assays 
formed cyclic structures due to the presence of several cysteine amino acids (formed of 
sulphide bonds). This is believed to have a negative affect on the peptides' ability to elicit 
specific IF]\;-yor IL-2 responses. Thus, further experimentation is needed to confirm the 
I at data. Ne\ertheless. the apparent boosts for Tat and RT imply that an elicited cellular 
immune response can be manipulated by the boost component of a vaccine to influence 
the speci licit)' of the response. In addition. the development of a broader cellular immune 
response is ad\antageous in that it decreases the possibility ofT-ceil escape (Sadagopal 
et aL 2(05). 
Comparing the ability of GagTN and GagR'I VLPs to enhance the elicited immune 
response. (iagTN appeared to induce stronger CD4 and eD8 T-cell responses than 
(iagRT. specifically to Gag. There are a few possible reasons as to \\hy this occurred. 
hrstly. (iagTN is a slightly smaller particulate antigen than GagRT. \\hich may have 
caused GagTN to be more easily taken up by the immune system. Alternatively, it is 
possible that the (Jag portion of each VLP folds differently. to accommodate the different 
accessory proteins. I-!ence, different Gag epitopes arc exposed to the immune system and 
elil'it \aried immune responses. This is corroborated by the varying sizes of the chimaerie 
VIY~ (Chapter -1-). \\hich suggest they are perhaps not folded in the same \\ay. Another 











(JagR I \'I.J>s could ha\\.: bccn as a rcsult of the immunodominant VYY RT epitope, 
\\hich might ha\c becn preferentially recogniscd by the mouse immune system (Larke et 
aL. 20()7), Thus. c\cn though both GagRT and GagTN VLPs elicited a boosted cellular 
immunc response. and appearcd to bc good candidates for use as a potential HIV vaccine, 
(iag!1\: did appcar to be better at inducing stronger cellular immune responses, 
In general. thc IJ.0i-, and IL-2 assay data displayed high non-spccific responses for the 
groups that reccivcd VLP inoculations compared to those that only received DNA 
inoculations, This is not uncommon when using VLPs produced in insect cells using the 
IiIVS. and has been linked to induction of the innate response through the presence of 
PAMPs deri\ed from insect ceil/baculovirus matter (Deml et aL 2005: Ludwig and 
\\'agner. 2()()7), This can be beneficial in that the PAMP recognition encourages the 
de\elopment of potcnt and broad Th I cellular and humoral immune responses: however 
it is unkl1ll\\n \\hether the non-specilic responses had a masking effect on the specificity 
of the responscs detected. and is something to keep in mind for future studies. 
In conclusion. while all the experiments reported here are preliminary studies. they do 
prO\ide \ital insight into the ability of these novel chimaeric VLPs to elicit an improved 
cellular immune rcsponse when used to boost a response primed by a DNA vaccine. It 
\\ill bc necessary in future studies to detelminc the functionality of the T cell responses 
induced. as research suggests that only when polyfunctional T cells are elicited, is the 
cellular immune response effective in controlling an HIV -1 infection (Pantaleo and Koup, 
200..J.: Sadagopal et aI., 20(5). For this purpose, no ELIspot is available, but intracellular 
cytokine staining in conjunction with flow cytometry can be used to identify those cells 
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In the \\orld \\e li\e in today, the IIIV/AIDS pandemic is likely to be one of the most 
serious crises humanity faces. About 2 million people die from HIV annually, there are 
:-:-.2 million people li\ing with HIV, and as many as 2.5 million being newly infected 
e\ery year (l !1\,)AIDS. 2007). With such devastating statistics, it is imperative for research 
to focus on the de\elopment and production of a suitable vaccine to eradicate HIV. In this 
study the production of two novel HIV chimaeric VLP \accine candidates were 
optimized and their ability to elicit an effective immune response in mice, when they 
\\ere used as boost components in a prime-boost vaccine strategy, was evaluated. 
6. I Optimization of production of the chimaeric VLP constructs 
Hefore our laboratories began research into chimaeric VLP design, no other studies 
documented the formation of VLPs with fusion proteins as large as RT (450 aa) and TN 
022 aa) incorporated into a type-I in-frame VLP (Halsey et al.l. The novel, multi-
antigenic nature of the chimaeric VLPs. CiagRT and GagTN, meant their usc in a vaccine 
could potentially induce broader, stronger cellular immune responses than those observed 
for (jag-only VI Ys. Ilowever, their expression in insect cells was not previously 
adequate to e\aluate their immunogenic abilities. Thus. it was of great interest to 
optimi£e the production of these VLPs in insect cells (using BEVS) for two reasons. 
Firstly. relati\ely large quantities of the VLPs were required for mouse immunogenicity 
studies. and therefore the best conditions for VLP expression had to be determined to 
obtain maximum yields. Secondly, it was of some relevance to analyse which factors 











could possibly be useful \\ hen producing other chimacric proteins in the same expression 
system, as \\ell as for potential commercial production of these YLPs in the future, if 
they are used as IIIV \accines. 
Although the optimal conditions to produce the respective YLP constructs were similar. 
se\cral of the findings from the experiments done were ditTerent to what \\as expected. It 
\\as interesting to lind that cell density was so intluential in the production of YLPs by 
the cells. regardless of the cell line used. Even more surprising was that MOl had sueh a 
negligible effCct on the quantity or quality of YLPs produced. Whether these 
characteristics arc unique to the production of these recombinant proteins or not, remains 
to be ill\estigated. but it was clear from these experiments that the value for empirical 
research should not be underestimated or substituted by theoretical predictions. 
Ihe expression of YLPs in insect cells using BEYS was slightly problematic in terms of 
the yields that \\ere obtained. Previous studies have documented as much as 5-20 mg/L 
of recombinant protein production using BEYS (Wagner et a1.. 1994a). In this study. 
almost IOOO-fold less of the respective YLPs were being expressed. even after 
optimization. This problem could have been the result of three possibilities. The first is 
that the large size of the YLPs probably contributed to their poorer production in insect 
cells. This is corroborated by the fact that other studies have shown an il1\'erse correlation 
bet\\cen chimaeric VLP yields and the size of the incorporated foreign proteins (Luo et 
aL. 1(92). ,1\ second possibility is that actual budding of the YLPs may have been 
inefficient leading to a large percentage of YLPs remaining in the cell lysate during 
puritication. The \\estern blot data of Chapter 3 does demonstrate that a fair amount of 
VLPs do remain in the cells despite the myristylation signal on Gag. and these are likely 
to be VLPs that budded into cytoplasmic vesicles. as opposed to out of the cell (Royer et 
al.. 19(1), To \\hat extent this occurs is unknown. but it may be of interest to evaluate 
this by extracting \'LPs from the cell lysate in addition to the cell culture supernatant in 
future studies. The last possibility is that the use of the Gag p24 ELISA drastically 
underestimated the amount of YLPs being isolated. While the ELISA is a common 











111\' \'I[>s (tll expose p24 molecules for detection purposes) is unknmvn. In addition, 
results can be ske\\ed by the presence of Gag clca\age products. Because proteolytic 
processing of the \TPs in insect cells was belie\l;~d to be partial (Cruz ct aL 1999), and 
the dominant product of the chimaeric VLP expression in insect cells was the chimaeric 
\'I.Ps. the (jag p24 rLlSA was deemed adequate to determine the optimization 
conditions for VLP production. However, alternative methods such as western blot 
densitometry. need to be explored for this purpose, because even though it is a more 
labour intensi\e method, it is likely to be more reliable. 
6.2 Immunogenicitv of the respective Gag VLPs 
Research has fanlllred the use of VLPs as boosting components because of their 
particulate nature and ability to present protein epitopes to the immune system in their 
nati\ e conformation (DemL Wild, and Wagner, 2004). Although using VLPs as the 
boosting components has only recently been investigated, it has proven to elicit strong 
cellular and humoral immune responses. Of note, a low dose of HIV -1 C Gag VLPs was 
able to boost significant Gag-specific T-cell immune responses in mice (Jaffray et a!., 
2()()4). 
In this study, an impressive boost effect in the cellular immune response was observed 
\\hen the respective VLPs were used as boost components to complement the 
pVRCgrttnC D~A \accine in mice. The GagTN VLPs seemed to induce better cellular 
responses than (j agRL especial I y wi th respect to Gag-speci tic responses, possibl y 
because the t\\O proteins f()lded differently, and therefore different epitopes were 
processed and displayed by MIlC class I and II molecules. GagTN \\as also a smaller 
\'IP than (jagRT. and was perhaps more easily taken up by APCs. 
A strong (jag-specific C04+ T-cell response was induced by both VLP constructs, but 
the (iag C08+ I-cell response was weak in the GagRT experiment. While a strong CD4 
response \\ as not surprising given the exogenous nature of VLPs, the poor CD8 response 











(Paliard ct al.. :W()(): \Vagner et al., 1994b) and the importance of a elL response in 
,-'ombating II IV (Koup et al.. 1994), Nonetheless, potent CD4 responses are also 
important to induce. since their involvement in the secretion of cytokines (such as IFN-, 
and T'J 1'-(1') induces protective immunity, and they have a major role in stimulating and 
maintaining CIL rcsponses (Kalams et al., 1999: Rosenberg et aL 1997). To improve the 
('/)I-\ response to (jagRI VLPs in future studies, it may be necessary to explore the use of 
adju\ants. as these have been used to enhance cellular immune responses in animal trials 
pre\iously (Huonaguro et al., 2007; Deml et al., 2005; Jiang et aI., 2006). Alternatively, 
future \accine studies should foeus on the use of GagTN VLPs as the boost candidate. 
:\ positin: (1)~+ I-cell response to RT was detected when GagRT VLPs \\ere employed 
as the boost components, suggesting that there was some CTL stimulation occurring. In 
addition. the presence of CD4-t- I-cell responses to RT and Tat suggested that the cellular 
immune response induced was broader than what was seen with using the DNA vaccine 
alone. This requires further affirmation, especially because of the questionable nature of 
the selected peptides in the FLispot assays. but it is indicati\e of a potentially successful 
elicitation of a \aried CD4 and CD~ response, which could possibly protect individuals 
against more than one IIIV strain. 
The lack of induction of a Gag humoral response in these experiments suggests that the 
prime-boost strategy may need to be optimized, or vaccinated mice will need to be 
monitored mer a longer period of time after inoculations. Ideally, an I IIV vaccine should 
elicit a potent cellular immune response and strong antibody response, \vith the particular 
induction of NAbs, as these are believed to be responsible for conveying protective 
immunit\ (1)oan et aL 2()OS). Thus, in order to do that with the CUITent ehimaeric VLPs, 
\11\ proteins could be incorporated onto the surface of the VLPs to form Type II 
chimaeric \'LPs. Type II VLPs are known to induce both the cellular and humoral arms 
of the immune response effectively, and are able to elicit Nabs as well (Ludwig and 











6.3 Perspecti\t~s for the future 
I he \\ork reported here has detailed the determination of the optimal conditions to 
produce the respective chimaeric VLPs in insect cells. as well as demonstrated the ability 
of these VLPs to elicit strong cellular immune responscs in mice. [n doing so. it has 
identified a coherent method of optimizing the production of recombinant proteins in an 
insect cell-baeulO\irus expression system. and the findings could theoretically be used as 
a guide for similar future studies when attempting to maximi7e the expression of other 
recombinant proteins. In addition. this study has elements which have the potential to be 
expanded in sneral directions. 
In terms of the optimization experiments that \vere done. other factors such as cell 
passage number and medium type could bc investigated as to their ability to influence the 
expression of the chimaeric VLPs. In addition. more of the parameters of thc factors that 
\\ere already imestigated could also be explored to confirm the trends observed here. The 
range of MOl could be extended to include MOls of 10 and 15. and more cell lines such 
as Iligh Five l \1 insect cells. could be investigated. 
With regard to the immunogenicity studies performed. they were able to clearly illustrate 
the significance of using a chimaeric VLP vaccine boost to induce strong cellular 
immune rcsponses. and both VLP candidates appeared to have the potential as elTective 
IIIV \accine candidates. Future immunogenicity studies can now explore a number of 
approaches. including combining different chimaeric VLPs as boost components. 
il1\estigating alternati\e immunization strategies such as intranasal or vaginal route of 
inoculation. and using adjuvants in addition to the chimaeric VLPs to enhance the CTL 
response elicited. Furthermore. the ability of thesc VLPs to induce strong cellular 
immune responses against I IIV in non-human primate experiments is worth investigating, 
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Appendix A: Baculovirus Expression Vector System 
A I: Bac-to-Bac" Baculo\irus Expression System 
'I, 
... ' .... ' 







bd' f' '0 l"' ,I, 
Figurt' ,\ I - Ihe Hac-to-Hac I' l3aculovirlls Expresion System (1Il\itrogen), The gene or interest is cloned 
into a pFastBaci\i donor plasmid (Appendix A2) as a mini-Tn7 element controlled by the plO or Polh 
promoter, The recombinant donor plasmid is transformed into competent E. coli DH I Ol3aci V1 cells 
c'olltaining a resident bac'mid (\\ith a mini-IlIlTn7 target site) and a helper plasmid, The bacmid /llcZli gene 
complimcnts a /ucZ deicction on the bacterial chromosome to produce blue colonies in the presence of X-
gal. and the inducer IPTG, The helper plasmid expresses transposition proteins (ill [mils) \vhich assists the 
mini-ln7 eicment in the donor vector to be transposed into the bacmid mini-IlIlTn7 target site, Successful 
transposition disntpts the /({c7.cx gene and white colonies containing recombinant bacmids can be selected, 
Bacmid D,\A is transfceted into insect cells to generate recombinant baclIlo\ irlls expressing the gene of 










III ..12: pFastBac Dual vector map 
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Figure \2 - pFastl3ac 1 \IDual: \ ector map and pPolh \1CS. This is a donor plasmid for the 8ac-to-8ac k 
Ilaclilm irus !>,pre'sion S\steill. \\ here the gene for a protein to be e\pressed b:- recombinant baclilovirus in 











Appendix B: Recipes for solutions and buffers used in this study 
B 1 - Bactel'ial strains and growth conditions 
1:'. cu/i D1I5o: l \1 and DHIOBac 1rvl (Invitrogen): Cultivated at 37 DC in Luria-Bertani (LB) 
broth under shaking conditions. and left to gro\v overnight. 
LB agar plates: 1.5'~o Bacto Agar, Ampicillin (100 flgiJl1l) [IPTG (40 flg/ml) and X-gal 
( 100 flg ml) \\ere added to the medium where necessary]. 
B2 - SDS-PAGE and Western blots 
."Ix Sample loading buffer: 315 mM Tris-HCI, 10</;) (w/v) SDS. 4(YYO glyceroL 40(/'i) 2-
mcrcapto-ethano\. ().025(~/() bromophenol blue: pH6.8 
I x Running buffer: 25 mM Tris-HCI, 200 mM glycine. 10 0/r) SDS in dH::,O 
Transf'cr buffer: 50 mM Tris base. 40 111M glycine. 20% (v/v) methanol: pH 9.2 
Blocking bufTer: 30 0 (\\ v) BSA, 0.1 (Yo (v/v) Tween-20 in PBS 
Washing bufTer: 0.1 (~() (\ v) Twcen-20 in PBS 
B3 - Coomassie Blue staining and destaining solutions 
('oomassie brilliant blue staining solution: 40 % (w/v) MethanoL 7 o;() (W/V) glacial acetic 
acid. 0.1 g ('oomassie Blue R in dH 20 
J)ctainin~ solution: 4() ° 0 (w/v) MethanoL 7 % (w/v) glacial acetic acid in dI bO 
B4 - rAdl:\PV D:\A extraction 
DNA extraction buffer: 0.1 M Tris-IICI (pH 8.c)). I 0 111M rDT A, 1M KCI 
B5 - Immunogenicity assays 
135.1 ELISPOT 
Coating bufTer: Ix PBS: pH 7.2 
RIO medium: 88.9 ( 1) RPM I medium with Glutamax + I % Penicillin Streptomycin + 10 
°0 FBS -r- 0.1 (~'O 2-ME (Sigma) 
Blocking solution: 88.9 (~;) RPMI medium with Glutamax + I % Penicillin Streptomycin 
~ 10 % FBS -,- 0.10 0 2-ME 
Wash bufTer I: O.()S °0 Tween-20 in PBS: pI 17.4 










Appendix C: Sequence data confirming intact genes in constructs 
('1 - Alignment of D:\,A sequence for gag gene in GagT:\, construct 
Fon\ard sequence: 
~pp~r :l~E: pFa~-~MgagC. from 4438 to 5427 
~C':i'2,- :::-j~: g~"J-±_FMlj. from 1 to 900 
~BD-HMgagC:gTN4_FM13 identity= 93.11%(838/900) gap=9.09%(90/990) 
"",., ~X;Cc~ ':CAA:":'AA}\CGTCCGTATACTCCGGAATATTAATAGATCATGGAGATAATTAAAAT 
, ! ' 111111 I I III II iii I II 
GGG""ASMRG~CGTGATTGTATACGACTCACTATAGGGCGAATTGGGCCCGACGTCGCAT 
44~~ CATAACCATCTCGCAAATAAATAAGTATTTTACTGTTTTCGTAACAGTTTTGTAATAAAA 
, c: J" AhI\C C-;:' A T AAA TA-;:'TCCGGATTA TTCATACCGTCCCACCATCGGGCGCGGA TCCAAGCTT 
1111 I! i I I 
;: -; ................................ TCCCGGCCGCCATGGCGGCCGCGGGAAT 
4618 GCCACCATGGGTGCTCGCGCATCTATCCTCAGAGGCGAAAAGTTGGATAAGTGGGAAAAA 




lO::' =. AC";.l\.CT =-A::;,;CC AGGAGGT AAAAAACACT ACA TGCTGAAGCA T A TCGTGTGGGCA TCT 














c.j 51 AAGGCTGCTC;ACC;GAAAGGTCTCTCAGAACTA TCCTATCGTTCAGAACCTTCAGGGGCAG 
,G38 ATGGTGCACCAAGCAATCAGCCCTAGAACCCTGAACGCATGGGTGAAGGTGATCGAGGAG 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II I II II I II I I II I I 
511 ATGGTGCACCAAGCAATCAGCCCTAGAACCCTGAACGCATGGGTGAAGGTGATCGAGGAG 
5C98 AAAGCCTTTTCTCCCGAGGTTATCCCCATGTTTACCGCCCTGAGCGAAGGCGCCACTCCT 
I I II I I II I II II I I II I II II I I II I II I II I II I II I II II II I II II I II I I I I II I 













,.~~D.2/". =: :",:;'h,=AC':A TGCTGAACACAGTGGGAGGACAC CAGGCCGCT A T GCAGATGTTG 
AAGGJ'., T AC~A TCilACGAGGAGGCAGCCGAA TGGGAC CGCCTCCACCCCGTGCACGC CGGA 
11I111111111111111111111111111111111111111111111111111111111 
.~GGATACCATCAACGAGGAGGCAGCCGAATGGGACCGCCTCCACCCCGTGCACGCCGGA 
:_'CC!\ '::'CGC eel' CGGACNlli TGAGAGAACCTCGCGGAAGTGA TA TTGCCGGTACTACCAGC 
1I11I1111111111111111111111111111111111111111111111111111111 
C'T A T CGC C: ::C CGGACNlli TGAGAGAACCTCGCGGAAGTGA T A TTGC CGG TACT ACCAGC 
ACCC,TCAi\GAGCAGA TTGCTTGGA TGACCAGCAACCCACCCA TCCCAGT GGGCGA T A TT 
I i 111111111111111111111111111111111111111111111111111111I II 
je,CC CTTCAAGAGCAGATTGCTTGGATGACCAGCAACCCACCCA TCCCAGTGGGCGA TA TT 
, ' 
! , I : 111111111II11 
;::; 7 ~ TJ:.J:!\lV:.,.AG:<::-;G.Z\r:'TATTTCTGGGGCTGAAC 
Reyerse sequence: 
T)[:t>~:C :ll:e: hC-pFBD-HMgagC, from 361 to 1382 
~~~eL ll~~: g'::'N~_R~13, from 10 to 896 
120 
RC nF2~-H~gagC:gTN4_RM13 identlty= 90.59%(809/893) gap=13.64%(141/1034) 
~=2 '::'GTGNlliTTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATNlliCAAGTT 
Ii I 111I II II II I i I I 
AAARKCAMATGATTCGCCAGCTATTTAGGTGACACTATAGAATACTCAA .......... . 
412 AP,CM\CAAC AA TTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTT 
:.)',- ........................................................... . 
~ -; 2 T APJo.;CJ'.J\.3TAi\]',p,CCTCTACNlli TGTGGTA TGGCTGATTA TGATCCTCTAGTACTTCTC 
III II I I III 
, ................................. GCTATGCATCCAACGCGTTGGGAGCTC 
l):o 2 GACAAGCTTGTCCAGACTGCAGGCTCTAGATTCGNlliGCGCCCGCGACTAGTGAGCTCGT 
I! I! I i I, II I 
77 TCCCATATGGTCGACCTGC .................................. AGGCGGC 
5", L. CGACGTAGCCCTTTGAA TTCTTA TTGGCTGACCGCCTCCCT ACCNlliGAGGCTTTTCAGA 
I i I I III II 1111111111111111111111111111111111111 
:~(3,=:"1J\ TT CI\=:T AGTCA TTA TTCTTCGCTGAGGGGGTCGCT ACCNlliGAGGCTTTTCAGA 




















: -1) ~T Cf',":' CT::Gc~GGCC CTCTTTGCCACACTTCCAGCAGCCTTTCTTC CTGGGGGCGCGGCAG 
(,,,;0 TTCC,'GGCAA TC;TGACCCTCCTTGCCACAA TTGAAGCACTTGACGATTCTCCTGGGACCC 
I11111111111111111111111111111111111111111111111111111111111 
1 , ' "='C=c;GGr'f',P,T:::TC:;ACCCTCCTTGCCACAATTGAAGCACTTGACGATTCTCCTGGGACCC 
::Jc L ~r;AM\GI'"'ACTG:~CTGCATCATGAT ATTGCCTGAGTTTGTCTGGCTCATGGCCTCAGCG 
! I111I11111 ! 111111111111111111111111111111111111111111111111 
-+" -' ~~ AAAGTT ACTC :=TCTGCATCATGATA TTGCCTGAGTTTGTCTGGCTCA TGGCCTCAGCG 
1212 AGAACTCTGGCCTTGTGCCCAGGTCCTCCCACGCCTTGACATGCTGTCATCATTTCCTCA 
111111111111111111111111111111111111111111111111111111111111 
c: 2:3 AGAi\CTCTGGCCTTGTGCCCAGGTCCTCCCACGCCTTGACATGCTGTCATCATTTCCTCA 
1 72 AGGGTGGCACCT(:;GACCGAGAGCTCTCAAGATGGTTTTGCAA TCGGGGTTAGCGTTTTGC 
II I II I II I I I I I I I I I I I I II I I II I I I II I I II I I I I II II I I II I I II II I I I I II I 
I. :,' f',.GC~C'T(::C::C f',.CCTGGACCGAGAGCTCTCAAGATGGTTTTGCAA TCGGGGTTAGCGTTTTGC 
:13;0 ACGAGCAGAGTATCTGTCATCCAGTTCTTAACCTCCTGAGTGGCTTGCTCAGCTCTAAGG 
II [ II [ 1111 [ [ [ [ [ 11111111111111 [ 11111111111111111 [ [ [ [ 111111111 
6'13 ACGAGCAGAGTATCTGTCATCCAGTTCTTAACCTCCTGAGTGGCTTGCTCAGCTCTAAGG 
c ~::J'" GTr~'TGAACAAc;:'CcGTCCACGTAATCCCTAAAAGGCTCCTTGGGTCCTTGGCGGATGTCG 
I [ 1111111111111111111111111111111111111111111111111111111111 
I:' .: :?TTcT(GAACi\A TCTGTCCACGTAA TCCCT AAAAGGCTCCTTGGGTCCTTGGCGGATGTCG 
~ c .. L AC;GATGGAGACGGGGGAGTACATTCTCACAA TTTTGTTCAGCCCCAGAA T AA TCCACCTT 
[ I II [ [ I [ [ I I I II I II I I I I II I I II I I I I I I II I II I II II [ I II I II I II I I I II I I 
':: 3 X::::;f',.TGGf',.G}\CGGGGGAGTACATTCTCACAATTTTGTTCAGCCCCAGAATAATCCACCTT 
,31;0 TTGTAAATATCGCCCACTGGGATGGGTGGGTTGCTGGTCATCCAAGCAATCTG ... CTCT 
111111111111111111111111111111111111111111111111111 II I 
223 TTGTAAATATCGCCCACTGGGATGGGTGGGTTGCTGGTCATCCAAGCAATCCTGCTCTTT 
13S9 ~GAJ\GGGTGCTGGT 
I Ii: ! I i 
F83 GAAGGGKKGCTGGG 
C2 - Alignment of D:\A sequence for gag gene in GagRT construct 
Forward sequence: 
Upper IlDe: pFBD-HMgagC, from 4532 to 5432 
Lower Ilne: gRT3_FM13, from 2 to 907 
pFBD H~gagC:gRT3._FM13 identity= 92.90%(838/902) gap=0.5S%(S/907) 
"":J.' ~ T:~r:::'~c;:'CCTAACAGTTTTGTAATAAAAAAACCTATAAATATTCCGGATTAT .... TCATA 
'I I 'I [I I 1111I I I I I 
GG l<Tc'Y SGAMGCMGTGATTGTATACGACTCACTAT AGGGCGAA TTGGGCCCGACGTCGCA 
.; = C; 7 CCGTCCCf',.CCAcCGGGCGCGGATCCAAGCTTGCCACCATGGGTGCTCGCGCATCTATCCT 
!III 1111 I I I I I 11111111111111111111111 
61 TGCTCCCGGCCCCCATGGCGGCCGCGGGAATTCGATTATGGGTGCTCGCGCATCTATCCT 
"":::c.\7 =AGAGGCGAAAAGTTGGATAAGTGGGAAAAAATCAGACTCAGGCCAGGAGGTAAAAAACA 












1 L ~ CA~~AGGCGAAAACTTGGATAAGTGGGAAAAAA TCAGACTCAGGCCAGGAGGTAAAAAACA 
-,7. 7 ,'1A.::'.;TG::·1 GA~;GCA.TATCGTGTGGGCATCTAGGGAGTTGGAGAGATTTGCACTGAACCC 
111111111111111111111111111111111111111111111111111111111111 
~,,~ CTACATGCTGAAGCATATCGTGTGGGCATCTAGGGAGTTGGAGAGATTTGCACTGAACCC 
-: -,;:: -, C(]CACTGCTGGAAACCTCAGAGGGCTGTAAGCAAA TCATGAAACAGCTCCAACCAGCCTT 
111111111111111111111111111111111111111111111111111111111111 
/ -+ ~ CGGACTGCTGC:;AAACCTCAGAGGGCTGT AAGCAAA TCATGAAACAGCTCCAACCAGCCTT 
-± ,; L -, i]CA.GA.CCGCPJ\CAGAAGAGCTGAAGTCCCTTTACAATACCGTGGCAACCCTCTATTGCGT 
111111111111111111111111111111111111111111111111111111111111 
"A.:~ACC'~.'"A,'.z"GAAGAGCTGAAGTCCCTTTACAATACCGTGGCAACCCTCTATTGCGT 
4 87 CCACGAGAAGATCGAGGTGAGAGACACAAAGGAGGCCCTGGACAAAATCGAGGAGGAGCA 
111111111111111111111111111111111111111111111111111111111111 
361 CCACGAGAAGATCGAGGTGAGAGACACAAAGGAGGCCCTGGACAAAATCGAGGAGGAGCA 
.;;. ~ 7 GAA TAAGTGCCAGCAGAAGACCCAGCAGGCAAAGGCTGCTGACGGAAAGGTCTCTCAGAA 
111111111111111111111111111111111111111111111111111111111111 
-±~'- GAA""'AAGTGCCAGCAGAAGACCCAGCAGGCAAAGGCTGCTGACGGAAAGGTCTCTCAGAA 





CCTC~AACGCA T:::GGTGAGGGTGATCGAGGAGAAAGCCTTTTCTCCCGAGGTTA TCCCCA T 
GT-:::'TI'l.CCGCCCTGAGCGAAGGCGCCACTCCTCAAGACCTGAACACTATGCTGAACACAGT 
i 11111111111111111111111111111111111111111111111111111111111 
E 1 GTTTACCGCCCTGAGCGAAGGCGCCACTCCTCAAGACCTGAACACTATGCTGAACACAGT 








~CG(:GGA.;'-~TGl\ T ATTGCCGGTACTACCAGCACCCTTCAAGAGCAGA TTGCTTGGA TGAC 
CAGCAACCCACCCATCCCAGTGCGCGATATTTAC.AAAAGGTGGATTATTCTGGGGCTGA 
1111111111111111111111111111111111 I1111 III i I III 1111 i ! III! 
CAGCAACCCACCCATCCCAGTGGGCGATATTTACAAAAAGKKGGATTATTCTGGGGCTGA 
5--;26 ,;CAAJ'..AT 












~'DPE:~ l~:-,2: RC-pFBD-HMgagC, from 505 to 1377 
~j'Nd ~LUC: SR'l"_KM13, from 16 to 886 
RC-c=B~-~~gag::::gRT~ RM13 identity= 89,05%(789/886) gap=0.23%(2/888) 
.; _,,' T JI.C.Aj\AT::C'l.-:"T.Z'I. TGGCTGATTATGATCCTCTAGTACTTCTCGACAAGCTTGTCGAGACT 
! Ii! II I I I I I 
!\Ar\;CAC;A~TG:::,Z'l.TTMGCCAGCTATTTAGGTGACACTATAGAATACTCAAGCTATGCATCC 
,'" GCAGGCTCT J'..G.Z'I. TTCGAAAGCGGCCGCGACTAGTGAGCTCGTCGACGTAGGCCTTTGAA T 
I ! I II I I: I: II 
c; , AACG.:c;,rTG(.~r;AG(·TCTCCCATATGGTCGACCTGCAGGCGGCCGCGAA TTCACTAGTGAT 
6ll T:::TT.Z'I. TTGGCTGAGGGGGTCGCTACCAAAGAGGCTTTTGAGACTGGTGAGAGGCTCTCTC 
I I I I ! I I I I I I II I I I II I II I III II 1111 II III I 1111 I I I! I I I I I I I II I 
-~ A:, .:'1'-:':; .-:CTG.Z'l.GGGGG TCGCT ACCAAAGAGGCTTTTGAGACTGGTGAGAGGCTCTCTC 
-7 '. TCAATTGC}CTCCTGCTTTGGAGCGGGGGTGGTCTCCTCAAATCTGAAAGACTCAGCGGGG 
I I I I I I I I I I I I! I I I I! I I I! I I I I I I I I I I I I I I I! I I I I I I! I I I I I I I I I I I I! I I 
TCAP.TTGGCTCCTGCTTTGGAGCGGGGGTGGTCTCCTCAAATCTGAAAGACTCAGCGGGG 
72 GGGGCGGTAGGCTCGGGTCTGTTTTGAAGGAAGTTGCCAGGGCGGCCCTTATGACTGGGC 
I ! I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I! I I I! I I I I! I! I I I I I I I I I I I 
GG.}GCGGT AGGer CGGGTCTG TTTTGAAGGAAGTTGCCAGGGCGGCC CTT A TGACTGGGC 
CJ'..AA TCTTT (- c: C.Z'l.GGAAGTTTGCTTGGCGCTCGGTGCAA TC CTTCA TCTGGTGGCC CTCT 
I I II I I I I I I I I II I II I I I II I I III III I I I III III II III! 11111 I II I II III I 
:'"AAA T CTTT C C CAGGAAGTTTGCTTGGCGCTCGGTGCAA TCCTT CAT CTGG TGGCCCTCT 
TTGCCACACTTCCAGCAGCCTTTCTTCCTGGGGGCGCGGCAGTTCCTGGCAATGTGACCC 









I I I I I 1 I I I I I I I I I I 1 I I I 1 I I I I I I II I I I I I I I 1\ I I I I 1\ I I I I I I I I I I I I I I I I 
CCAGGTCCTCCCACGCCTTGACATGCTGTCATCATTTCCTCAAGGGTGGCACCTGGACCG 
AGAGCTCrCAAGATGGTTTTGCAATCGGGGTTAGCGTTTTGCACGAGCAGAGTATCTGTC 
I I I I I I I I I I I I I I I I I 1 I I II I I I! I I I I I I I! I I I I 1\ I I I I I I I I I I I I I I I I I I I 




ACGTAA TCe (::T AAAAGGCTCCTTGGGTCCTTGGCGGA TGTCGAGGA TGGAGACGGGGGAG 











;A.c~n\A T::' "i\AAGGGCTCCTTCCCTCCTTCCCCCATCTCCACCA TCCACAC . CCCCAC 
:'/\CP,Cj'TCT:.·"ZI. ... 'l\AJ:TTTCTTCAGCCCCACAATAATCCACCTTTTGTAAATATCCCCCACT 
11111111111111111111111 1111111 i 1111111111 III 1111I1 I ! I I II ! II 
I" T,ZI.~.ZI. TTCT'~ACAA TTTTCTTCAC . CCCACAAT AATCCACCTTTTGTAAATATCGCCCACT 
GCCATCCCTGGGTTCCTCCTCATCCAACCAATCTCCTCTTGAACCCTC 
Ii' ! , I 11111111111111111111111 I II II :! 
CGGATGCCTGGCTTCCTGCTCATCCAACCAATCTCCTCTTCAAACCKK 
('3 - Alignment of D:\A sequence for TN gene in GagTl'I construct 
Forward sequence: 
~pp(r ~in~: RC-HMgagTN, from 1 to 735 
~o~~r iln~: CagTK3-MI3R, from 116 to 850 
QC-H~gagTN:GagTN3-M:3R identity= 99.86%(734/735) gap=0,00%(0/735) 
TCAGTCCTTGTAGTACTCCCCGTCCTTCTCGCCCCCCAGGTGCCGCCGGGCCACCCTGCT 
II i II 1111111 111111111111111111111111111111111111111111111111 
-'~ TCAGTCCTTGTAGTACTCCCCCTCCTTCTCGCCGGCCACGTGGCCCCCCGCCAGGCTCCT 
" GT CGAACACCCAGCGCAGCACCTCGCGGTCCGCGTCCTCCA TCCCGTCCTGGCTCA TCGG 
! I : ! I i II ! I i 1111111111111111111111111111111111111111111111111 
: 7:C ::;TCGAACACCCACCGCACCACCTCGCGGTCCCCGTCCTCCATGCCGTGCTGGCTCATGGG 
GTGCACCAGGCAGTTGTTCTCGCCCTTGTTGGCCTCCTCCACCTCGCGGGCCTCCACGGG 
! i Iii 1111I1111111111111111 111111111111111111111111111111111 
236 CTGCAGCAGGCAGTTGTTCTCGCCCTCGTTGGCCTCCTCCACCTCGCGGCGGTCCACGCG 
:Sl CACCAGCTTGAACCACCAGCCGAAGGTCAGGGGGTAGCGCACGCCGGCCCCGGGGGTGTA 





























G~;( 'c~r;CGC:;GCT CGGTGCGGCGGA TGCGCTCGCGCACGGCGGGCCAGCCCACCA CGAGGCA 
GTGG~AGGAGCAGTATTTGCAGTAGCACTTGTTGCAGGGGGTGTTGGGCTGGCTGCCGGG 
! iii I ! 111111111 111111111111111111111111I1I1111111I : 11111111 ! 
GTGGTAGGAGCAGTATTTGCAGTAGCACTTGTTGCAGGGGGTGTTGGGCTGGCTGCCGGG 
G 1 GTGGTTCCACCGCTCCAGGTTGGGGTCGATGGGCTCCATCCGTTTCTTGCGCCCGTAGGA 
: ~ I I I I i I : : I I ! I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
;TG~TTCCAGGGCTCCAGGTTGGGGTCGATGGGCTCCATCCGTTTCTTGCGCCCGTAGGA 
II! II i 111111111 
8j~ GATGCCCACGCCCTT 
Re\erse sequence: 
~CCEr ~~~E: HMgsgTK, from 1310 to 2271 
~~~~l ~:~E: Cag~N -M13F, from 2 to 850 
~Mg~g~~:GagTN3-M13F identity= 95,63%(809/846) gap=12.51%(121/967) 
~i 2 '0:::'--~TC':CACC.l\GTCTCAAAAGCCTCTTTGGTAGCGACCCCCTCAGCCAAGAATTCAAAGG. 
II I II II ! I ! I II 
.......................... TGCTCCCGGCCGCCATGGCGGCCGCGGGAATTCG 
,-.~" S ... ::: JI.TGGTGGGCATCAGCTACGGCCGCAAGAAGCGCCGCCAGCGCCGCAGCACCCCGCC 
I I I III II I I I I I II l,JJ 111,lllll I,lL! 1IIIUlit 11111 U II III 111111 
4 ATTCATGGTGCGCATCAGCTACGGCCGCAAGAAGCGCCGCCAGCGCCGCAGCACCCCGCC 
~~~s CAGCAGCGAGGACCACCAGAACCCCATCAGCAAGCAGCCCCTGCCCCAGACCCGCGGCGA 
111111111111111 LI kllIIIJI.~:brt.I.'ln;r;'~~;;'l:tllU·1111111 JIJ 
lL4 CAGCAGCGAGGACCACCAGAACCCCATCAGCAAGCAGCCCCTGCCCCAGACCCGCGGCGA 
l·~ ') CCCCACCGGCAGCGAGGAGAGCAAGAAGAAGGTGGAGAGCAAGACCAAGACCGACCCCTT 
11111111111111,111. ttl 1,:I:I·;I;Vj'ttIJI1JIIIIII II fA 
~ 4 CC:::CACCGGCAGCGAGGAGAGCAAGAAGAAGGTGGAGAGCAAGACCAAGACCGACCCCTT 
1665 CGACTGCAAGTACTGCAGCTACCACTGTCTGGTGTGCTTCCAGACCAAGGGCCTGGGCAT 
III 1II11 I II i 1l1~I'itflbJ;I~~tlllllll j ,II 1·1 
244 CGAC~GCAA(:;TACTGCAGCTACCACTGTCTGGTGTGCTTCCAGACCAAGGGCCTGGGCAT 
=- 7::' 5 C=TCCT ACGGGCGCAAGAAACGGATGGAGCCCA TCGACCCCAACCTGGAGCCCTGGAACCA 
1111 I 1·1 III hi L I 
' .. 4 CTCCTACGGGCGCAAGAAACGGATGGAGCCCATCGACCCCAACCTGGAGCCCTGGAACCA 
2.78=: CCCCGGCAGCCAGCCCAACACCCCCTGCAACAAGTGCTACTGCAAATACTGCTCCTACCA 
IIIIIJ 1111l11111.,h:~Flf 11.llrlfl~II}:tJIJ;P:·t~··ld::Il·lllj 111111111 
3:::4 CCCCGGCAGCCAGCCCAACACCCCCTGCAACAAGTGCTACTGCAAATACTGCTCCTACCA 
1845 CTGCCTCG~GGTGGGCTGGCCCGCCGTGCGCGAGCGCATCCGCCGCACCGAGCCCGCCGC 
111111111111.111 t I Jill 
42~ CTGC~TCGTGGTGGGCTGGCCCGCCGTGCGCGAGCGCATCCGCCGCACCGAGCCCGCCGC 
1'0 ~ CGAGGGCGTGGGCCCCGCCAGCCAGGACCTGGACAAGCACGGCGCCCTGACCAGCAGCAA 













II I I I I I 11111 II III II Ilil IJ.1111141111lllJ 111'1>1 1,111.11 II L1111111 
c"""' CACC::~CCCACAACAACCCCGACTGCGCCTGGCTGCAGGCCCAGGAGGAGGAGGAGGACGT 
~.j L ::l SGG C~TCCC::CGTC:;C::GCCCCCAGGTGCCCCTGCGCCCCATGACCTACAAGGCCGCCTTCGA 
111111111111111111 t hili IJ 1lllllllllll!.ll HJ 1111 j 11111111 j 
""" GGGC~-;:'CCC~'GT(~CGCCCCCAGGTGCCCCTGCGCCCCATGACCTACAAGGCCGCCTTCGA 
2,; 8 5 CCTC?AGCTTCTTCCTGAAGGAGAAGGGCGGCCTGGAGGGCCTGATCCACAGCAAGCGCCG 
111111111111111 rTlr'lIUIHI,fHrlllllllnT'":ll~JllIlllllllrlllli 
::'6'+ CC~3AGCTTC::"TCCTGAAGGAGAAGGGCGGCCTGGAGGGCCTGATCCACAGCAAGCGCCG 
2 ~ ~ S CCAGGACAT 2CT~;GACCTGTGGGTGTACCACACCCAGGGCT ACTTCCCCGACTGGCAGAA 
1111111111111111 IF:Al'd.·~;JI·li~H:"hl;Jkkla:111 LIlt 1111111.1" 
72 c 2CI'l.'GGA2AT CC::TGGACCTGTGGGTGTACCACACCCAGGGCTACTTCCCCGACTGGCAGAA 
22v5 CTACACCCCC::GGCCCCGGCGTGCGCTACCCCCTGACCTTCGGCTGGTGCTTCAAGCTGGT 
1IIIIIIIIIIIIIIfi Hr 111H4IllJlll~rf;EIJrIIJlllllllllr 
. i 'J.Jo ''::TACIICCCCC::GGCCCCGGCGTGCGCTACCCCCTGACCTTCGGCTGGTGCTTCAAGCTGGT 
1111111 
('4 - Alignment of O'iA sequence for RT gene in GagRT construct 
Forward sequence: 
• '" CJ ~:'.:lFc: HiV1gdOh!.T, from 1561 to 2429 
~.:::'!ic"" ::.~.~: GAG::;:T9_','113F, from 31 to 899 
HMgagRT:GAGRT9_~13F identity= 91.88%(826/899) gap=O.OO%(O/899) 
153: AACATCATCGGCCGGAACATGCTGACCCAGCTGGGCTGCACCCTGAACTTCCCCATCAGC 
I I II I I II II II I 
C3KTAMGAGGTCGTGATTGTATACGACTCACTATAGGGCGAATTGGGCCCGACGTCGCAT 
~ c; 91 CCCl'o. TCGAG.lI.CCG~GCCCGTGAAGCTGAAGCCCGGCATGGACGGCCCCAAGGTGAAGCAG 





I I I II I II I I I I I I I II I II I II I II I I I II I II II II II I II I I I I II II II I I I I I I I 
GAGGGCAAGATC:ACCAAGATCGGCCCCGAGAACCCCTACAACACCCCCATCTTCGCCATC 









































I I II I I I I I I I I II I III I I I I I 1111 III 111111 III II 11111 1111 I I I I II III 
C~TCAc"'CTG';ACCAC~CCAGATCTACCCCGGCATCAAGGTGCGGCAGCTGTGCAAGCTGCT 
Re\erse sequence: 
Upper llne: RC-HMgagRT, from 1 to 758 
Lower line: GAGRT9_M13R, from 123 to 880 








I I I II I I I I I I I I I I I III I III I II I 11111 III III III I II I II I I I I II I I I I I I I 
2~~ CTTGCCCCAGGTCACGATGCTCTCCAGGCTGATCTTCTGCACGGCCTCGGTCAGCTGCTT 




























6 c. 3 GTT(:AGCTTGCCCACCAGCTTCTGGATGTCGTTCACGGTCCAGCTGTCCTTCTCGGGCAG 
5~1 CTGGATGGGCTGCACGGTCCACTTGTCGGGGTGCAGCTCGTAGCCCATCCACAGGAAGGG 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I " " I " I " I " I I I " I I 
66~ CTGGATGGGCTGCACGGTCCACTTGTCGGGGTGCAGCTCGTAGCCCATCCACAGGAAGGG 
GGGC1CC"TTCTGGTGCTTCTTGTCGGGGGTGGTGAAGCCCCACTTCAGCAGGTGCTCCCG 
II I I I I " I I I I " I " I I I I " I " I I I " I I " " " " I" I I I " I " I II I II I GGGCTCCTTCTGGTGCTTCTTGTCGGGGGTGGTGAAGCCCCACTCCAGCAGGTGCTCCCG 
CAGCTCCTCGATCTTGGCCCGGTGCTGGCCGATCTCCAGGTCGCTGCCCACGTACAGGGC 
I I I I I I I I I I I I I I I " I I I " I I " I II I I I I I I I II I " " " I I I " I " I II " I I 783 CAGCTCCTCGATCTTGGCCCGGTGCTGGCCGATCTCCAGGTCGCTGCCCACGTACAGGGC 
721 GGCCATGTACTGGTAGATCACGATCTCGGGGTTCTTGG 
11111111111111111111111111111111111111 











Appendi:\ 0: Positive controls and antibodies used for western blots 
Tahle 01- P()siti\i:~ control proteins used in SDS-PAGE and western blotting 
Protein Details I Size (kDa) Sourer 
--~----+---
BH\ () PI")) C,lS Commercial I 
-
(Jag 11\ \-\ 55 
Ciag i H 1\-\ pl7 p2..+ protein 41 Commercial-
i 
'\ef Recombinant III \'-1 Bru Ner U-', coli) 27 \-likrogen " 
,-
RT i H 1\-\II'\Il' Re\ erse Transcriptase dimer (E coli) 51, 66 D, Stammers 
Qualm BiologicaL Inc, (iaithcrsburg, LISA, 
fl'l Biotcch O~k Pic F',l'sti FiliaaL Tartu, estonia 
'\ationallnstitutc for Biological Standards and Control ('!18SC). Centralised Facility for 
\\I)S Rt?agcnts, \1edical Research Council (MRC). lnited Kingdom (liK), 
Tahle 02 - Primary antibodics uscd in wcstern blotting 




Polyclonal antiscrum to recombinant I i p2..+ Rabbit 1:2000 I ,\RP432 I IIIV-1 11:\11' p24 GST (Ecoli), ! 
'~' 
I Monoclonal antibody (IgG I ) to lilY-I 






Antiserum to Recombinant 
ARP428 
HIV -I LA V Reverse Transcriptase 
'\ational Institutc for Biological Standards and Control ('!IBSC). Centralized Facility for 
,"-IDS Reagents, Medical Research Council (MRC). Llnited Kingdom (UK). 
FIT Biotech (hJ Pic. Tampcre Finland. 
Tahle 03 - Secondary antibodies used in western blotting 
Antigen lIost Dilution Details 
\Iouse I!.! CJ (joat 1:5000 Affinity purified alkaline phosphatase conjugate 
-----~- --,-,~ --
Rab~g(_j_ (joat 1:5000 Affinity purified alkaline phosphatase conjugate 





G, Reid I 
FIT 
Biotech ~ 


























/\ppendix E: GaL! p24 ELISA and ANOV A raw data 
Table El -(Jag p2..J. LLISA results ofGagRT optimi/ation samples 
Cell I Time post 'lean of HI\ I A:\O\A~ I 
, density infection pH produced I of H 1\' p24 I 
CcllliJlc 
i 
(cells/ml) 1\101 (hrs) (Jlg/ml) produced 
~[,ni pro insect cells ~_ .'I ,OOl ! 05 0.1 4R 22.53 2.3900R24 
-------
I LJ ,nl pro Insect l'ells I .'I,OOl·05 1.0 48 21,40 2.123151() 
i T.ni pro insl'ct cells .'100 E-t-05 5,0 4R 7,24 I 1,9495538 
c---~- -_ .. _-
, I ,nl pro insect cells I .'I.OOE+O.'l 0.1 72 137.78 4.08069235 I I 
: T,ni pro insect cells 5.00E+05 1.0 72 31.99 3..+3027495 I -- ----------
T,ni pro insect cells 5 ,OOE '05 5.0 72 43.02 3,60117475 
1--
I 
T,ni pro insect c~_I.:' : .'I,OOU05 0,1 96 61.13 3.ROm357 
I [,nl pro insect cells : 5J)OE-t05 1.0 96 84.61 4,4246475 
[,ni pro insL'c_t cells I .'I ,OOL j 05 5.0 96 99.79 4.5994R755 
~~b_ectcelb 
I 
5,00E+05 I 0.1 120 In.31 I 5.09310765 
I.nl pro insect cells .'I,00E-05 1.0 120 130.04 
I 
4,7963 I 835 ! 
I 
T,ni pro Insect cells I .'I,00E+05 5.0 120 174.9.'1 5,00552585 
, 'I ,ni pro insect cells _ +-.JJlOE:+-Q6_ 0.1 48 7.92 1,9305321 1- -- -- -- -- --- - - - -------1--- - -
I I,ni pro insect cells I I ,OOE '06 1.0 48 8,60 2.1357406 
c 
I 
I.ni pro insect c~ll~ i I ,OOE t-06 5,0 4f) I (U13 2,231.'16025 
--
I,ni pro_insect cells I I,OOE+06 O. I 72 192.1.'1 .'1,0557533 
0- I --.. 
_GI~Ij)ro insect cells I I .00ll 06 1.0 72 IOR,05 4.4.'13 I 088 
I,nl pro insect cells I 1.00l106 5.0 72 56.93 4.0257577 I ---- -Ii"; pm ;''',,' "II, I I ,OOE ~06 0.1 96 196.30 4.f)388818 
r,ni pro insect cells I I ,OOE~06 1.0 96 212.58 .'I,2R774595 
I T.nl pro insect cells 1.00H06 5,0 96 187.77 5,23124355 
I 
I .ni pro insect cells I .OOE +06 0.1 120 277.61 5,5882136 I 
[,ni pro insect cells 1.00E+06 1.0 120 188,54 5.023R2345 
[,ni pm insect cells I,OOE+06 5.0 120 *362.85 5.68309415 
~: -----------1----
~,-~ro insect ceIL"--_____ 2,00E-06 0.1 48 8.22 1,9.'165R215 
I I ,ni pro insect cel~~ __ 
I 2,OOE-06 1.0 4R 10,50 2,22652185 ! 
i T.ni pro insect cells ! 2,00E+06 5,0 48 10..+5 2,1488563 I 
! T,ni pro insect cells I 2.00E+06 0.1 72 32.13 2.9068367 
I ,ni pro insect cells 2.00E+06 I .0 72 34.3.'1 .'..'1.'6.'479 
I I ,ni pro insect cells 
I 
2001:-,-06 5.0 72 31.70 I 3.1769042 i 
I T.ni pm insect celb 
I 2.00E+06 0.1 96 .'1.'1.07 3.9907626 I 
I.ni pro insect celJ,; i 2.00E+06 1.0 96 42.74 3.7.'1334405 










_-_f._ll_i ,--pl_'o_i_ll_se_c_t _ce_I_ls __ --,: _2.00E+06 I 0.1 I 120 I 39.07 II 3.66360775 I 
; 
4.12883745 T.lli IJIO IIlSlTt celb ; 2'()()E+_0() ___ ~ _ I~O ~ 67.751 
1.111 Pl~) Illsel·t l't'lls 0_0_0_F_+(l.0-+--_5_._0__+----12-(-1 +-____ 7_2_._7_1-+1 ____ 3:l~ 
SI1.) ilN'ct cl'lls I 5.00L' 05 0.1 48 1.841 0.21302585 
. ------- ---~------'--+___-__I-----_'__j-------+, -----'--'----'--'----1 
Sf) Insect celIs , 5.00E-05 1.0 48 16.51 ! U5327785 
~--------+---+----~---------~------~ 
SIt) In,.;ct cell, ~.()OE-05 5.0 48 i 3.27 I 0.60430105 
~----------------~---__+-----+-- ----+___-----___+---------1 
I 5'()OET05 0.1 72 3.24 0.65836495 
SI1.) Insect Ct'lls 5.00E+05 1.0 72 11.65 I 2.25302895 
Sf9 insect cells I 5.00E+O_5_-+-__ 5_.0---+ ____ 7_2--+ ____ 2_C_J._19---+1 __ L62:~0567lj 
. ..:'il1.) i 12s_-ec_'t C_'l_' II_s ___ --+-: _5_.0_0_L_' 1_0_5-+ __ 0_. _I --+--____ 9_6__+-----1 4_._I_Cl-\I ___ 2 .3 6 ~ 5085 I 
: 5 00 J-'-O 5 1.0 96 I 18.71 i 2.51503105 SIl) Insect cells 
--~-----+---+-----+-----------+--
SI1.)lnsel'1cells 5.00E·05 5.0 96 74.70 4.27717095 i--------------,-----"-----+----t--------t---------+-----------1 
St1.) insect cells ,5.00F+05 0.1 120 4.21 1,42720245 
I 
~S-·t-t)-i-n-sc-'c-'t-c-e-lls-,,-----~l-~--·-()O-F+-O-)----t--_1_.0--+ ____ 1_2_0-r ____ 2_9_.2_6-+ ___ 1._7_9_82_5_4_6~ 
Sf9 insect cells i 5.00E+05 5.0 120 25.3 I 1.79065825 
, I 
SIt) insect cells 1 I.OOE i 06 0.1 48 5.881 1.66496525 I 
--+----~---+--~-+-------~~-----~~~-~~--~~ 




St'! Insect cells I .OOE: 06 5.0 48 25.67 3.2416561 
r-------- ----~----_+_---+_-----t__----~_+----~~~ 
I 
St1.) 11lsectcells 1.001:-'06 0.1 72 47.21 3.73174215 
c--- ----------- -,---------t-----t---'------1'----------1-----------1 
" 
SI1.) Insect cells 
SI1.) insect cells 
SI1.J insect cells 
SI1.) insc'L't cclb 
Stl) insect cells 
SI1.) insect cell, 
72 70.66 3.94641985 -- ---+----------
72 47.52 
i I.OOf> 0_6-+_0_._1__ .I2_O_-+-_____ IYI (2) .. ~49t ____ 4.0_8_5_97_4_2~ 
" SI1.J inscct cells I I.OOE '06 1.0 120 v 4.51914025 
~ S 11.J insect ce II s W-'<-l(-.::) E=--""0.....:6-+----'5-' . .:.0-+-____ 1-=-2.::.0_+_----.---C..6.:.O:..::. 6-'.1-+-__ 4:..:... ("-)9'---'8_._9 ___ 9-=-3---=-6-'----15 
_ SI'!_I_ns_ec.1 cells ______ -1-_2_._0_0_E_-_O_6--t--_O_.I-+ ______ 4_8-r ____ 1_4_._17-+ ___ 2.3304273 
I Stt) insect cells I 2()OE ·06 1.0 48 9.10 2.1625555 
iSIl)insectcells 2.00E+06 5.0 48 29.02 3,2017371 
I 
'~SI1.J insect cells 2.00E,06 0.1 72 45.30 3.29897105 
I SI1.) insect cells ,2.00Ec-06 1.0 72 102.94 4.57216015 
I --- --------:....c-'-~-=---------t---.:....:....:'---'-'--+_-'--'-f-------If---------'--"_+-----------------1 
i SI1.J insect celb I 2.00E+06 5.0 72 47.49 3.83340875 
I 
SIl) insect cells I 2.00[+06 0.1 96 144.86 4.5758228 
:---- -- -- ---- ------ ---+-----_+-----+--------t---------t-------------I 
SI1.) insect cells ! '.OOE+06 1.0 96 196.34 4.8890508 
SIt) insect cells 2.00E+06 5.0 96 50.12 3.90534985 
SI1.) insect cells I 2.00E+06 0.1 120 63.50 4.1118265 
SIt) inse0.cells_ ,2.00E-06 ____ 1_:'O_I-____ IJ(~ __ !)Q..~~~____ 4.(~658R3 
SI1.) ii1~eet cells I : 2.00F+06 5.0 I 120 52.00 393724605 












Table E2 (jug p2~ [LISA results ol'CagT:\ optimi/ution samples 
, -----
l 
--- - ~ --- -- -- - --------
I 
: 
I Cell I Time post 'lean of HI" , A:\O' A mean 
I 
density infection I p24 produced I of HI" p24 I 
Cell line ( cells/ml) MOl (hrs) (ng/ml) i produced 
_1:21_1 pro insect cells ! :'.00[+0:' 0.1 
I 
48 19.1:' I 2.861345 
i 
I 
82.771 I 1.111 pro insect cells :'.OOHOS 1.0 48 4.~OO I 145 
I , 
I 
I .111 pro Illsect cell~ , :'.OOHOS 5.0 48 ~ 7.09 ~.549~ I ~ , 
-
I 
I .111 pro ilhCCl cells :'.OOE ~05 0.1 i 72 103.:'4 4.6397985 
I .111 pro IlbCC1_Ctells :,J101:::+0:, 1.0 72 146.10 4.981695 
1.111 pro illsect cells :'.OOE c05 5.0 72 92.64 I 4.460348 
: 
96i I 1.111 pro illstect cells 
I 
5.00Et OS O. I , 148.10 4.978421 :' 
1.111 pro IIlStect_c~.':,,-_ : 5.00Ei 05 1.0 i 96l __ 11- r : 4.746~94 . , i- -- --+- ---- ).-)~- - - ---------j 
T.lli pro illseet cells :'.OOE+05 5.0 i 96 
I 
I :'2.~9 I 5.0134145 
I 
•. _LIlI pro illsect cells :'.OOE +-05 0.1 1201- 221.46 4.994674:' ~--
_-'_~~~_P~) l~se.0cells :'.OOE! 0:' 1.0 
, 120 125.08 4.8092445 
I .ni pro illsect cells 
, 
:'.OObOS ·0 i 120 I 196.05 5.271171 , ). i 
I .Ili pro~l_sect~ells 
, 
I .OO[ '06 O. I I, 48 
i 
77.90 ~.7518545 i I I I ------'----I ------------t--- -- - ------
T.ni pro insec.tcell~ I I .00 E +06 1.0 . 48 I 97.03 I ~.91 0509 
~ I.ni pro insect cells i 1.001:::106 5.0 48 84.98 ! ~.7650365 i _. 
f ! 
I I I .nl pro insect c~I~,,-_ 1'(10E+06 0.1 72 103.86 4.617969 
" 
i I.ni pro insect cells 1.00b06 1.0 72 25n~ 5.0 1294~:' 
T.ni pro insect cells 1.00[+06 5.0 I 72 46.82 ~996:'2.9456 
I.ni pro insect cells 
I 
I.OOE+06 O. I I 96 304.79 5.4744205 -
__ 1~IIPro insect cl'lIs .. -J- 1.00l~· 06 1.0 96 1:'3.03 4.9403805 
_I :~_rO_i!lSect cells 
I 
1.00[r06 5.0 96 14:'.26 4.9706615 I 
T.lli ero_Insect cells L I.OOE+06 0.1 120 3:'1.02 :'.644~245 -
I I.ni pro insec~cel":. I 1.00H06 1.0 120 19·U8 5.161949 
! 
I I T.ni pro insect cells I.OOE+06 5.0 120 460.51 6.105239 
I +-, 
_l:0j.E~o insec"t cells i 2.00E+06 O. I 48 20AO 2.8:'8~72 
rIlIJ)r()~I1SCCl (l'lIs ! 2.00L 106 I .0 48 .':'.89 ~.:'479845 : I -- ---- --- --- --- -- ---f-- - --- -- ----
I .ni pro insect cells 
I 
2.00E+06 5.0 48 ~:'.60 ~.S71962 
T.lli pro illsect ctells 2.00E 106 0.1 
I 
72 44.99 3.8051655 
i 
·1 .ni pro insect cells 2.00E+06 1.0 
, 
72 5:'.41 ~.93000~ 
-----... , 
! I.ni pro insect cells I 2.00E+06 5.0 I 72 97.67 4.579258 --
1 
l~liJ~I()_~nSCCI~I~ 2.00[J 06 0.1 
, 
96 7:'.28 4.3141805 
- --- ------ ----1----------- -- -
T.lli pro illsect cells 2.00E ,06 I .0 96 I 49.87 I 3.844521 
! T.ni pro insect cells ! 2.00E t 06 5.0 96 67.2S 4.2088545 
I .nl pro InSl'ct cells 2.00E+06 0.1 120 95.56 4.553692 ----,--










_I_.ni pro il~~_cL_·t_c_el_ls_· _--;-'}~gOEt-06 5.0 I. ____ _20 I 7(~.541 4.-' 1527551 
Sll) IIlsect ct.'lls t ).()OE~~ ___ 0.1 f ___ 48: _______ ).16~--1~640Q.~ 
St1) insect cells ! 5.0Of+05 1.0 i 48 I' 17.47 2.656-'()4 
.. ____ · ___ --l-I _______ +-__ .1- --------'.r--------t----------! 
Stt) insect ceiL; 1 5.00E' 05 5.0 48 -'2.28 -'.42250-' 
St9 insect cl'lls I 5.00E+05 0.1 I 72 29.11 3.-'704675 
----+-----+---~-
St1) insect cells i )J)OE+05 1.0 I 72 60.08 -'.3861225 -,--'----+---'-------__+------+-------__1 , 
St9 insect cells i 5.00E-'-05 5.0 I 72 92.X I 4.0260635 
f------------+,-=-:....:..::..::..c.c---=-=--+-~=_+-----=-l___-----=---=-=_+---'---'-_____1 
I Sf9insectcells ! 5.00E+0) 0.1 96 101.31' 3.-'997215 
, 
Stt) insect cells ).OOE' 05 1.0 96 83.70 -'.-'97586 
c------------~,- -~---=-=--=-+_---=--=-+----~~-------=--~--~--~ 
: Sfl) insect ct.'lls I 5.00E ,OS 5.0 96 114.47 I 4.4893515 
! St9 insect cells 5.00E+05 0.1 I 120 21,.92 2.584555 -_. 
St1)insectccll, 1 ).OOE05 1.0 i 120 64.36 3.7028115 ------------+ -----+---r------_+_------j-------___i 
: .. ')f~insect cells i 5.001::+05 5.0 120 71,.90 4.2811575 
S(1) insect cl'lls I .OOE~ 06 O.I! 48 21.S7 -'.080956 
---- --- -- . ------+-----+---j------_+_------~-----___i 
SI9 insect cells 1.00E+06 1.0 48 41.72 3.560146 
SIt) insect cells 1.00E+06 5.0 l. 48 202.76 4.6002895 
_' _S_ll)_I_·n_s_t'L_'t_c_e_ll_s ___ --+I __ I.OOE ,06 0.1 72 I) 1.84 i 4.442265 
S(1) IIlSt'ct ct.'11s I.OOIJ06 1.0 i 72 214.95 I 5.0032X6 
--- ------------+---~--------+------+---------I 
Stt) insect cells i 1.00E+06 5.0 72 184.24 5.138867 
,----------~ 
St1) insect cells i I.OOE+_ .. 0 __ 6_+ __ 0_._I-t-____ 9_6+-____ -'_0_8_.3_3 .. _ 5.3087525 
St1) insect cells 1.00E+06 1.0 i 96 168.97 4.8803145 
c------- -------~--=--~~----=-~----=-~------=-~---=-4------=--=----=-~~ 
~_~It) insect c~s ___ --+_I ._O_O_E_' _0_6+-_5_.0_-+ ____ 9_6-+ ____ 1_9_7_. 7_8--+ ___ 5_.1_5_1_8_2_4__15 
i SIt) insect cells 1 1.00EI06 0.1 120 190.40 4.8474795 
~--------~----~--_+-----l___---~~_+---~-------
i SllJinsl'ctcells I 1.00E+06 1.0 120 169.04 4.961018 
! Sf) insect cells I 1.00E+06 5.0 i 120 278.43 5.6291475 
i SIt) insect cells I 2.00~-~06- -O~-I-- 48 28.75 --3~22()rn 
I 1.0 ! SIt) insect cells 2.00Et06 48 41.83 3.723669 
St1) insect cells i 2.00E+06 5.0 : 48 43.63 3.747812 
I Sf9 insect cells jl 2.001-':+06 0.1 72 48.43 I 3.B223315 
~, ------------t---=-~-~-+--=-~+-----=--+----~-=-+--~~~~~~ 
Stt) insect cells 
Stt) insect cl'lls 
I Stt) ilN.Tt celb 
1 
I 
,I Stt)_insect cells 
Stt) insect cells 
, Stt) insect L'l'lls 
I 2.001::+06 1.0 I 72 68.61 4.2271355 
i 2.00E+06 5.0 72 94.61 4.449X23 
-~-------+---+------+-------+------~ 
I 2.00E+06 0.1 96 I1.UOI 4.7187775 
I 2.001:-:+06 !.-2..1 __ ~_____ 60.~7 ~ ___ 4_._1 0_22~05_ 
2.00E+06 5.0 I 96 63.72 4.1540155 
2.00[.,.06 0.1 120 59.77 
'if----S_tlJ_l_n_St_'l_'I_C_c_lls_: ____ --+--_2.00[106 1.0 120 60.18 \ 
















Tahle E3 :\\10\'.\ summary for GagRT data 
--- ----------~---~----~-------~--~ 
Factors/factor interactions I Sum Ii 'lean I : I 
, ______ t_es!,ed, _______ +---D_f_ Sq I Sq I F value L?r(>F) 
Line 1 15.256 I 15.25() i 12.0387: 0.00089 I *** 
----,---
Densit) ____ +---__ 2__+_, ~3_8_.c)_9_7--1-_19_.~3~4_9__+_1~1~5~.2=--:6~8~3___i1---=-3.~O-'-5-=E--06 *** --
Multiplicity 2 3.165 1.583 1.2489 0.29306 
r-~-~-------~---+------+---~---+------
I Timc 3 10(d96 35.599 28.0916 4.3()E-12 *** 
~ 
, I 
Line:Dcnsity 2 34.951 17.475 I 13.7902 8.71 E-06 *** 
--~-------~--
inc:Multiclicity_,_ 2 2.794 
Iknsity:\!ll1ltiplicity 4 I 0.879 I 
Linc:Time 3 9.441 I 
c--
Density:Timc () 2.632 
c--
MlIltipl~city:Tirl~(?_ l---- 6 _~? 1 
Line:Dcnsity:Multiplicity 4 2.018 i 
I.inc:Densit,,:Timc 6 3.937 
-
Line:~'1ttltiplicity:Time 6 2.305 
Dcnsity:\ll1ltiplicity:Til11c 12 7.32() 
Linc:Density:Multiplicity:Timc 12 3.521 
Residuals 71 89.974 









Dcnsit~y___ 2 18.9 
, I\lultiplicity 2 4.119 
Time 3 32.327 
1.397 1.1026 0.33764 
0.22 0.1734 0.95132 
3.147 I 2.4833 0.06776 
0.439 i 0.3462 i 0.90984 
0.136 0.1077~ 0.99529 
0.504 0.3981 0.80937 
0.656 0.5178 0.79297 
0.384 0.3032 0.93328 
0.61 0.4817 0.91905 
0.293 0.2316 i 0.99612 
1.267 I 
Mean 









Line:Dcnsity 2 11.832 5.916 6.877 0.001862 ** 
L,hi~l~: M ul tip I ic i t Y __ , ______ +-_--=-2 _+-~2~.4-=1-=6+__--1.==2-=0-=-8-+--=I-.4~(-)4~4__+__-'-O ._2_,_5_22_4_7_ 
• Dcnsity:MlIltiplicity 4 1.65 0.413 0.47% 0.750574 
Linc:Til11c 3 1.312 0.437 0.5084 0.677769 ,-, ---------+- -------l------~--'------+--
Dcnsity:Til11e 6 3.249 0.542 0.6295 0.706144 
,---,----f--------=-+-----=----+-----=-~=--+~----=-+----
l'ylultiplicity:Time 6 5.009 0.835 0,9704 0.451617 
L.ine:D~nsity:Multiplicity_ __-+--__ 4--+--_2_.2_6_3--+--_ 0.566 0,6576 0.623499 
Linc:Dcnsity:Time 6 0.481 0.08 0.0932 0.99684 










Density: Multiplicity: Time 
Ijne:DensitY:MlIltipliCitY:Time __ i __ 12 O.9(~J O.(~~l .~ 
R es_i u_L_la Is __ 7_1--...L_6 _1 . on I 0.86 ! 
Sig:nificant codes: *** - p -S:O.OOOI 
** - p -S:O.OOI 
* - p -s:O.05 
. - p -s:0.1 
no code - p -S:I.O 
I host' ~rollps \\ ith I or more * are deemed as major htctors or factor interactions. 
Appendix F: Quantification ofYLP stocks 
135 
Table Fl Quantification 0(' GagTN and GagRT VLP stocks. batches I and 2. USll1g 
,,'estern blot densitometry ~l/3 
--_. 
, Average amount I 
: I Quantitation Quantitation of \'LPs in stocks Std deviation I 
\'LP 'hIcks , 1 (~tg/rnl) 2 (~lg/ml) (~tg/ml) (~g/ml) 
(jagT,\ Batch I i 14.36 17.8 16.08 2.43 
: 
(jagT,\ Batch :: 22.74 17.54 20.14 3.68 
i (jagR I Batch I i 1.13 3.97 2.55 i 2.01 
, (JagRT Batch :: i 17.16 13.18 15.17 i 2.81 , 
Appendix G: Endotoxin data 
Table G 1 The endotoxin results of the respective VLP stock solutions and the mouse 
inoculations 
I (ja~T,\ I ! 0.116 79.992 1/322 0.248 
~~---~I ----rl ------4-------~----------------~ 
: (ja~ T,\ ') I 0.101 50.047 1/403 0.124 
:! =Cj=a:;R==r===:~, ===-__ 7 1--~0~.1~0~4~----6~0~.~04-8-+-1-/5~1~------------1-.'1-7-7~ 
(jagl? [ __ .L. :: _: 0.094 34.32 1302 _ __ i _ _ __ J.l~14 











Appendix H: Cell surface marker data 
Tahle Ht The proportion (as (Yc) of events in the lymphocyte gate) of Band T cclls in 
thc spleens ofthc mice groups vaccinated with GagTN VLP experiment 1 vaccines. 
Vaccine ! CD3/CDt9 I CD3+ CD3+/CD4+ CD3+/CD8+ CD4+/CD8+ CDt9+ 
Groue i :\'egatin ratio -- --
I I 12.7 40.5 . 35.9 12.5 i 2.9 46.8 
2[ 15.1 i 38.2 27.3 12.1 2.3 46.7 
I 3 . 13.5 I 37.6 27.5 12.8 2.1 48.9 
~ 
-l-I I-l-J) 43.8 34.1 13.5 2.5 41.6 
L--________ 
---~-
5 . 17.1 41.1 29.7 13.5 2.2 41.8 
I -~----- ----- ------
6 15.5 43.0 31.4 I 14.2 2.2 41.6 
---
7 . 17.-1- 37.0 27.2 12.5 2.2 45.6 
I 
~ . 14.6 40.4 31.2 12.9 2.4 45.0 ( , , 
------ --
Tahle H2 Thc proportion (as % of events in the lymphocyte gate) of Band T cells in 
thc splecns urthc mice groups vaccinated with GagRT VLP experiment 1 vaccines. 
~ 
: CD3/CDt9 I CD3+ Vaccine 
I, :\egatin Group 






























CD3+/CD4+ CD3+/CD8+ i CD4+/CD8+ CD19+ 
ratio 
32.8 13.6 2.4 38.7 
31.3 14.3 2.2 37.0 
29.0 13.7 2.1 40.0 
----
33.2 14.7 2.3 36.3 
29.5 14.4 2.0 40.4 
32.4 15.2 2.1 36.6 
- -------- ----- ---- -~ - --- -~---
29.1 13.7 2.1 39.3 
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